



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE	REQUEST ID
15/606,265	05/26/2017	Andrew L. Paris III	25412-0003003	151403

Acknowledgement of Loss of Entitlement to Entity Status Discount

The entity status change request below filed through Private PAIR on 11/01/2021 has been accepted.

CERTIFICATIONS:

Change of Entity Status:

☒ Applicant changing to regular undiscounted fee status.

NOTE: Checking this box will be taken to be notification of loss of entitlement to small or micro entity status, as applicable.

This portion must be completed by the signatory or signatories making the entity status change in accordance with 37 CFR 1.4(d)(4).

Signature:	/Jeffrey J. Barclay/
Name:	Jeffrey J. Barclay
Registration Number:	48950



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	ISSUE DATE	PATENT NO.	ATTORNEY DOCKET NO.	CONFIRMATION NO.
15/606,265	05/08/2018	9965651	25412-0003003	1070

26161 7590 04/18/2018
FISH & RICHARDSON P.C. (BO)
P.O. BOX 1022
MINNEAPOLIS, MN 55440-1022

ISSUE NOTIFICATION

The projected patent number and issue date are specified above.

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b) (application filed on or after May 29, 2000)

The Patent Term Adjustment is 0 day(s). Any patent to issue from the above-identified application will include an indication of the adjustment on the front page.

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (<http://pair.uspto.gov>).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Application Assistance Unit (AAU) of the Office of Data Management (ODM) at (571)-272-4200.

APPLICANT(s) (Please see PAIR WEB site <http://pair.uspto.gov> for additional applicants):

Andrew L. Paris III, Victor, NY;
Vigilytics LLC, Victor, NY;

The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for business investment, innovation, and commercialization of new technologies. The USA offers tremendous resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to encourage and facilitate business investment. To learn more about why the USA is the best country in the world to develop technology, manufacture products, and grow your business, visit SelectUSA.gov.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor : Andrew L. Paris III Art Unit : 2493
Serial No. : 15/606,265 Examiner : Don Gordon Zhao
Filed : May 26, 2017 Confirmation No. : 1070
Notice of Allowance Date: January 5, 2018
Title : USING DE-IDENTIFIED HEALTHCARE DATA TO EVALUATE
POST-HEALTHCARE FACILITY ENCOUNTER TREATMENT
OUTCOMES

MAIL STOP ISSUE FEE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REPLY TO NOTICE OF ALLOWANCE

In response to the Notice of Allowance dated January 5, 2018, enclosed is a completed Part B - Fee(s) Transmittal.

Apply the issue fee and any other necessary charges or credits to Deposit Account 06-1050, referencing the above attorney docket number.

COMMENTS ON EXAMINER'S REASONS FOR ALLOWANCE

It is recognized that in accordance with M.P.E.P. § 1302.14, the Examiner's reasons for allowance need not set forth all of the details as to why the claims are allowed. In the above-referenced application, it is not conceded that the Examiner's stated reasons for allowance are the only reasons for which the claims are allowable. The Examiner's reasons for allowance indicate that particular claim elements are not disclosed or suggested by the prior art of record, yet the claims may be patentable for other reasons as well, including the inventive combination of all of the recited claim elements. It is not conceded that the specific limitations identified by the Examiner are necessary to distinguish the art of record or to satisfy the requirements of 35 U.S.C. § 112. Moreover, the Examiner does not assert, and it would not be conceded, that the Examiner's reasons have any bearing on the patentability of claims in any other applications directed to the disclosed subject matter.

In addition, each dependent claim stands on its own and may be allowable on its own merits. In particular, each dependent claim may be allowable on the basis of a combination of

First Named Inventor : Andrew L. Paris III
Serial No. : 15/606,265
Filed : May 26, 2017
Page : 2 of 2

Attorney Docket: 25412-0003003

some of the features recited in the dependent claim and its base claim(s), which combination of features may not include all of the limitations identified in the Examiner's reasons for allowance.

Respectfully submitted,

Date: 3/28/18

/Natalie K Galley/

Natalie K. Galley, Ph.D
Reg. No. L1010

Customer Number 26161
Fish & Richardson P.C.
Telephone: +1 (617) 956-5911
Facsimile: (877) 769-7945

23728616.doc

PART B - FEE(S) TRANSMITTAL

**Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
or Fax (571)-273-2885**

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

26161 7590 01/05/2018

FISH & RICHARDSON P.C.
P.O. BOX 1022
MINNEAPOLIS, MN 55440-1022

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

(Depositor's name)
(Signature)
(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
15/606,265	05/26/2017	Andrew L. Paris III	25412-0003003	1070

TITLE OF INVENTION: USING DE-IDENTIFIED HEALTHCARE DATA TO EVALUATE POST-HEALTHCARE FACILITY ENCOUNTER TREATMENT OUTCOMES

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	SMALL	\$480	\$0	\$0	\$480	04/05/2018

EXAMINER	ART UNIT	CLASS-SUBCLASS
ZHAO, DON GORDON	2493	726-009000

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).

☐ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.

☐ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. **Use of a Customer Number is required.**

2. For printing on the patent front page, list

(1) the names of up to 3 registered patent attorneys or agents OR, alternatively,

1 Fish & Richardson P.C.

(2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.

2 _____
3 _____

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE
Vigilytics LLC

(B) RESIDENCE: (CITY and STATE OR COUNTRY)
Victor, NY

Please check the appropriate assignee category or categories (will not be printed on the patent): ☐ Individual ☒ Corporation or other private group entity ☐ Government

4a. The following fee(s) are submitted:

☒ Issue Fee

☐ Publication Fee (No small entity discount permitted)

☐ Advance Order - # of Copies _____

4b. Payment of Fee(s): (**Please first reapply any previously paid issue fee shown above**)

☐ A check in the amount of the fee(s) is enclosed.

☐ Payment by credit card. Form PTO-2038 is attached.

☒ The Director is hereby authorized to charge the required fee(s), or credit any overpayment, to Deposit Account Number 06-1050.

5. **Change in Entity Status** (from status indicated above)

☐ Applicant certifying micro entity status. See 37 CFR 1.29

☐ Applicant asserting small entity status. See 37 CFR 1.27.

☐ Applicant changing to regular undiscounted fee status.

NOTE: Absent a valid certification of Micro Entity Status (see form PTO/SB/15A and 15B), issue fee payment in the micro entity amount will not be accepted at the risk of application abandonment.

NOTE: If the application was previously under micro entity status, checking this box will be taken to be a notification of loss of entitlement to micro entity status.

NOTE: Checking this box will be taken to be a notification of loss of entitlement to small or micro entity status, as applicable.

The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above.

NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.

Authorized Signature /Natalie K Galley/

Date 3/28/18

Typed or printed name Natalie K. Galley, Ph.D

Registration No. L1010

Electronic Patent Application Fee Transmittal				
Application Number:		15606265		
Filing Date:		26-May-2017		
Title of Invention:		USING DE-IDENTIFIED HEALTHCARE DATA TO EVALUATE POST-HEALTHCARE FACILITY ENCOUNTER TREATMENT OUTCOMES		
First Named Inventor/Applicant Name:		Andrew L. Paris		
Filer:		Natalie K. Galley/Cathy O'Brien		
Attorney Docket Number:		25412-0003003		
Filed as Small Entity				
Filing Fees for Utility under 35 USC 111(a)				
Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Basic Filing:				
Pages:				
Claims:				
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				
UTILITY APPL ISSUE FEE	2501	1	480	480

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Extension-of-Time:				
Miscellaneous:				
Total in USD (\$)				480

Electronic Acknowledgement Receipt

EFS ID:	32191753
Application Number:	15606265
International Application Number:	
Confirmation Number:	1070
Title of Invention:	USING DE-IDENTIFIED HEALTHCARE DATA TO EVALUATE POST-HEALTHCARE FACILITY ENCOUNTER TREATMENT OUTCOMES
First Named Inventor/Applicant Name:	Andrew L. Paris
Customer Number:	26161
Filer:	Natalie K. Galley/Lisa Peterson
Filer Authorized By:	Natalie K. Galley
Attorney Docket Number:	25412-0003003
Receipt Date:	29-MAR-2018
Filing Date:	26-MAY-2017
Time Stamp:	10:58:53
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	DA
Payment was successfully received in RAM	\$ 480
RAM confirmation Number	032918INTEFSW00009552061050
Deposit Account	
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

File Listing:					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Miscellaneous Incoming Letter	Reply.pdf	60215	no	2
			57627675610b1a4787f662a4c440996b128583e8		
Warnings:					
Information:					
2	Issue Fee Payment (PTO-85B)	PartB.pdf	94207	no	1
			336374a0496a4141788079cdbbf6c99285ec9f72		
Warnings:					
Information:					
3	Fee Worksheet (SB06)	fee-info.pdf	30419	no	2
			5a372b75768cad24570094bb98b717d89639c2d6		
Warnings:					
Information:					
Total Files Size (in bytes):			184841		
This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503. <u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application. <u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course. <u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.					



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

NOTICE OF ALLOWANCE AND FEE(S) DUE

26161 7590 01/05/2018
FISH & RICHARDSON P.C. (BO)
P.O. BOX 1022
MINNEAPOLIS, MN 55440-1022

EXAMINER

ZHAO, DON GORDON

ART UNIT

PAPER NUMBER

2493

DATE MAILED: 01/05/2018

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

15/606,265

05/26/2017

Andrew L. Paris III

25412-0003003

1070

TITLE OF INVENTION: USING DE-IDENTIFIED HEALTHCARE DATA TO EVALUATE POST-HEALTHCARE FACILITY ENCOUNTER TREATMENT OUTCOMES

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	SMALL	\$480	\$0	\$0	\$480	04/05/2018

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

HOW TO REPLY TO THIS NOTICE:

I. Review the ENTITY STATUS shown above. If the ENTITY STATUS is shown as SMALL or MICRO, verify whether entitlement to that entity status still applies.

If the ENTITY STATUS is the same as shown above, pay the TOTAL FEE(S) DUE shown above.

If the ENTITY STATUS is changed from that shown above, on PART B - FEE(S) TRANSMITTAL, complete section number 5 titled "Change in Entity Status (from status indicated above)".

For purposes of this notice, small entity fees are 1/2 the amount of undiscounted fees, and micro entity fees are 1/2 the amount of small entity fees.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Maintenance fees are due in utility patents issuing on applications filed on or after Dec. 12, 1980. It is patentee's responsibility to ensure timely payment of maintenance fees when due. More information is available at www.uspto.gov/PatentMaintenanceFees.

PART B - FEE(S) TRANSMITTAL

**Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
or Fax (571)-273-2885**

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

26161 7590 01/05/2018
FISH & RICHARDSON P.C. (BO)
P.O. BOX 1022
MINNEAPOLIS, MN 55440-1022

Certificate of Mailing or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

(Depositor's name)
(Signature)
(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
15/606,265	05/26/2017	Andrew L. Paris III	25412-0003003	1070

TITLE OF INVENTION: USING DE-IDENTIFIED HEALTHCARE DATA TO EVALUATE POST-HEALTHCARE FACILITY ENCOUNTER TREATMENT OUTCOMES

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	SMALL	\$480	\$0	\$0	\$480	04/05/2018

EXAMINER	ART UNIT	CLASS-SUBCLASS
ZHAO, DON GORDON	2493	726-009000

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363). ☐ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. ☐ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required.	2. For printing on the patent front page, list (1) The names of up to 3 registered patent attorneys or agents OR, alternatively, 1 _____ (2) The name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed. 2 _____ 3 _____
---	---

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY)

Please check the appropriate assignee category or categories (will not be printed on the patent) : ☐ Individual ☐ Corporation or other private group entity ☐ Government

4a. The following fee(s) are submitted: ☐ Issue Fee ☐ Publication Fee (No small entity discount permitted) ☐ Advance Order - # of Copies _____	4b. Payment of Fee(s): (Please first reapply any previously paid issue fee shown above) ☐ A check is enclosed. ☐ Payment by credit card. Form PTO-2038 is attached. ☐ The director is hereby authorized to charge the required fee(s), any deficiency, or credits any overpayment, to Deposit Account Number _____ (enclose an extra copy of this form).
---	---

5. Change in Entity Status (from status indicated above)

- ☐ Applicant certifying micro entity status. See 37 CFR 1.29
- ☐ Applicant asserting small entity status. See 37 CFR 1.27
- ☐ Applicant changing to regular undiscounted fee status.

NOTE: Absent a valid certification of Micro Entity Status (see forms PTO/SB/15A and 15B), issue fee payment in the micro entity amount will not be accepted at the risk of application abandonment.

NOTE: If the application was previously under micro entity status, checking this box will be taken to be a notification of loss of entitlement to micro entity status.

NOTE: Checking this box will be taken to be a notification of loss of entitlement to small or micro entity status, as applicable.

NOTE: This form must be signed in accordance with 37 CFR 1.31 and 1.33. See 37 CFR 1.4 for signature requirements and certifications.

Authorized Signature _____ Date _____

Typed or printed name _____ Registration No. _____



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
15/606,265	05/26/2017	Andrew L. Paris III	25412-0003003	1070

26161 7590 01/05/2018
FISH & RICHARDSON P.C. (BO)
P.O. BOX 1022
MINNEAPOLIS, MN 55440-1022

EXAMINER

ZHAO, DON GORDON

ART UNIT	PAPER NUMBER
----------	--------------

2493

DATE MAILED: 01/05/2018

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b) (Applications filed on or after May 29, 2000)

The Office has discontinued providing a Patent Term Adjustment (PTA) calculation with the Notice of Allowance.

Section 1(h)(2) of the AIA Technical Corrections Act amended 35 U.S.C. 154(b)(3)(B)(i) to eliminate the requirement that the Office provide a patent term adjustment determination with the notice of allowance. See Revisions to Patent Term Adjustment, 78 Fed. Reg. 19416, 19417 (Apr. 1, 2013). Therefore, the Office is no longer providing an initial patent term adjustment determination with the notice of allowance. The Office will continue to provide a patent term adjustment determination with the Issue Notification Letter that is mailed to applicant approximately three weeks prior to the issue date of the patent, and will include the patent term adjustment on the patent. Any request for reconsideration of the patent term adjustment determination (or reinstatement of patent term adjustment) should follow the process outlined in 37 CFR 1.705.

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

OMB Clearance and PRA Burden Statement for PTOL-85 Part B

The Paperwork Reduction Act (PRA) of 1995 requires Federal agencies to obtain Office of Management and Budget approval before requesting most types of information from the public. When OMB approves an agency request to collect information from the public, OMB (i) provides a valid OMB Control Number and expiration date for the agency to display on the instrument that will be used to collect the information and (ii) requires the agency to inform the public about the OMB Control Number's legal significance in accordance with 5 CFR 1320.5(b).

The information collected by PTOL-85 Part B is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Notice of Allowability	Application No. 15/606,265	Applicant(s) PARIS, ANDREW L.	
	Examiner Don Zhao	Art Unit 2493	AIA (First Inventor to File) Status No

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to the communications on 10/16/2017.
☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on _____.
2. ☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on _____; the restriction requirement and election have been incorporated into this action.
3. ☒ The allowed claim(s) is/are 1-20. As a result of the allowed claim(s), you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see http://www.uspto.gov/patents/init_events/pph/index.jsp or send an inquiry to PPHfeedback@uspto.gov.
4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

Certified copies:

- a) ☐ All b) ☐ Some *c) ☐ None of the:
 1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

- | | |
|--|--|
| 1. ☐ Notice of References Cited (PTO-892) | 5. ☒ Examiner's Amendment/Comment |
| 2. ☐ Information Disclosure Statements (PTO/SB/08),
Paper No./Mail Date _____ | 6. ☒ Examiner's Statement of Reasons for Allowance |
| 3. ☐ Examiner's Comment Regarding Requirement for Deposit
of Biological Material | 7. ☐ Other _____. |
| 4. ☒ Interview Summary (PTO-413),
Paper No./Mail Date <u>12/15/2017</u> . | |

/Don Zhao/
Primary Examiner, Art Unit 2493

DETAILED ACTION

This is a response to the communications filed on 10/16/2017, in which claims 1-20 are presented for examination. Claims 1, 7, and 14 are in independent form. Applicant's submission filed on 10/16/2017 has been entered. The present application is being examined under the pre-AIA first to invent provisions.

Examiner's Note on Double Patenting

Regarding the double patenting issues, the Applicant agreed to further limit the minimum number of individuals to be included in report in response to the request; see the Interview Summary. Specifically, the claimed invention now focuses on a feature of having “at least a minimum number of individuals to be included in a report in response to the request, wherein the minimum number of individuals are selected according to at least a privacy-preserving rule that disallows same individuals to be included within a defined period of time.” This limitation overcomes the previous double patenting rejection. Accordingly, the double patenting rejection is withdrawn.

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Art Unit: 2493

Authorization for Examiner's Amendment was after a telephone interview with Applicant Representative Natalie Galley.

The application has been amended by the Examiner's Amendment as follows. The following listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Currently Amended) A computer-implemented method comprising:
 - receiving a request from a user device for information that characterizes a group composed of multiple individuals from a set of de-identified medical data representing characteristics of the individuals pre- or post-encounter with a healthcare facility, wherein the request contains identifying data for each member in the group of multiple individuals who have had an encounter with a healthcare facility;
 - producing, by a hardware processor, a request token for each individual included in the group of individuals;
 - comparing the request tokens to tokens associated with the de-identified data to find matching tokens and to determine whether the group includes at least a minimum number of individuals to be included in a report in response to the request wherein the minimum number of individuals are selected according to at least a privacy-preserving rule that disallows same individuals to be included within a defined period of time;
 - producing the requested information that characterizes the group, an identity of the individuals being unattainable from the produced information; and
 - providing the produced medical information to report the characteristics of the group of individuals absent authorization from the individuals in the group of individuals identified in the request containing identifying data.

Art Unit: 2493

2. (Previously Presented) The computer-implemented method of claim 1, wherein the provided information is medical data in conformity with the Health Insurance Portability and Accountability Act (HIPAA).

3. (Previously Presented) The computer-implemented method of claim 1, wherein receiving the request for information that characterizes the group of individuals includes receiving personally identifiable information associated with the individuals of the group.

4. (Previously Presented) The computer-implemented method of claim 1, in which producing the requested information includes encrypting respective data that identifies each individual.

5. (Previously Presented) The computer-implemented method of claim 1, in which the tokens associated with data and the request tokens are similarly encrypted.

6. (Previously Presented) The computer-implemented method of claim 1, in which the data represents medical-related information associated with the individuals of the group.

7. (Currently Amended) A system comprising:
a computing device comprising:
a memory configured to store instructions; and
a processor to execute the instructions to perform operations comprising:
receiving a request from a user device for information that characterizes a group composed of multiple individuals from a set of de-identified data representing characteristics of the individuals pre-or post-encounter with a healthcare facility, wherein the request contains identifying data for each member in the group of multiple individuals who have had an encounter with a healthcare facility;
producing, by a hardware processor, a request token for each individual included in the group of individuals;
comparing the request tokens to tokens associated with the medical data to find matching tokens and to determine whether the group includes at least a minimum number of individuals to be included in a report in response to the request wherein the minimum number of

Art Unit: 2493

individuals are selected according to at least a privacy-preserving rule that disallows same individuals to be included within a defined period of time;

producing the requested information that characterizes the group, an identity of the individuals being unattainable from the produced information; and

providing the produced medical information to report the characteristics of the group of individuals absent authorization from the individuals in the group of individuals identified in the request containing identifying data.

8. (Previously Presented) The system of claim 7, wherein the provided information is medical data in conformity with the Health Insurance Portability and Accountability Act (HIPAA).

9. (Previously Presented) The system of claim 7, wherein the request for information that characterizes a group of individuals includes personally identifiable information associated with the individuals of the group.

10. (Original) The system of claim 7, in which the data that identifies each individual is encrypted.

11. (Previously Presented) The system of claim 7, in which the tokens associated with the data and the request tokens are similarly encrypted.

12. (Previously Presented) The system of claim 7, in which producing the requested information includes determining if the group includes at least a minimum number of individuals.

13. (Previously Presented) The system of claim 7, in which the data represents medical-related information associated with the individuals of the group.

14. (Currently Amended) One or more computer readable storage devices storing instructions that are executable by a processing device, and upon such execution cause the processing device to perform operations comprising:

Art Unit: 2493

receiving a request from a user device for information that characterizes a group composed of multiple individuals from a set of de-identified data representing characteristics of the individuals pre-or post-encounter with a healthcare facility, wherein the request contains identifying data for each member in the group of multiple individuals who have had an encounter with a healthcare facility;

producing, by a hardware processor, a request token for each individual included in the group of individuals;

comparing the request tokens to tokens associated with the medical data to find matching tokens and to determine whether the group includes at least a minimum number of individuals to be included in a report in response to the request, wherein the minimum number of individuals are selected according to at least a privacy-preserving rule that disallows same individuals to be included within a defined period of time;

producing the requested information that characterizes the group, an identity of the individuals being unattainable from the produced information; and

providing the produced medical information to report the characteristics of the group of individuals absent authorization from the individuals in the group of individuals identified in the request containing identifying data.

15. (Previously Presented) The computer readable storage devices of claim 14, wherein the provided information is medical data in conformity with the Health Insurance Portability and Accountability Act (HIPAA).

16. (Previously Presented) The computer readable storage devices of claim 14, wherein receiving the request for information that characterizes the group of individuals includes receiving personally identifiable information associated with the individuals of the group.

17. (Previously Presented) The computer readable storage devices of claim 14, in which producing the requested information includes encrypting respective data that identifies each individual.

Art Unit: 2493

18. (Original) The computer readable storage devices of claim 14, in which the tokens associated with the medical data and the request tokens are similarly encrypted.

19. (Previously Presented) The computer readable storage devices of claim 14, in which the data represents medical-related information associated with the individuals of the group.

20. (Previously Presented) The computer readable storage devices of claim 14, in which producing the requested information includes determining if the group includes at least a minimum number of individuals.

Allowable Subject Matter

Claims 1-20 are allowed.

All previous rejections and objections are withdrawn.

This communication warrants no examiner's reason for allowance, as applicant's reply makes evident the reason for allowance, satisfying the record as whole as required by rule 37 CFR 1.104 (e). In this case, the substance of applicant's remarks in the Amendment/Remarks filed on 10/16/2017 and the clarification of claim language entered by Examiner's Amendment on 12/15/2017 point out the reason claims are patentable and non-obvious over the prior art of record. Thus, the reason for allowance is in all probability evident from the record and no statement for examiner's reason for allowance is necessary (see MPEP 1302.14).

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to DON ZHAO whose telephone number is (571)272-9953. The examiner can normally be reached on Monday ~ Friday, 7:30 A.M ~ 5:00 P.M EST ALT FRIDAY.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Carl G. Colin can be reached on (571) 272-3862. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Don Zhao/
Primary Examiner, Art Unit 2493
12/22/2017

Issue Classification 	Application/Control No. 15606265	Applicant(s)/Patent Under Reexamination PARIS, ANDREW L.
	Examiner DON ZHAO	Art Unit 2493

CPC						
Symbol					Type	Version
G06F		21	/	6254	F	2013-01-01
G06F		19	/	322	I	2013-01-01
G06F		19	/	325	I	2013-01-01
G06Q		50	/	24	I	2013-01-01
H04L		63	/	0428	I	2013-01-01
			/			
			/			
			/			
			/			
			/			
			/			
			/			
			/			
			/			
			/			
			/			

CPC Combination Sets					
Symbol		Type	Set	Ranking	Version

NONE		Total Claims Allowed: 20	
(Assistant Examiner)	(Date)		
/DON ZHAO/ Primary Examiner.Art Unit 2493	12/22/2017	O.G. Print Claim(s) 1	O.G. Print Figure FIG. 3
(Primary Examiner)	(Date)		

Issue Classification 	Application/Control No. 15606265	Applicant(s)/Patent Under Reexamination PARIS, ANDREW L.
	Examiner DON ZHAO	Art Unit 2493

☒ Claims renumbered in the same order as presented by applicant ☐ CPA ☐ T.D. ☐ R.1.47															
Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original
	1		17												
	2		18												
	3		19												
	4		20												
	5														
	6														
	7														
	8														
	9														
	10														
	11														
	12														
	13														
	14														
	15														
	16														

NONE	Total Claims Allowed: 20	
(Assistant Examiner)	(Date)	
/DON ZHAO/ Primary Examiner.Art Unit 2493	12/22/2017	O.G. Print Claim(s) 1
(Primary Examiner)	(Date)	O.G. Print Figure FIG. 3

Search Notes 	Application/Control No. 15606265	Applicant(s)/Patent Under Reexamination PARIS, ANDREW L.
	Examiner DON ZHAO	Art Unit 2493

CPC- SEARCHED		
Symbol	Date	Examiner
G06F19/322, G06F19/366, G06Q50/22, G06F21/6245	7/10/2017	DZ
G06F19/322, G06F19/325, G06F19/366, G06Q50/22, G06Q50/24, G06F21/6245, H04L63/0428	12/22/2017	DZ

CPC COMBINATION SETS - SEARCHED		
Symbol	Date	Examiner

US CLASSIFICATION SEARCHED			
Class	Subclass	Date	Examiner

* See search history printout included with this form or the SEARCH NOTES box below to determine the scope of the search.

SEARCH NOTES		
Search Notes	Date	Examiner
EAST Searches include CPC, KWIC, keyword searches incombination with CPC,and inventor searches. No double patenting found.	7/10/2017	DZ
NPL searches using GOOGLE.See attached search note printout(s).	7/17/2017	DZ
Updated EAST Searches include CPC, KWIC, keyword searches incombination with CPC,and inventor searches. No double patenting found with added limitations.	12/22/2017	DZ
EAST Interference Searches of CPC and inventor names with text Search. No double patenting found.	12/22/2017	DZ
NPL searches using GOOGLE.See attached search note printout(s).	12/22/2017	DZ

INTERFERENCE SEARCH

	/DON ZHAO/ Primary Examiner.Art Unit 2493
--	--

US Class/ CPC Symbol	US Subclass / CPC Group	Date	Examiner
G06	F19/322, F19/325, F19/366, Q50/22, Q50/24, F21/6245	12/22/2017	DZ
H04	L63/0428	12/22/2017	DZ

	/DON ZHAO/ Primary Examiner.Art Unit 2493
--	--

Features and uses of high-fidelity **medical** simulations that lead to effective learning: a BEME systematic review

S Barry Issenberg, WC McGaghie, ER Petrusa... - **Medical ...**, 2005 - Taylor & Francis

... Third, to **create** a culture of best evidence **medical** education among teachers, administrators, educational institutions, and national and international organizations ... The question was used to **generate** ... The pilot literature search **generated** approximately 200 references ...

☆  Cited by 2451 Related articles All 22 versions

Preferred **reporting** items for systematic reviews and meta-analyses: the PRISMA statement

..., A Liberati, J Tetzlaff, DG Altman, Prisma Group - ... **medicine**, 2009 - journals.plos.org

... assessment of serious harms [39], which may rely on spontaneous **reports** by investigators ... Institute (Ottawa, Canada); Cynthia Mulrow, MD, MSc, Annals of Internal **Medicine** (Philadelphia, Pennsylvania, US); Maryann Napoli, Center for **Medical** Consumers (New ...

☆  Cited by 28083 Related articles All 41 versions 

CONSORT 2010 statement: updated guidelines for **reporting** parallel group randomised trials

KF Schulz, DG Altman, D Moher - BMC **medicine**, 2010 - bmcmedicine.biomedcentral.com

... Randomisation: Sequence **generation**. 8a. Method used to **generate** the random allocation sequence. 8b ... Implementation. 10. Who **generated** the random allocation sequence, who enrolled participants, and who assigned participants to interventions. Blinding. 11a ...

☆  Cited by 8565 Related articles All 111 versions 

Improving the **reporting** quality of nonrandomized evaluations of behavioral and public health interventions: the TREND statement

..., C Lyies, N Crepaz, TREND Group - American journal of ..., 2004 - ajph.aphapublications.org

... 2). Behavioral and social science theories provide a framework for **generating** cumulative knowledge ... expanding, research synthesis becomes an important tool for **creating** a cumulative ... Furthermore, page limitations in many journals **create** strong pressure toward shorter rather ...

☆  Cited by 1183 Related articles All 12 versions 

The brief symptom inventory: an introductory **report**

LR Derogatis, N Melisaratos - Psychological **medicine**, 1983 - cambridge.org

... four treatment facilities: (1) the Out-patient Psychiatry Division of the Johns Hopkins **Medical** Institutions; (2 ... and (4) the Out-patient Psychiatry Division of the University of Wisconsin School of **Medicine** ... The stability coefficients listed in Table 3 were **generated** from BSI data on a ...

☆  Cited by 5591 Related articles All 11 versions 

The feasibility of **creating** a checklist for the assessment of the methodological quality both of randomised and non-randomised **studies** of health care interventions.

SH Downs, N Black - Journal of Epidemiology & Community Health, 1998 - jech.bmj.com

... 5 6 The objective of this study was to test the feasibility of **creating** a valid ... 1 Rosenberg W, Donald A. Evidence based **medicine**: an approach to clinical problem-solving ... 8 Colditz GA, Miller JN, Mosteller F. How study design affects outcomes in comparisons of therapy I: **medical** ...

☆  Cited by 3594 Related articles All 13 versions 

Consolidated criteria for **reporting** qualitative research (COREQ): a 32-item checklist for interviews and focus **groups**

A Tong, P Sainsbury, J Craig - ... journal for quality in health care, 2007 - academic.oup.com

... in COREQ, a 32-item checklist, can help researchers to **report** important aspects ... CONSORT statement is associated with improvements in the quality of **reports** of randomized ... Submitted to Biomedical Journals published by the International Committee of **Medical** Journal Editors ...

☆  Cited by 3113 Related articles All 35 versions 

Physical status: The use of and interpretation of anthropometry, **Report** of a WHO Expert Committee

World Health Organization - 1995 - apps.who.int

... Geneva, Switzerland, which will be glad to provide the latest **information** on any ... Rapporteur) Dr C. Victora, Department of Social **Medicine**, Faculty of **Medicine**, Federal University of ... Public Health Institute, Helsinki, Finland (Temporary Adviser) Dr J. Villar, **Medical** Officer, Special ...

☆ 77 Cited by 7553 Related articles All 4 versions 77

Meta-analysis of observational **studies** in epidemiology: a proposal for **reporting**

DF Stroup, JA Berlin, SC Morton, I Olkin... - Jama, 2000 - jamanetwork.com

... All Rights Reserved. Access Provided by Google Scholar. JAMA. Sign In. **Individual** Sign In.

Sign in**Create** an Account. JAMA Network ... Lang TA, Secic M. How to **Report** Statistics in **Medicine** ...

Cole MG, Bellavance F. Depression in elderly **medical** inpatients ...

☆ 77 Cited by 9719 Related articles All 44 versions

Receiver-operating **characteristic** (ROC) plots: a fundamental evaluation tool in clinical **medicine**.

MH Zweig, G Campbell - Clinical chemistry, 1993 - clinchem.aaccjnls.org

... plots **generated**, numerous other assessments, compari ... it (7), and eventually ROC analysis made its way into other areas of **medicine** ... will not submit to it. We note that exploration of the usefulness of **medical information**, such as test data, involves many factors or ...

☆ 77 Cited by 5742 Related articles All 12 versions

EAST Search History

EAST Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	0	15/606265.APP.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 15:50
L3	125532	(G06F19/322 G06F19/325 G06F19/366 G06Q50/22 G06Q50/24 G06F21/6245 H04L63/0428).CPC.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2017/12/22 16:09
L6	6889	(Rawlings NEAR3 Jean Anderson NEAR3 David Kraus NEAR3 Carl Paris NEAR3 Andrew).INV.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L7	31	L6 AND ((report\$3) near11 (encounter characteristics group))	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L8	1	14/082433.app.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L9	29157	(G06F19/322 G06F19/366 G06Q50/22 G06F21/6245).CPC.	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L10	2374	L9 AND ((report\$3) near11 (encounter characteristics group))	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L11	2	L10 AND ((non?identifiable de\$1identified) near4 (medical healthcare)) same token	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L12	2	L10 AND ((non?identifiable de\$1identified) near2 (medical healthcare)) same token	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L13	2	L10 AND ((non?identifiable de\$1identified) adj2 (data information) with (medical healthcare)) same token	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L14	2253	L10 AND ((report\$3) near11 (encounter characteristics group)) AND (Medical health healthcare)	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L15	2	L10 and (non\$1identified de\$1identified) and authorization near3 absent	US-PGPUB; USPAT; USOCR;	OR	ON	2017/12/22 16:10

			FPRS; EPO; JPO; IBM_TDB			
L16	29157	(G06F19/322 G06F19/366 G06Q50/22 G06F21/6245).CPC.	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L17	6889	(Rawlings NEAR3 Jean Anderson NEAR3 David Kraus NEAR3 Carl Paris NEAR3 Andrew).INV.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L18	17	L16 AND L6	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L19	14629	726/2,7,9,17,19.ccls.	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L20	4	726/2,7,9,17,19.ccls. AND L6	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L21	0	L16 AND (MEDICAL with (report) same (medical adj provider adj identifier))	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L22	2374	L16 AND ((report\$3) near11 (encounter characteristics group))	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L23	8	L6 AND ((report\$3) near11 (encounter characteristics group)) AND (Medical health healthcare)	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L24	3	(MEDICAL with (information report) same (medical adj provider adj identifier))	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L25	22	(MEDICAL with (information report) same (medical adj3 provider adj3 identifier))	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L26	1	14/082433.app.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L27	11	((Andrew) near2 (Paris)).INV.	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L28	6889	(Rawlings NEAR3 Jean Anderson NEAR3 David Kraus NEAR3 Carl Paris NEAR3 Andrew).INV.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L29	1	12/827745.APP.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO;	OR	ON	2017/12/22 16:10

			IBM_TDB			
L30	760	group near3 (private individual patients) with medical near3 (information record encounter\$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L31	12	L28 and L30	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L32	10	L31 and @ad<"20121121"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L33	6	L31 and @pd<"20121121"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L34	50	INGENIX.AS.	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L35	7	L30 AND INGENIX.AS.	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L36	7	L35 and @ad<"20121121"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L37	7	L35 and @PD<"20121121"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L38	1	L35 and @PD<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L39	1	L35 and @PD<"20090701" and (group near5 (patients or health near3 members))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L40	17	L28 and @PD<"20090701" and (group near5 (patients or health near3 members))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO;	OR	ON	2017/12/22 16:10

			IBM_TDB			
L41	229	L30 and @PD<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L42	183	L41 and (group near5 (patients or health near3 members))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L43	179	L41 and (group near5 (patients or health near3 members)) WITH (medical near5 (information record))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L44	2	(encrypted with (provider adj identifier\$1)) same match\$3 and database	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L45	89	("20030097358" "20040199781" "20050256740" "20050256741" "20050268094" "3752904" "5471382" "5652842" "5664109" "5704044" "5724575" "5754938" "5793969" "5890129" "6012051" "6079021" "6249768" "6302844" "7376677" "20050065912" "20050256742" "20060026156" "5301105" "5606610" "5666492" "5799086" "5799308" "5821871" "5823948" "5926810" "6085322" "6449621" "6732113" "6915265" "20020198473" "20050165623" "20080147554" "20100217973" "5758085" "5832449" "5915240" "5961593" "5991731" "5995939" "6266675" "7184947" "3896266" "4979832" "4993068" "5003539" "5825906" "5956716" "6496931" "7386526" "5005200" "5070452" "5299121" "5758095" "5867821" "5970462" "6014631" "7200578" "20050027564" "20050234740" "20050236474" "20100114607" "5214702" "5371797" "5644778" "6317700" "6397224" "6421650" "6654724" "20040215981" "5502764" "5581749" "5787186" "5876926" "5907677" "5918208" "5920854" "6018713" "20080091474" "6003006" "6024287" "6341267" "6734886" "7309001" "20020143434").PN.	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L46	802	database and (APK ANONYMOUS\$2 adj Practitioner adj identifier)	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L47	660	(associat\$3 cross?reference\$1) same de?identified	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10

L48	185	de?identif\$3 and provider near2 (credential or identification\$1 or identifier\$1 or ID or certificate or passport descriptor)	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L49	32	(US-20080147554-\$ or US-20020016923-\$ or US-20070130465-\$ or US-20080306872-\$ or US-20080304663-\$ or US-20080133273-\$ or US-20080040151-\$ or US-20050267782-\$ or US-20050119941-\$ or US-20060020611-\$ or US-20070185737-\$ or US-20060004772-\$ or US-20080120296-\$ or US-20080010254-\$ or US-20040078236-\$ or US-20090287502-\$ or US-20080281631-\$ or US-20080137848-\$ or US-20110255690-\$ or US-20070033419-\$ or US-20120246661-\$ or US-20090257586-\$).did. or (US-5721777-\$ or US-8296341-\$ or US-6302844-\$ or US-6874085-\$ or US-8037052-\$ or US-7716487-\$ or US-6947561-\$ or US-8131646-\$ or US-8055910-\$ or US-8108355-\$).did.	US-PGPUB; USPAT	OR	ON	2017/12/22 16:10
L50	165	(random adj3 sequence) and frame with block and portion with key	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L51	2	12/684748.APP.	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L52	1	L51 and (unencrypted near3 (medical adj provider adj identifier))	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L53	1	L52	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L54	183	L41 and (group near5 (patients or health near3 members))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L55	152357	G06F19\$.CPC.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L56	464	L30 AND G06F19\$.CPC.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L57	1	L29 AND G06F19\$.CPC.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10

L58	118	L28 AND G06F19\$.CPC.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L59	20439	G06F19/322.CPC.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L60	3941	G06F19/366.CPC.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L61	75	G06F19/322.CPC. AND (de?identif\$3 and provider near2 (credential or identification\$1 or identifier\$1 or ID or certificate or passport descriptor))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L62	0	L60 AND L61	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L63	0	G06F19/366.CPC. AND de?identif\$3 and provider near2 (credential or identification\$1 or identifier\$1 or ID or certificate or passport descriptor)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L64	28	G06F19/366.CPC. AND de?identif\$3	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L65	0	L61 AND L64	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L66	6	L61 and @PD<"20090701" and (group near5 (patients or health near3 members))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L67	7	L64 and @PD<"20090701" and (group near5 (patients or health near3 members))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10

L68	2	G06F19/322.CPC. and (encrypted near3 (medical adj provider adj identifier))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L69	46	(US-20080147554-\$ or US-20020016923-\$ or US-20070130465-\$ or US-20080306872-\$ or US-20080304663-\$ or US-20080133273-\$ or US-20080040151-\$ or US-20050267782-\$ or US-20050119941-\$ or US-20060020611-\$ or US-20070185737-\$ or US-20060004772-\$ or US-20080120296-\$ or US-20080010254-\$ or US-20040078236-\$ or US-20090287502-\$ or US-20080281631-\$ or US-20080137848-\$ or US-20110255690-\$ or US-20070033419-\$ or US-20120246661-\$ or US-20090257586-\$ or US-20100325148-\$ or US-20100287190-\$ or US-20080306952-\$ or US-20070219824-\$).did. or (US-20070106753-\$ or US-20070106752-\$ or US-20060089857-\$ or US-20070192140-\$ or US-20050177050-\$ or US-20100217973-\$).did. or (US-5721777-\$ or US-8296341-\$ or US-6302844-\$ or US-6874085-\$ or US-8037052-\$ or US-7716487-\$ or US-6947561-\$ or US-8131646-\$ or US-8055910-\$ or US-8108355-\$).did. or (WO-2010129653-\$ or CA-2760773-\$ or WO-2007108814-\$).did. or (WO-2010129653-\$).did.	US-PGPUB; USPAT; FPRS; EPO	OR	ON	2017/12/22 16:10
L70	20	L69 AND G06F19/322.CPC.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L71	10	L70 and @PD<"20090701" and (group near5 (patients or health near3 members))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L72	5	L66 AND L71	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L73	1	726/09	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L74	2597	726/9.ccls.	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L75	3	L74 and @PD<"20090701" and (group near5 (patients or health near3	US-PGPUB; USPAT;	OR	ON	2017/12/22 16:10

		members))	USOCR; FPRS; EPO; JPO; IBM_TDB			
L76	1	L28 and 726/9.ccls.	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L77	0	L30 and 726/9.ccls.	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L78	26	L30 and "726".clas.	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L79	6	L78 AND G06F19/322.CPC.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L80	1	L79 and @PD<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L81	1	("20060184524" "20110258000").PN. AND G06F19/322.CPC.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L82	8655	726/26.CCLS.	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L83	0	L66 AND 726/26.CCLS.	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L84	2	L30 AND 726/26.CCLS.	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L85	2	L49 AND 726/26.CCLS.	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L86	55	(US-20080147554-\$ or US- 20020016923-\$ or US-20070130465-\$ or US-20080306872-\$ or US- 20080304663-\$ or US-20080133273-\$ or US-20080040151-\$ or US- 20050267782-\$ or US-20050119941-\$ or US-20060020611-\$ or US- 20070185737-\$ or US-20060004772-\$ or US-20080120296-\$ or US- 20080010254-\$ or US-20040078236-\$ or US-20090287502-\$ or US- 20080281631-\$ or US-20080137848-\$ or US-20110255690-\$ or US- 20070033419-\$ or US-20120246661-\$ or US-20090257586-\$ or US- 20100325148-\$ or US-20100287190-\$ or US-20080306952-\$ or US-	US-PGPUB; USPAT; FPRS; EPO	OR	ON	2017/12/22 16:10

		20070219824-\$).did. or (US-20070106753-\$ or US-20070106752-\$ or US-20060089857-\$ or US-20070192140-\$ or US-20050177050-\$ or US-20100217973-\$ or US-20070043594-\$ or US-20030154405-\$ or US-20080071577-\$ or US-20100162355-\$ or US-20060184524-\$).did. or (US-5721777-\$ or US-8296341-\$ or US-6302844-\$ or US-6874085-\$ or US-8037052-\$ or US-7716487-\$ or US-6947561-\$ or US-8131646-\$ or US-8055910-\$ or US-8108355-\$ or US-7900245-\$ or US-8229742-\$ or US-7650628-\$ or US-5956400-\$).did. or (WO-2010129653-\$ or CA-2760773-\$ or WO-2007108814-\$).did. or (WO-2010129653-\$).did.				
L87	15	L86 and pharmac\$3	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L88	8	L86 and pharmac\$3 and encrypt\$3 with (id identifier token)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L89	4	L88 and (id identifier token) near5 (compar\$3 comparison match\$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L90	3	L88 and (id identifier token) near5 (compar\$3 comparison)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L91	3	L88 and (id identifier token) near5 (match\$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L92	2	L90 and L91	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L93	1	L91 NOT L92	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L94	22	L86 and PRODUC\$3 near3 information	US-PGPUB;	OR	ON	2017/12/22

			USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB			16:10
L95	9	L94 and (id identifier token) near5 (compar\$3 comparison match\$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L96	2	L92 and (id identifier token) near5 (compar\$3 comparison match\$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L97	8	L86 and (produce producing provid\$3) adj3 medical adj3 information	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L98	2	L89 and L97	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L99	2	L98 and (pharmac\$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L100	2	L98 and (pharmac\$3) and (visit\$3 encounter\$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L101	1	L98 and (pharmac\$3) and (visit\$3 and encounter\$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L102	1	L98 and (pharmac\$3) and (encounter\$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L103	1	L98 and (pharmac\$3) and (encounter\$3) and (medical center)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L104	1	L98 and (pharmac\$3) and	US-PGPUB;	OR	ON	2017/12/22

		(encounter\$3) and (institution)	USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB			16:10
L105	4	L89 and (unattain\$4 attain\$4 obtain\$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L106	1	L89 and (unattain\$4 attain\$4 obtain\$3) with pharmac\$3	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L107	1	L89 and health adj2 record	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L108	1	L89 and de-identifi\$3	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L109	14	L86 and de-identifi\$3 with record	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L110	5	L86 and de-identifi\$3 with record and pharmac\$4	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L111	20	L86 and de-identifi\$3	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L112	2	("20080133273" "20090287502").pn. and request\$3	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L113	1	("20080133273" "20090287502").pn. and (compar\$3 match\$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L114	32423	("20080133273" "20090287502").pn.	US-PGPUB;	OR	ON	2017/12/22

		encrypt\$3 WITH ID	USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB			16:10
L115	2	("20080133273" "20090287502").pn. AND encrypt\$3 WITH ID	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L116	1	("20080133273").pn. AND encrypt\$3 WITH ID	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L117	1	("20080133273" "20090287502").pn. and minimum	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L118	55	(US-20080147554-\$ or US- 20020016923-\$ or US-20070130465-\$ or US-20080306872-\$ or US- 20080304663-\$ or US-20080133273-\$ or US-20080040151-\$ or US- 20050267782-\$ or US-20050119941-\$ or US-20060020611-\$ or US- 20070185737-\$ or US-20060004772-\$ or US-20080120296-\$ or US- 20080010254-\$ or US-20040078236-\$ or US-20090287502-\$ or US- 20080281631-\$ or US-20080137848-\$ or US-20110255690-\$ or US- 20070033419-\$ or US-20120246661-\$ or US-20090257586-\$ or US- 20100325148-\$ or US-20100287190-\$ or US-20080306952-\$ or US- 20070219824-\$).did. or (US- 20070106753-\$ or US-20070106752-\$ or US-20060089857-\$ or US- 20070192140-\$ or US-20050177050-\$ or US-20100217973-\$ or US- 20070043594-\$ or US-20030154405-\$ or US-20080071577-\$ or US- 20100162355-\$ or US-20060184524-\$).did. or (US-5721777-\$ or US- 8296341-\$ or US-6302844-\$ or US- 6874085-\$ or US-8037052-\$ or US- 7716487-\$ or US-6947561-\$ or US- 8131646-\$ or US-8055910-\$ or US- 8108355-\$ or US-7900245-\$ or US- 8229742-\$ or US-7650628-\$ or US- 5956400-\$).did. or (WO-2010129653-\$ or CA-2760773-\$ or WO-2007108814-\$).did. or (WO-2010129653-\$).did.	US-PGPUB; USPAT; FPRS; EPO	OR	ON	2017/12/22 16:10
L119	5	L118 and number with match	US-PGPUB; USPAT; USOCR; FPRS;	OR	ON	2017/12/22 16:10

			EPO; JPO; IBM_TDB			
L120	2	("20080133273" "20090287502").pn. AND portion	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L121	4	("20080133273" "20090287502" "20060020611").pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L122	2	L121 AND number near6 (patients users individuals)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L123	2	L121 AND group near6 (patients users individuals)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L124	1	L121 AND group near6 (patients users individuals) with number	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L125	55	(US-20080147554-\$ or US- 20020016923-\$ or US-20070130465-\$ or US-20080306872-\$ or US- 20080304663-\$ or US-20080133273-\$ or US-20080040151-\$ or US- 20050267782-\$ or US-20050119941-\$ or US-20060020611-\$ or US- 20070185737-\$ or US-20060004772-\$ or US-20080120296-\$ or US- 20080010254-\$ or US-20040078236-\$ or US-20090287502-\$ or US- 20080281631-\$ or US-20080137848-\$ or US-20110255690-\$ or US- 20070033419-\$ or US-20120246661-\$ or US-20090257586-\$ or US- 20100325148-\$ or US-20100287190-\$ or US-20080306952-\$ or US- 20070219824-\$).did. or (US- 20070106753-\$ or US-20070106752-\$ or US-20060089857-\$ or US- 20070192140-\$ or US-20050177050-\$ or US-20100217973-\$ or US- 20070043594-\$ or US-20030154405-\$ or US-20080071577-\$ or US- 20100162355-\$ or US-20060184524-\$).did. or (US-5721777-\$ or US- 8296341-\$ or US-6302844-\$ or US- 6874085-\$ or US-8037052-\$ or US- 7716487-\$ or US-6947561-\$ or US- 8131646-\$ or US-8055910-\$ or US-	US-PGPUB; USPAT; FPRS; EPO	OR	ON	2017/12/22 16:10

		8108355-\$ or US-7900245-\$ or US-8229742-\$ or US-7650628-\$ or US-5956400-\$).did. or (WO-2010129653-\$ or CA-2760773-\$ or WO-2007108814-\$).did. or (WO-2010129653-\$).did.				
L126	10	L125 AND group near6 (patients users individuals) with number	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L127	2	L125 AND group near6 number NEAR5 (patients users individuals)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L128	7	L125 AND (LEAST MINIMUM) near3 number	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L129	657	medical same de-identified	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L130	790	medical same de-identifi\$6	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L131	1169	medical near4 (information database record) and de-identifi\$6	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L132	13	L131 AND (MINIMUM) adj2 number with group	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L133	43	L131 AND (MINIMUM) with group	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L134	287	(MINIMUM) near3 number near3 (individual users) with group	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L135	68	L134 and (medical healthcare)	US-PGPUB;	OR	ON	2017/12/22

			USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB			16:10
L136	6	L135 and @pd<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L137	16	L135 and @ad<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L138	1	("20080133273").pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L139	4	"20080133273" "20090287502"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L140	1	L139 and de?identif\$3	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L141	2	L139 and identif\$3	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L142	1	L139 and identif\$3 and group	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L143	1	L139 and identif\$3 same group	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L144	57	(US-20080147554-\$ or US- 20020016923-\$ or US-20070130465-\$ or US-20080306872-\$ or US- 20080304663-\$ or US-20080133273-\$ or US-20080040151-\$ or US- 20050267782-\$ or US-20050119941-\$ or US-20060020611-\$ or US- 20070185737-\$ or US-20060004772-\$	US-PGPUB; USPAT; FPRS; EPO	OR	ON	2017/12/22 16:10

		or US-20080120296-\$ or US-20080010254-\$ or US-20040078236-\$ or US-20090287502-\$ or US-20080281631-\$ or US-20080137848-\$ or US-20110255690-\$ or US-20070033419-\$ or US-20120246661-\$ or US-20090257586-\$ or US-20100325148-\$ or US-20100287190-\$ or US-20080306952-\$ or US-20070219824-\$).did. or (US-20070106753-\$ or US-20070106752-\$ or US-20060089857-\$ or US-20070192140-\$ or US-20050177050-\$ or US-20100217973-\$ or US-20070043594-\$ or US-20030154405-\$ or US-20080071577-\$ or US-20100162355-\$ or US-20060184524-\$ or US-20110231422-\$ or US-20040143403-\$).did. or (US-5721777-\$ or US-8296341-\$ or US-6302844-\$ or US-6874085-\$ or US-8037052-\$ or US-7716487-\$ or US-6947561-\$ or US-8131646-\$ or US-8055910-\$ or US-8108355-\$ or US-7900245-\$ or US-8229742-\$ or US-7650628-\$ or US-5956400-\$).did. or (WO-2010129653-\$ or CA-2760773-\$ or WO-2007108814-\$).did. or (WO-2010129653-\$).did.				
L145	4	L144 and authorization with absent	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L146	7	medical with authorization near3 absent	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L147	10	(non\$1identified de\$1identified) and authorization near3 absent	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L148	10	(non\$1identified de\$1identified) and authorization near3 absent and group	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L149	11	((Andrew) near2 (Paris)).INV.	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L150	6889	(Rawlings NEAR3 Jean Anderson NEAR3 David Kraus NEAR3 Carl Paris NEAR3 Andrew).INV.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L151	1	12/827745.APP.	US-PGPUB;	OR	ON	2017/12/22

			USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB			16:10
L152	760	group near3 (private individual patients with medical near3 (information record encounter\$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L153	12	L150 and L152	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L154	10	L153 and @ad<"20121121"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L155	6	L153 and @pd<"20121121"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L156	50	INGENIX.AS.	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L157	7	L152 AND INGENIX.AS.	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L158	1	L157 and @PD<"20090701" and (group near5 (patients or health near3 members))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L159	17	L150 and @PD<"20090701" and (group near5 (patients or health near3 members))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L160	229	L152 and @PD<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L161	183	L160 and (group near5 (patients or health near3 members))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L162	179	L160 and (group near5 (patients or	US-PGPUB;	OR	ON	2017/12/22

		health near3 members)) WITH (medical near5 (information record))	USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB			16:10
L163	2	(encrypted with (provider adj identifier\$1)) same match\$3 and database	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L164	89	("20030097358" "20040199781" "20050256740" "20050256741" "20050268094" "3752904" "5471382" "5652842" "5664109" "5704044" "5724575" "5754938" "5793969" "5890129" "6012051" "6079021" "6249768" "6302844" "7376677" "20050065912" "20050256742" "20060026156" "5301105" "5606610" "5666492" "5799086" "5799308" "5821871" "5823948" "5926810" "6085322" "6449621" "6732113" "6915265" "20020198473" "20050165623" "20080147554" "20100217973" "5758085" "5832449" "5915240" "5961593" "5991731" "5995939" "6266675" "7184947" "3896266" "4979832" "4993068" "5003539" "5825906" "5956716" "6496931" "7386526" "5005200" "5070452" "5299121" "5758095" "5867821" "5970462" "6014631" "7200578" "20050027564" "20050234740" "20050236474" "20100114607" "5214702" "5371797" "5644778" "6317700" "6397224" "6421650" "6654724" "20040215981" "5502764" "5581749" "5787186" "5876926" "5907677" "5918208" "5920854" "6018713" "20080091474" "6003006" "6024287" "6341267" "6734886" "7309001" "20020143434").PN.	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L165	802	database and (APK ANONYMOUS\$2 adj Practitioner adj identifier)	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L166	660	(associat\$3 cross?reference\$1) same de?identified	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L167	185	de?identif\$3 and provider near2 (credential or identification\$1 or identifier\$1 or ID or certificate or passport descriptor)	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L168	32	(US-20080147554-\$ or US- 20020016923-\$ or US-20070130465-\$ or US-20080306872-\$ or US- 20080304663-\$ or US-20080133273-\$ or US-20080040151-\$ or US- 20050267782-\$ or US-20050119941-\$ or US-20060020611-\$ or US- 20070185737-\$ or US-20060004772-\$ or US-20080120296-\$ or US- 20080010254-\$ or US-20040078236-\$	US-PGPUB; USPAT	OR	ON	2017/12/22 16:10

		or US-20090287502-\$ or US-20080281631-\$ or US-20080137848-\$ or US-20110255690-\$ or US-20070033419-\$ or US-20120246661-\$ or US-20090257586-\$).did. or (US-5721777-\$ or US-8296341-\$ or US-6302844-\$ or US-6874085-\$ or US-8037052-\$ or US-7716487-\$ or US-6947561-\$ or US-8131646-\$ or US-8055910-\$ or US-8108355-\$).did.				
L169	165	(random adj3 sequence) and frame with block and portion with key	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L170	2	12/684748.APP.	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L171	183	L160 and (group near5 (patients or health near3 members))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L172	152357	G06F19\$.CPC.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L173	464	L152 AND G06F19\$.CPC.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L174	118	L150 AND G06F19\$.CPC.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L175	20439	G06F19/322.CPC.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L176	3941	G06F19/366.CPC.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L177	75	G06F19/322.CPC. AND (de?identif\$3 and provider near2 (credential or identification\$1 or identifier\$1 or ID or certificate or passport descriptor))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L178	28	G06F19/366.CPC. AND de?identif\$3	US-PGPUB; USPAT;	OR	ON	2017/12/22 16:10

			USOCR; FPRS; EPO; JPO; IBM_TDB			
L179	0	L177 AND L178	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L180	75	G06F19/322.CPC. AND (de?identif\$3 and provider near2 (credential or identification\$1 or identifier\$1 or ID or certificate or passport descriptor))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L181	6	L177 and @PD<"20090701" and (group near5 (patients or health near3 members))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L182	1	726/09	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L183	2597	726/9.ccls.	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L184	3	L183 and @PD<"20090701" and (group near5 (patients or health near3 members))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L185	1	L150 and 726/9.ccls.	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L186	0	L152 and 726/9.ccls.	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L187	26	L152 and "726".clas.	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L188	6	L187 AND G06F19/322.CPC.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L189	1	L188 and @PD<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L190	1	("20060184524" "20110258000").PN. AND G06F19/322.CPC.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO;	OR	ON	2017/12/22 16:10

			IBM_TDB			
L191	8655	726/26.CCLS.	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L192	0	L181 AND 726/26.CCLS.	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L193	2	L152 AND 726/26.CCLS.	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L194	2	L168 AND 726/26.CCLS.	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L195	55	(US-20080147554-\$ or US-20020016923-\$ or US-20070130465-\$ or US-20080306872-\$ or US-20080304663-\$ or US-20080133273-\$ or US-20080040151-\$ or US-20050267782-\$ or US-20050119941-\$ or US-20060020611-\$ or US-20070185737-\$ or US-20060004772-\$ or US-20080120296-\$ or US-20080010254-\$ or US-20040078236-\$ or US-20090287502-\$ or US-20080281631-\$ or US-20080137848-\$ or US-20110255690-\$ or US-20070033419-\$ or US-20120246661-\$ or US-20090257586-\$ or US-20100325148-\$ or US-20100287190-\$ or US-20080306952-\$ or US-20070219824-\$).did. or (US-20070106753-\$ or US-20070106752-\$ or US-20060089857-\$ or US-20070192140-\$ or US-20050177050-\$ or US-20100217973-\$ or US-20070043594-\$ or US-20030154405-\$ or US-20080071577-\$ or US-20100162355-\$ or US-20060184524-\$).did. or (US-5721777-\$ or US-8296341-\$ or US-6302844-\$ or US-6874085-\$ or US-8037052-\$ or US-7716487-\$ or US-6947561-\$ or US-8131646-\$ or US-8055910-\$ or US-8108355-\$ or US-7900245-\$ or US-8229742-\$ or US-7650628-\$ or US-5956400-\$).did. or (WO-2010129653-\$ or CA-2760773-\$ or WO-2007108814-\$).did. or (WO-2010129653-\$).did.	US-PGPUB; USPAT; FPRS; EPO	OR	ON	2017/12/22 16:10
L196	15	L195 and pharmac\$3	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L197	8	L195 and pharmac\$3 and encrypt\$3 with (id identifier token)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L198	4	L197 and (id identifier token) near5	US-PGPUB;	OR	ON	2017/12/22

		(compar\$3 comparison match\$3)	USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB			16:10
L199	0	L197 and (id identifier token) near5 (compar\$3 comparison match\$3) same group	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L200	0	L197 and (id identifier token) near5 (compar\$3 comparison match\$3) same set	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L201	3	L197 and (id identifier token) near5 (compar\$3 comparison)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L202	3	L197 and (id identifier token) near5 (match\$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L203	2	L201 and L202	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L204	13084	L182 L183 L184 "s661" "s662" L185 L186 L187 "s666" L188 L189 L190 L191 L192 L193 "s673" L194 L195 L196 L197 L198 L199 L200 L201 L202 L203	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L205	10078	726/7,9,17,19.ccls.	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L206	1	L205 and @PD<"20090701" and (group near5 (patients or health near3 members)) and (authorization authenticaton) near3 (absent without)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L207	10078	726/7,9,17,19.ccls.	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L208	3	L207 and @PD<"20090701" and (group near5 (patients or health near3 members)) and (authorization authenticaton)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L209	59	(US-20080147554-\$ or US-	US-PGPUB;	OR	ON	2017/12/22

		20020016923-\$ or US-20070130465-\$ or US-20080306872-\$ or US-20080304663-\$ or US-20080133273-\$ or US-20080040151-\$ or US-20050267782-\$ or US-20050119941-\$ or US-20060020611-\$ or US-20070185737-\$ or US-20060004772-\$ or US-20080120296-\$ or US-20080010254-\$ or US-20040078236-\$ or US-20090287502-\$ or US-20080281631-\$ or US-20080137848-\$ or US-20110255690-\$ or US-20070033419-\$ or US-20120246661-\$ or US-20090257586-\$ or US-20100325148-\$ or US-20100287190-\$ or US-20080306952-\$ or US-20070219824-\$).did. or (US-20070106753-\$ or US-20070106752-\$ or US-20060089857-\$ or US-20070192140-\$ or US-20050177050-\$ or US-20100217973-\$ or US-20070043594-\$ or US-20030154405-\$ or US-20080071577-\$ or US-20100162355-\$ or US-20060184524-\$ or US-20110231422-\$ or US-20040143403-\$ or US-20070157297-\$ or US-20020188869-\$).did. or (US-5721777-\$ or US-8296341-\$ or US-6302844-\$ or US-6874085-\$ or US-8037052-\$ or US-7716487-\$ or US-6947561-\$ or US-8131646-\$ or US-8055910-\$ or US-8108355-\$ or US-7900245-\$ or US-8229742-\$ or US-7650628-\$ or US-5956400-\$).did. or (WO-2010129653-\$ or CA-2760773-\$ or WO-2007108814-\$).did. or (WO-2010129653-\$).did.	USPAT; FPRS; EPO			16:10
L210	9	L209 and report\$3 same authorization	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2017/12/22 16:10
L211	0	"20060004772".pn. and (weaken\$3 groups sufficiently large) with (individual near3 identif\$3) and (track\$3) with individule	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2017/12/22 16:10
L212	18	("5220501" "5517405" "5592553" "5696824" "5754938" "5768382" "5790668" "5815665" "5857021" "5875302" "5890129" "5915001" "5996076" "6006333" "6016480" "6038315" "6052730" "6317834").PN. OR ("8296341").URPN.	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L213	18	("5220501" "5517405" "5592553" "5696824" "5754938" "5768382" "5790668" "5815665" "5857021" "5875302" "5890129" "5915001" "5996076" "6006333" "6016480"	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10

		"6038315" "6052730" "6317834").PN. OR ("8296341").URPN. and (without absent) near5 authorization				
L214	18	("5220501" "5517405" "5592553" "5696824" "5754938" "5768382" "5790668" "5815665" "5857021" "5875302" "5890129" "5915001" "5996076" "6006333" "6016480" "6038315" "6052730" "6317834").PN.	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L215	2	L214 and (without absent) near5 authorization	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L216	14	report\$3 with group SAME (without absent) near5 authorization	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L217	1	"8078625".PN. and (response respond\$3)	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L218	5	"20110184748." "pn." and (report\$3 characteristic)	US-PGPUB; USPAT; USOCR	OR	ON	2017/12/22 16:10
L219	60	(US-20080147554-\$ or US- 20020016923-\$ or US-20070130465-\$ or US-20080306872-\$ or US- 20080304663-\$ or US-20080133273-\$ or US-20080040151-\$ or US- 20050267782-\$ or US-20050119941-\$ or US-20060020611-\$ or US- 20070185737-\$ or US-20060004772-\$ or US-20080120296-\$ or US- 20080010254-\$ or US-20040078236-\$ or US-20090287502-\$ or US- 20080281631-\$ or US-20080137848-\$ or US-20110255690-\$ or US- 20070033419-\$ or US-20120246661-\$ or US-20090257586-\$ or US- 20100325148-\$ or US-20100287190-\$ or US-20080306952-\$ or US- 20070219824-\$).did. or (US- 20070106753-\$ or US-20070106752-\$ or US-20060089857-\$ or US- 20070192140-\$ or US-20050177050-\$ or US-20100217973-\$ or US- 20070043594-\$ or US-20030154405-\$ or US-20080071577-\$ or US- 20100162355-\$ or US-20060184524-\$ or US-20110231422-\$ or US- 20040143403-\$ or US-20070157297-\$ or US-20020188869-\$ or US- 20110184748-\$).did. or (US-5721777-\$ or US-8296341-\$ or US-6302844-\$ or US-6874085-\$ or US-8037052-\$ or US- 7716487-\$ or US-6947561-\$ or US- 8131646-\$ or US-8055910-\$ or US- 8108355-\$ or US-7900245-\$ or US- 8229742-\$ or US-7650628-\$ or US- 5956400-\$).did. or (WO-2010129653-\$ or CA-2760773-\$ or WO-2007108814-\$).did. or (WO-2010129653-\$).did.	US-PGPUB; USPAT; FPRS; EPO	OR	ON	2017/12/22 16:10
L220	20	L219 and hipaa	US-PGPUB;	OR	ON	2017/12/22

			USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB			16:10
L221	60	(US-20080147554-\$ or US-20020016923-\$ or US-20070130465-\$ or US-20080306872-\$ or US-20080304663-\$ or US-20080133273-\$ or US-20080040151-\$ or US-20050267782-\$ or US-20050119941-\$ or US-20060020611-\$ or US-20070185737-\$ or US-20060004772-\$ or US-20080120296-\$ or US-20080010254-\$ or US-20040078236-\$ or US-20090287502-\$ or US-20080281631-\$ or US-20080137848-\$ or US-20110255690-\$ or US-20070033419-\$ or US-20120246661-\$ or US-20090257586-\$ or US-20100325148-\$ or US-20100287190-\$ or US-20080306952-\$ or US-20070219824-\$).did. or (US-20070106753-\$ or US-20070106752-\$ or US-20060089857-\$ or US-20070192140-\$ or US-20050177050-\$ or US-20100217973-\$ or US-20070043594-\$ or US-20030154405-\$ or US-20080071577-\$ or US-20100162355-\$ or US-20060184524-\$ or US-20110231422-\$ or US-20040143403-\$ or US-20070157297-\$ or US-20020188869-\$ or US-20110184748-\$).did. or (US-5721777-\$ or US-8296341-\$ or US-6302844-\$ or US-6874085-\$ or US-8037052-\$ or US-7716487-\$ or US-6947561-\$ or US-8131646-\$ or US-8055910-\$ or US-8108355-\$ or US-7900245-\$ or US-8229742-\$ or US-7650628-\$ or US-5956400-\$).did. or (WO-2010129653-\$ or CA-2760773-\$ or WO-2007108814-\$).did. or (WO-2010129653-\$).did.	US-PGPUB; USPAT; FPRS; EPO	OR	ON	2017/12/22 16:10
L222	32	("20060004772" "20060229919" "20110258000" "20060020611" "20080133273" "20090070146" "20040143403" "20090287502" "20080147554" "20110184748" "20060184524" "20100162355" "20070043594" "20110225007").PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2017/12/22 16:10
L223	23	L221 NOT "32"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2017/12/22 16:10
L224	10	L223 and medical same report	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO;	OR	ON	2017/12/22 16:10

			DERWENT; IBM_TDB			
L225	7	L224 and @ad<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2017/12/22 16:10
L226	60	(US-20080147554-\$ or US-20020016923-\$ or US-20070130465-\$ or US-20080306872-\$ or US-20080304663-\$ or US-20080133273-\$ or US-20080040151-\$ or US-20050267782-\$ or US-20050119941-\$ or US-20060020611-\$ or US-20070185737-\$ or US-20060004772-\$ or US-20080120296-\$ or US-20080010254-\$ or US-20040078236-\$ or US-20090287502-\$ or US-20080281631-\$ or US-20080137848-\$ or US-20110255690-\$ or US-20070033419-\$ or US-20120246661-\$ or US-20090257586-\$ or US-20100325148-\$ or US-20100287190-\$ or US-20080306952-\$ or US-20070219824-\$).did. or (US-20070106753-\$ or US-20070106752-\$ or US-20060089857-\$ or US-20070192140-\$ or US-20050177050-\$ or US-20100217973-\$ or US-20070043594-\$ or US-20030154405-\$ or US-20080071577-\$ or US-20100162355-\$ or US-20060184524-\$ or US-20110231422-\$ or US-20040143403-\$ or US-20070157297-\$ or US-20020188869-\$ or US-20110184748-\$).did. or (US-5721777-\$ or US-8296341-\$ or US-6302844-\$ or US-6874085-\$ or US-8037052-\$ or US-7716487-\$ or US-6947561-\$ or US-8131646-\$ or US-8055910-\$ or US-8108355-\$ or US-7900245-\$ or US-8229742-\$ or US-7650628-\$ or US-5956400-\$).did. or (WO-2010129653-\$ or CA-2760773-\$ or WO-2007108814-\$).did. or (WO-2010129653-\$).did.	US-PGPUB; USPAT; FPRS; EPO	OR	OFF	2017/12/22 16:10
L227	39	("20060004772" "20060229919" "20070219824" "20080010254" "20110258000" "20060020611" "20080133273" "20090070146" "20040143403" "20090287502" "20080147554" "20110184748" "20080120296" "20060184524" "20100162355" "20070043594" "20110225007").PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2017/12/22 16:10
L228	47	L226 NOT L227	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2017/12/22 16:10

L229	37	L228 AND @AD<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2017/12/22 16:10
L230	8	L229 AND TOKEN	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2017/12/22 16:10
L231	29	L229 NOT L230	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2017/12/22 16:10
L242	60	(US-20080147554-\$ or US-20020016923-\$ or US-20070130465-\$ or US-20080306872-\$ or US-20080304663-\$ or US-20080133273-\$ or US-20080040151-\$ or US-20050267782-\$ or US-20050119941-\$ or US-20060020611-\$ or US-20070185737-\$ or US-20060004772-\$ or US-20080120296-\$ or US-20080010254-\$ or US-20040078236-\$ or US-20090287502-\$ or US-20080281631-\$ or US-20080137848-\$ or US-20110255690-\$ or US-20070033419-\$ or US-20120246661-\$ or US-20090257586-\$ or US-20100325148-\$ or US-20100287190-\$ or US-20080306952-\$ or US-20070219824-\$).did. or (US-20070106753-\$ or US-20070106752-\$ or US-20060089857-\$ or US-20070192140-\$ or US-20050177050-\$ or US-20100217973-\$ or US-20070043594-\$ or US-20030154405-\$ or US-20080071577-\$ or US-20100162355-\$ or US-20060184524-\$ or US-20110231422-\$ or US-20040143403-\$ or US-20070157297-\$ or US-20020188869-\$ or US-20110184748-\$).did. or (US-5721777-\$ or US-8296341-\$ or US-6302844-\$ or US-6874085-\$ or US-8037052-\$ or US-7716487-\$ or US-6947561-\$ or US-8131646-\$ or US-8055910-\$ or US-8108355-\$ or US-7900245-\$ or US-8229742-\$ or US-7650628-\$ or US-5956400-\$).did. or (WO-2010129653-\$ or CA-2760773-\$ or WO-2007108814-\$).did. or (WO-2010129653-\$).did.	US-PGPUB; USPAT; FPRS; EPO	OR	ON	2017/12/22 16:10
L243	6	L242 AND TOKEN near5 (request\$3 match\$3 medical de\$1identified)	US-PGPUB; USPAT; USOCR; FPRS;	OR	ON	2017/12/22 16:10

			EPO; JPO; DERWENT; IBM_TDB			
L244	4	L242 AND TOKEN near5 (generat\$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2017/12/22 16:10
L247	0	15/606265.APP.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/12/22 16:10
L255	39	221 AND (RULES Policy)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2017/12/22 17:10
L256	8	221 AND (RULES Policy) near5 number	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2017/12/22 17:10
L257	0	221 AND (RULES Policy) near5 number with time	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2017/12/22 17:11
L259	0	225 AND (RULES Policy) near5 number with time	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2017/12/22 17:12

EAST Search History (Interference)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L2	48379	(G06F19/322 G06F19/325 G06F19/366 G06Q50/22 G06Q50/24 G06F21/6245 H04L63/0428).CPC.	US- PGPUB; USPAT	OR	ON	2017/12/22 16:09
L4	2277	(Rawlings NEAR3 Jean Anderson NEAR3 David Kraus NEAR3 Carl Paris NEAR3 Andrew).INV.	US- PGPUB; USPAT	OR	ON	2017/12/22 16:09
L5	18	2 AND 4	US- PGPUB; USPAT	OR	ON	2017/12/22 16:09
L232	0	15/"Term Removed"	US- PGPUB;	OR	ON	2017/12/22 16:10

			USPAT			
L233	29150	(G06F19/322 G06F19/366 G06Q50/22 G06F21/6245).CPC.	US-PGPUB; USPAT	OR	ON	2017/12/22 16:10
L234	417	L233 AND (((report\$3) near11 (encounter characteristics group))).CLM.	US-PGPUB; USPAT	OR	ON	2017/12/22 16:10
L235	2	L234 AND (((non?identifiable de\$1identified) near4 (medical healthcare)) same token).CLM.	US-PGPUB; USPAT	OR	ON	2017/12/22 16:10
L236	2277	(Rawlings NEAR3 Jean Anderson NEAR3 David Kraus NEAR3 Carl Paris NEAR3 Andrew).INV.	US-PGPUB; USPAT	OR	ON	2017/12/22 16:10
L237	3	L236 AND (((non?identifiable de\$1identified) near4 (medical healthcare)) same token).CLM.	US-PGPUB; USPAT	OR	ON	2017/12/22 16:10
L238	3	Vigilytics.AS.	US-PGPUB; USPAT	OR	ON	2017/12/22 16:10
L239	3	L238 AND (((report\$3) near11 (encounter characteristics group))).CLM.	US-PGPUB; USPAT	OR	ON	2017/12/22 16:10
L240	3	L238 AND (((non?identifiable de\$1identified) near4 (medical healthcare)) same token).CLM.	US-PGPUB; USPAT	OR	ON	2017/12/22 16:10
L241	2	L233 AND L238	US-PGPUB; USPAT	OR	ON	2017/12/22 16:10
L248	0	15/"Term Removed"	US-PGPUB; USPAT	OR	ON	2017/12/22 16:10
L249	2	("9665685" "9323892").PN.	US-PGPUB; USPAT	OR	ON	2017/12/22 16:10
L250	2	("9665685" "9323892").PN. AND (group with minimum).CLM.	US-PGPUB; USPAT	OR	ON	2017/12/22 16:10
L251	2	("9665685" "9323892").PN. AND (group with (minimum number)).CLM.	US-PGPUB; USPAT	OR	ON	2017/12/22 16:10
L252	2	(((non?identifiable de\$1identified) near4 (medical healthcare)) same encounter\$3).CLM.	US-PGPUB; USPAT	OR	ON	2017/12/22 16:10
L253	5	(((non?identifiable de\$1identified) same encounter\$3).CLM.	US-PGPUB; USPAT	OR	ON	2017/12/22 16:10
L254	2	L253 AND (group with (minimum number)).CLM.	US-PGPUB; USPAT	OR	ON	2017/12/22 16:10
L261	0	253 AND (RULES Policy) near5 number with time	US-PGPUB; USPAT	OR	ON	2017/12/22 17:12
L262	2	236 AND (RULES Policy) near5 number with time	US-PGPUB; USPAT	OR	ON	2017/12/22 17:13
L263	192	2 and report and (medical healthcare clinic\$4) AND (RULES Policy) near5	US-PGPUB;	OR	ON	2017/12/22 17:14

		number with time	USPAT			
L264	2	2 and (report and (medical healthcare clinic\$4) AND (RULES Policy) near5 number with time).clm.	US-PGPUB; USPAT	OR	ON	2017/12/22 17:14
L265	192	263 and (G06F19/322 G06F19/325 G06F19/366 G06Q50/22 G06Q50/24 G06F21/6245 H04L63/0428).CPC.	US-PGPUB; USPAT	OR	ON	2017/12/22 17:15
L266	10	265 AND (((report\$3) near11 (encounter characteristics group))).CLM.	US-PGPUB; USPAT	OR	ON	2017/12/22 17:15

12/ 22/ 2017 5:17:26 PM
C:\ Users\ dzhao\ Documents\ EAST\ Workspaces\ 15-606265 P158 con of de-ID rpt med info.wsp

Zhao, Don

From: Natalie Galley <galley@fr.com>
Sent: Friday, December 22, 2017 1:03 PM
To: Zhao, Don
Cc: Jeffrey Barclay; APS Outgoing
Subject: RE: Application No.: 15/606,265; Attorney Docket No.: 25412-0003003; Interview Agenda
Attachments: 25412-0003003 claims.doc

Examiner,

Thank you again for your cooperation. The Applicant is agreement with your suggestion, and attached is a word document of the claims as you requested for an Examiner's Amendment. For your convenience, in the word file we have adjusted the claims to appear as if the previous amendments were entered, and included your amendment as well.

Thank you again,

Natalie Galley, Ph.D., J.D. :: Associate :: Fish & Richardson P.C.
One Marina Park Drive, Boston, MA 02210-1878
617 956 5911 direct :: 617 542 5070 main :: 617 542 8906 fax

From: Zhao, Don [mailto:Don.Zhao@USPTO.GOV]
Sent: Thursday, December 21, 2017 6:49 AM
To: Natalie Galley <galley@fr.com>
Cc: Jeffrey Barclay <Barclay@fr.com>; APS Outgoing <APSO@fr.com>
Subject: RE: Application No.: 15/606,265; Attorney Docket No.: 25412-0003003; Interview Agenda

Hi Natalie,

We discussed this case about the double patenting issue last Friday 12/15. Since the clock is high on my end, I would like to follow up with you on this case to see if we could agree to advance the prosecution.

I suggests filing a e-TD or include the disclosed "privacy-preserving rules" for determining the minimum number of individuals to be included in report in response to the request.

Specifically to independent claims, please consider to recite:

- comparing the request tokens to tokens associated with the medical de-identified data to find matching tokens and to determine whether the group includes at least a minimum number of individuals to be included in a report in response to the request, wherein the minimum number of individuals are selected according to at least a privacy-preserving rule that disallows same individuals to be included within a defined period of time.

The support is found in the specification below.

[036] In addition to determining that a minimum number of matches has been found operations may also include processing of other privacy-preserving rules.

For example, a rule may not allow the same user 302 (e.g., hospital 150) to submit more than one request message 306 containing substantially the same identifying data 404 within a defined period of time, e.g., six months. Identifying substantially the same identifying data 404 from a user 302 may involve comparing the identifying data 404 from different stored request messages 306 and checking that

at least a minimum variation exists in the request messages 306. For example, this may involve checking that the identifying data 404 for at least five patients does not match the identifying data 404 for any previous search request 306 by the user 302. Especially when combined with the size requirements and less than 100% capture rate, such rules greatly reduce the possibility of identifying any one person's data.

Please let me know as soon as possible.

Thanks,

Don

Don Zhao
Primary Examiner of AU2493

U.S. Patent & Trademark Office
Technology Center, AU 2493
500 Dulany St, Jefferson Bldg.
Alexandra, VA 22314
Tel: (571)272-9953 / Fax: (571)273-9953

From: Natalie Galley [<mailto:galley@fr.com>]

Sent: Thursday, August 10, 2017 5:07 PM

To: Zhao, Don <Don.Zhao@USPTO.GOV>

Cc: Jeffrey Barclay <Barclay@fr.com>; APS Outgoing <APSO@fr.com>

Subject: Application No.: 15/606,265; Attorney Docket No.: 25412-0003003; Interview Agenda

Examiner Zhao,

Attached please find an agenda for the interview on August 14th at 1:30 for application 15/606,265. Thank you for your consideration, and we will call you at 571-272-9953 at the appointed time.

Best regards,

Natalie Galley, Ph.D., J.D. :: Law Clerk :: Fish & Richardson P.C.
One Marina Park Drive, Boston, MA 02210-1878
617 956 5911 direct :: 617 542 5070 main :: 617 542 8906 fax

This email message is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized use or disclosure is prohibited. If you are not the intended recipient, please contact the sender by reply email and destroy all copies of the original message.

This email message is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized use or disclosure is prohibited. If you are not the intended recipient, please contact the sender by reply email and destroy all copies of the original message.

PENDING CLAIMS WITH EXAMINER'S AMENDMENT

1. (Previously Presented) A computer-implemented method comprising:
receiving a request from a user device for information that characterizes a group composed of multiple individuals from a set of de-identified medical data representing characteristics of the individuals pre- or post-encounter with a healthcare facility, wherein the request contains identifying data for each member in the group of multiple individuals who have had an encounter with a healthcare facility;

producing, by a hardware processor, a request token for each individual included in the group of individuals;

comparing the request tokens to tokens associated with the de-identified data to find matching tokens and to determine whether the group includes at least a minimum number of individuals to be included in a report in response to the request wherein the minimum number of individuals are selected according to at least a privacy-preserving rule that disallows same individuals to be included within a defined period of time;

producing the requested information that characterizes the group, an identity of the individuals being unattainable from the produced information; and

providing the produced medical information to report the characteristics of the group of individuals absent authorization from the individuals in the group of individuals identified in the request containing identifying data.

2. (Previously Presented) The computer-implemented method of claim 1, wherein the provided information is medical data in conformity with the Health Insurance Portability and Accountability Act (HIPAA).

3. (Previously Presented) The computer-implemented method of claim 1, wherein receiving the request for information that characterizes the group of individuals includes receiving personally identifiable information associated with the individuals of the group.

4. (Previously Presented) The computer-implemented method of claim 1, in which producing the requested information includes encrypting respective data that identifies each individual.

5. (Previously Presented) The computer-implemented method of claim 1, in which the tokens associated with data and the request tokens are similarly encrypted.

6. (Previously Presented) The computer-implemented method of claim 1, in which the data represents medical-related information associated with the individuals of the group.

7. (Currently Amended) A system comprising:
a computing device comprising:
a memory configured to store instructions; and
a processor to execute the instructions to perform operations comprising:
receiving a request from a user device for information that characterizes a group composed of multiple individuals from a set of de-identified data representing characteristics of the individuals pre-or post-encounter with a healthcare facility, wherein the request contains identifying data for each member in the group of multiple individuals who have had an encounter with a healthcare facility;
producing, by a hardware processor, a request token for each individual included in the group of individuals;
comparing the request tokens to tokens associated with the medical data to find matching tokens and to determine whether the group includes at least a minimum number of individuals to be included in a report in response to the request wherein the minimum number of individuals are selected according to at least a privacy-preserving rule that disallows same individuals to be included within a defined period of time;
producing the requested information that characterizes the group, an identity of the individuals being unattainable from the produced information; and
providing the produced medical information to report the characteristics of the group of individuals absent authorization from the individuals in the group of individuals identified in the request containing identifying data.

8. (Previously Presented) The system of claim 7, wherein the provided information is medical data in conformity with the Health Insurance Portability and Accountability Act (HIPAA).

9. (Previously Presented) The system of claim 7, wherein the request for information that characterizes a group of individuals includes personally identifiable information associated with the individuals of the group.

10. (Original) The system of claim 7, in which the data that identifies each individual is encrypted.

11. (Previously Presented) The system of claim 7, in which the tokens associated with the data and the request tokens are similarly encrypted.

12. (Previously Presented) The system of claim 7, in which producing the requested information includes determining if the group includes at least a minimum number of individuals.

13. (Previously Presented) The system of claim 7, in which the data represents medical-related information associated with the individuals of the group.

14. (Currently Amended) One or more computer readable storage devices storing instructions that are executable by a processing device, and upon such execution cause the processing device to perform operations comprising:

receiving a request from a user device for information that characterizes a group composed of multiple individuals from a set of de-identified data representing characteristics of the individuals pre-or post-encounter with a healthcare facility, wherein the request contains identifying data for each member in the group of multiple individuals who have had an encounter with a healthcare facility;

producing, by a hardware processor, a request token for each individual included in the group of individuals;

comparing the request tokens to tokens associated with the medical data to find matching tokens and to determine whether the group includes at least a minimum number of individuals to be included in a report in response to the request, wherein the minimum

number of individuals are selected according to at least a privacy-preserving rule that disallows same individuals to be included within a defined period of time;

producing the requested information that characterizes the group, an identity of the individuals being unattainable from the produced information; and

providing the produced medical information to report the characteristics of the group of individuals absent authorization from the individuals in the group of individuals identified in the request containing identifying data.

15. (Previously Presented) The computer readable storage devices of claim 14, wherein the provided information is medical data in conformity with the Health Insurance Portability and Accountability Act (HIPAA).

16. (Previously Presented) The computer readable storage devices of claim 14, wherein receiving the request for information that characterizes the group of individuals includes receiving personally identifiable information associated with the individuals of the group.

17. (Previously Presented) The computer readable storage devices of claim 14, in which producing the requested information includes encrypting respective data that identifies each individual.

18. (Original) The computer readable storage devices of claim 14, in which the tokens associated with the medical data and the request tokens are similarly encrypted.

19. (Previously Presented) The computer readable storage devices of claim 14, in which the data represents medical-related information associated with the individuals of the group.

20. (Previously Presented) The computer readable storage devices of claim 14, in which producing the requested information includes determining if the group includes at least a minimum number of individuals.



generating medical reports on for reporting characteristics of a group of individu 

All News Images Shopping Maps More Settings Tools

About 553,000,000 results (0.51 seconds)

Teaching Ideas and Classroom Activities for Health Care

<https://books.google.com/books?isbn=0766844900>

Lee Haroun, Susan R. Royce - 2004 - Medical

Finding local sources of individual or groups, information for patient research (telephone education calls, visits) 14-3 What's My Learning Style? ... Developing teaching aids Individual, written (create a puzzle) Chapter 15 Documentation Activity Title Topic Type of Activity 15-1 Docu-Match Medical records vocabulary Whole ...

Writing a Field Report - Organizing Your Social Sciences Research ...

libguides.usc.edu/writingguide/fieldreport ▼

by RV Labaree - 2009

We are all observers of people, their interactions, places, and events; however, your responsibility when writing a field report is to create a research study based on data generated by the act of ... The characteristics of an occupied space and the human use of the place where the observation(s) are being conducted. Objects ...

Glossary of Study Designs - EAL

<https://www.andean.org/study-designs> ▼

A descriptive study of one (case study or case report) or a series of patients (case series) defined by eligibility criteria, and where the unfolding course of events ... A study that involves the identification of a group (cohort) of individuals with specific characteristics in common and follows them over time to gather data about ...

Observational Studies: Cohort and Case-Control Studies - NCBI - NIH

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2998589/> ▼

by JW Song - 2010 - Cited by 242 - Related articles

The modern epidemiological definition of the word now means a "group of people with defined characteristics who are followed up to determine incidence of, ... Retrospective cohort studies, also known as historical cohort studies, are carried out at the present time and look to the past to examine medical events or outcomes ...

Publication Characteristics (Publication Types) with Scope Notes

<https://www.nlm.nih.gov/mesh/pubtypes.html> ▼

A large enough group of patients is studied and closely monitored by physicians for adverse response to long-term exposure, over a period of about three years in either the United States or a foreign country. Clinical Trial, Phase IV: Work that is a report of a planned post-marketing study of diagnostic, therapeutic, ...

Case report - Wikipedia

https://en.wikipedia.org/wiki/Case_report ▼

In medicine, a case report is a detailed report of the symptoms, signs, diagnosis, treatment, and follow-up of an individual patient. Case reports may contain a demographic profile of the patient, but usually describe an unusual or novel occurrence. Some case reports also contain a literature review of other reported cases.

[PDF] Guideline for Industry Structure and Content of Clinical Study Reports

<https://www.fda.gov/.../GuidanceComplianceRegulatoryInformation/.../UCM073113...> ▼

Jul 17, 1996 - TABLE OF CONTENTS FOR THE INDIVIDUAL CLINICAL STUDY REPORT This guideline was developed within the Expert Working Group (Efficacy) of the International Conference on. 1 ... Although this guideline does not create or confer any rights for or on any person and does not operate to bind.

[PDF] Paving the Way for Personalized Medicine - FDA

<https://www.fda.gov/downloads/ScienceResearch/SpecialTopics/.../UCM372421.pdf> ▼

used to create a bioresorbable tracheal splint for treating a critically-ill infant. Each of these examples ... diagnostics. I am pleased to offer this report, Paving the Way for Personalized Medicine: FDA's Role in a New Era of Medical Product "The tailoring of medical treatment to the individual characteristics of each patient.

CONSORT 2010 Explanation and Elaboration: updated guidelines for ...

www.bmj.com/content/340/bmj.c869 ▼

by D Moher - 2010 - Cited by 8542 - Related articles

Mar 24, 2010 - Reporting is not only often incomplete but also sometimes inaccurate. Of 119 reports stating that all participants were included in the analysis in the groups to which they were originally assigned (intention-to-treat analysis), 15 (13%) excluded patients or did not analyse all patients as allocated.18 Many ...

Clinical Pharmacy and Therapeutics E-Book

<https://books.google.com/books?isbn=0702048488>

Roger Walker, Cate Whittlesea - 2011 - Medical

Information from Yellow Card reports is entered into a database, suspected reactions are categorised using the internationally accepted Medical Dictionary for ... a particular adverse event in two groups of patients, those taking the drug of interest and, another group, matched for all important characteristics except the use of ...

Report Generation Tool - You have been looking for - windward.net

[Ad] www.windward.net/report/generation ▼

Publish visually impressive reports in a wide array of formats. Free Demo!

Industries: Energy, Government, Healthcare, Insurance, Software

Enterprise Reporting · Document Generation · Web Based Reporting · Try It For Free

Grow™ The #1 Report Generator - Data Reporting Dashboards

[Ad] www.grow.com/Generator_Tool/BI_Reports ▼

Accelerate Your Growth w/Grow's BI Solution. Schedule A Free Demo Today.

Private & Secure · Super Simple Setup · Start a Trial · Integrate All Your Data

"Amazing product, awesome team and services." -- g2crowd

Start a Trial Now · Grow Case Studies · Home · Integrations / Connectors

Searches related to generating medical reports on for reporting characteristics of a group of individuals

case series

field report example pdf

field report example

field visit report sample

what is field report

example of field trip report essay

how to write a field trip report

field work report sample

1 2 3 4 5 6 7 8 9 10 Next

22314, Alexandria, VA - From your Internet address - Use precise location - Learn more

[Help](#) [Send feedback](#) [Privacy](#) [Terms](#)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor :	Andrew L. Paris III	Art Unit :	2493
Serial No. :	15/606,265	Examiner :	Don Gordon Zhao
Filed :	May 26, 2017	Conf. No. :	1070
Title :	USING DE-IDENTIFIED HEALTHCARE DATA TO EVALUATE POST-HEALTHCARE FACILITY ENCOUNTER TREATMENT OUTCOMES		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REPLY TO ACTION OF JULY 14, 2017

Please consider the following reply.

List of claims (replacing prior versions).

1. (Currently Amended) A computer-implemented method comprising:
receiving a request from a user device for ~~medical~~ information that characterizes a group composed of multiple individuals from a set of de-identified medical data representing ~~pre- or post-encounter~~ characteristics of the individuals pre- or post-encounter with a healthcare facility, wherein the request contains identifying data for each member in the group of multiple individuals who have had an encounter with a healthcare facility;
producing, by a hardware processor, a request token for each individual included in the group of individuals;
comparing the request tokens to tokens associated with the ~~medical~~ de-identified data to find matching tokens and to determine whether the group includes at least a minimum number of individuals to be included in a report in response to the request;
producing the requested ~~medical~~ information, ~~the identity of the individuals being unattainable from the produced medical information without the individuals in the group having authorized production of such medical information~~ that characterizes the group, an identity of the individuals being unattainable from the produced information; and
providing the produced medical information to report the characteristics of the group of individuals absent authorization from the individuals in the group of individuals identified in the request containing identifying data.
2. (Currently Amended) The computer-implemented method of claim 1, wherein the provided ~~medical~~ information is medical data in conformity with the Health Insurance Portability and Accountability Act (HIPAA).
3. (Currently Amended) The computer-implemented method of claim 1, wherein receiving the request for ~~medical~~ information that characterizes the group of individuals includes receiving personally identifiable information associated with the individuals of the group.

4. (Currently Amended) The computer-implemented method of claim 1, in which producing the requested ~~medical~~ information includes encrypting respective data that identifies each individual.

5. (Currently Amended) The computer-implemented method of claim 1, in which the tokens associated with ~~medical~~ data and the request tokens are similarly encrypted.

6. (Currently Amended) The computer-implemented method of claim 1, in which the ~~medical~~ data represents medical-related information associated with the individuals of the group.

7. (Currently Amended) A system comprising:
a computing device comprising:
a memory configured to store instructions; and
a processor to execute the instructions to perform operations comprising:
receiving a request from a user device for ~~medical~~ information that characterizes a group composed of multiple individuals from a set of de-identified ~~medical~~ data representing ~~pre-or post-encounter~~ characteristics of the individuals pre-or post-encounter with a healthcare facility, wherein the request contains identifying data for each member in the group of multiple individuals who have had an encounter with a healthcare facility;
producing, by a hardware processor, a request token for each individual included in the group of individuals;
comparing the request tokens to tokens associated with the medical data to find matching tokens and to determine whether the group includes at least a minimum number of individuals to be included in a report in response to the request;
producing the requested ~~medical~~ information ~~with the identity of the individuals being unattainable from the produced medical information without the individuals in the group having authorized production of such medical information that characterizes the group, an~~ identity of the individuals being unattainable from the produced information; and

providing the produced medical information to report the characteristics of the group of individuals absent authorization from the individuals in the group of individuals identified in the request containing identifying data.

8. (Currently Amended) The system of claim 7, wherein the provided ~~medical~~ information is medical data in conformity with the Health Insurance Portability and Accountability Act (HIPAA).

9. (Currently Amended) The system of claim 7, wherein the request for ~~medical~~ information that characterizes a group of individuals includes personally identifiable information associated with the individuals of the group.

10. (Original) The system of claim 7, in which the data that identifies each individual is encrypted.

11. (Currently Amended) The system of claim 7, in which the tokens associated with the ~~medical~~ data and the request tokens are similarly encrypted.

12. (Currently Amended) The system of claim 7, ~~in which the data server provides in~~ which producing the requested ~~medical~~ information includes determining if the group includes at least a minimum number of individuals.

13. (Currently Amended) The system of claim 7, in which the ~~medical~~ data represents medical-related information associated with the individuals of the group.

14. (Currently Amended) One or more computer readable storage devices storing instructions that are executable by a processing device, and upon such execution cause the processing device to perform operations comprising:

receiving a request from a user device for ~~medical~~ information that characterizes a group composed of multiple individuals from a set of de-identified ~~medical~~ data representing ~~pre-or post-encounter~~ characteristics of the individuals pre-or post-encounter with a healthcare facility.

wherein the request contains identifying data for each member in the group of multiple individuals who have had an encounter with a healthcare facility;

producing, by a hardware processor, a request token for each individual included in the group of individuals;

comparing the request tokens to tokens associated with the medical data to find matching tokens and to determine whether the group includes at least a minimum number of individuals to be included in a report in response to the request;

producing the requested ~~medical~~ information ~~with the identity of the individuals being unattainable from the produced medical information without the individuals in the group having authorized production of such medical information~~ that characterizes the group, an identity of the individuals being unattainable from the produced information; and

providing the produced medical information to report the characteristics of the group of individuals absent authorization from the individuals in the group of individuals identified in the request containing identifying data.

15. (Currently Amended) The computer readable storage devices of claim 14, wherein the provided ~~medical~~ information is medical data in conformity with the Health Insurance Portability and Accountability Act (HIPAA).

16. (Currently Amended) The computer readable storage devices of claim 14, wherein receiving the request for ~~medical~~ information that characterizes the group of individuals includes receiving personally identifiable information associated with the individuals of the group.

17. (Currently Amended) The computer readable storage devices of claim 14, in which producing the requested ~~medical~~ information includes encrypting respective data that identifies each individual.

18. (Original) The computer readable storage devices of claim 14, in which the tokens associated with the medical data and the request tokens are similarly encrypted.

First Named Inventor : Andrew L. Paris III
Serial No. : 15/606,265
Filed : May 26, 2017
Page : 6 of 9

Attorney's Docket No.: 25412-0003003

19. (Currently Amended) The computer readable storage devices of claim 14, in which the ~~medical~~ data represents medical-related information associated with the individuals of the group.

20. (Currently Amended) The computer readable storage devices of claim 14, in which producing the requested ~~medical~~ information includes determining if the group includes at least a minimum number of individuals.

First Named Inventor : Andrew L. Paris III
Serial No. : 15/606,265
Filed : May 26, 2017
Page : 7 of 9

Attorney's Docket No.: 25412-0003003

Amendments to the Drawings:

The attached replacement sheets of drawings replace the original sheets including Figs 1-7.

In the Figures no changes have been made, and the replacement figures are submitted in response to the objection that the drawings have broken or blurred letters which were identified as being difficult to read.

Attachments following last page of this Amendment:

Replacement Sheet (7 pages)

REMARKS

The Applicant appreciates and would like to thank Examiner Zhao for taking time out of his schedule to discuss the subject application on 14 August 2017 with Applicant's representatives, Jeffrey J. Barclay (Reg. No. 48,950) and Natalie K. Galley. Along with discussing the double patenting rejection, the current action and pending claims were discussed. The Applicant would also like to thank Examiner Zhao for agreeing to review claim amendments provided by the undersigned representative. Attached is the e-mail sent from Applicants' representative to the Examiner with an Applicant-proposed amendment, and an email with the Examiner's claims including changes to those claims. The current response largely reflects the claims communicated by the Examiner.

Claims 1-20 are pending, with claims 1, 7, and 14 being independent. Claims 1-9, 11-17, 19, and 20 have been amended. Support for the claim amendments can be found throughout the application as filed. No new subject matter has been added.

Claims 1, 3, 5, 7, 9, 14, and 16 were objected to due to informalities. Applicant requests reconsideration and withdrawal of this rejection in view of the claim amendments presented above.

Allowable Subject Matter

Applicant thanks the Examiner for indicating that claims 1-20 are allowable over prior art.

Rejection Under 35 U.S.C. § 112

Claims 1-20 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA), second paragraph, as allegedly being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. Applicant requests reconsideration and withdrawal of this rejection in view of the claim amendments presented above.

First Named Inventor : Andrew L. Paris III
Serial No. : 15/606,265
Filed : May 26, 2017
Page : 9 of 9

Attorney's Docket No.: 25412-0003003

Double Patenting Rejection

Claims 1-20 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-26 of U.S. Patent No. US 9,323,892. As discussed during the interview, Applicant submits the amendments with this response and requests withdrawal of this rejection.

CONCLUSION

Applicant respectfully asserts that the claims under examination are in condition for allowance. Accordingly, Applicant requests the timely issuance of a Notice of Allowance. If a discussion would be helpful, the Examiner is invited to call the undersigned at the telephone number provided below.

Apply any necessary charges or credits to Deposit Account 06-1050, referencing the above attorney docket number.

Respectfully submitted,

Date: 10/16/17

/Natalie K Galley/
Natalie K. Galley, Ph.D.
Reg. No. L1010

Customer Number 26161
Fish & Richardson P.C.
Telephone: (617) 956-5911
Facsimile: (877) 769-7945

23672157.doc

Appendix A

August 23, 2017 email: Applicant's Representative to Examiner

From: Natalie Galley
Sent: Wednesday, August 23, 2017 10:33 AM
To: 'Zhao, Don'
Subject: RE: Application No.: 15/606,265; Attorney Docket No.: 25412-0003003; Interview Agenda
Attachments: 25412-0003003 claims.doc

Examiner, attached for your review are draft claims as we discussed during the interview. Thank you again for your time, and for your willingness to review the claims which you will see are closer to the first continuation application rather than the parent application.

Thank you again.

Best regards,

Natalie Galley, Ph.D., J.D. :: Law Clerk :: Fish & Richardson P.C.
One Marina Park Drive, Boston, MA 02210-1878
617 956 5911 direct :: 617 542 5070 main :: 617 542 8906 fax

1. A computer-implemented method comprising:

receiving a request from a user device for information that characterizes a group composed of multiple individuals from a set of de-identified data representing characteristics of the individuals pre-or post-encounter with a healthcare facility, wherein the request contains identifying data for each member in the group of multiple individuals who have had an encounter with a healthcare facility;

producing, by a hardware processor, a request token for each individual included in the group of individuals;

comparing the request tokens to tokens associated with the de-identified data to find matching tokens;

producing the requested information that characterizes the group, the identity of the individuals being unattainable from the produced information; and

providing the produced information to report the characteristics of the group of individuals absent authorization from the individuals in the group of individuals identified in the request containing identifying data.

2. The computer-implemented method of claim 1, wherein the provided information is medical information in conformity with the Health Insurance Portability and Accountability Act (HIPAA).

3. The computer-implemented method of claim 1, wherein receiving the request for information that characterizes the group of individuals includes receiving personally identifiable information associated with each of the individuals in the group.

4. The computer-implemented method of claim 1, in which producing the requested information includes encrypting respective data that identifies each individual.

5. The computer-implemented method of claim 1, in which the tokens associated with data and the request tokens are similarly encrypted.

6. The computer-implemented method of claim 1, in which the data represents medical-related information associated with the individuals of the group.

7. A system comprising:

a computing device comprising:

a memory configured to store instructions; and

a processor to execute the instructions to perform operations comprising:

receiving a request from a user device for information that characterizes a group composed of multiple individuals from a set of de-identified data representing characteristics of the individuals pre-or post-encounter with a healthcare facility, wherein the request contains identifying data for each member in the group of multiple individuals who have had an encounter with a healthcare facility;

producing, by a hardware processor, a request token for each individual included in the group of individuals;

comparing the request tokens to tokens associated with the de-identified data to find matching tokens;

producing the requested information that characterizes the group, the identity of the individuals being unattainable from the produced information; and

providing the produced information to report the characteristics of the group of individuals absent authorization from the individuals in the group of individuals identified in the request containing identifying data.

8. The system of claim 7, wherein the provided information is medical information in conformity with the Health Insurance Portability and Accountability Act (HIPAA).

9. The system of claim 7, wherein the request for information that characterizes a group of individuals includes personally identifiable information associated with each of the individuals of the group.

10. The system of claim 7, in which the data that identifies each individual is encrypted.

11. The system of claim 7, in which the tokens associated with the data and the request tokens are similarly encrypted.

12. The system of claim 7, in which the data server provides the requested information if the group includes at least a minimum number of individuals.

13. The system of claim 7, in which the data represents medical-related information associated with the individuals of the group.

14. One or more computer readable storage devices storing instructions that are executable by a processing device, and upon such execution cause the processing device to perform operations comprising:

receiving a request from a user device for information that characterizes a group composed of multiple individuals from a set of de-identified data representing characteristics of the individuals pre-or post-encounter with a healthcare facility, wherein the request contains identifying data for each member in the group of multiple individuals who have had an encounter with a healthcare facility;

producing, by a hardware processor, a request token for each individual included in the group of individuals;

comparing the request tokens to tokens associated with the de-identified data to find matching tokens;

producing the requested information that characterizes the group, the identity of the individuals being unattainable from the produced information; and

providing the produced information to report the characteristics of the group of individuals absent authorization from the individuals in the group of individuals identified in the request containing identifying data.

15. The computer readable storage devices of claim 14, wherein the provided information is medical information in conformity with the Health Insurance Portability and Accountability Act (HIPAA).

16. The computer readable storage devices of claim 14, wherein receiving the request for information that characterizes the group of individuals includes receiving personally identifiable information associated with each of the individuals in the group.

17. The computer readable storage devices of claim 14, in which producing the requested information includes encrypting respective data that identifies each individual.

18. The computer readable storage devices of claim 14, in which the tokens associated with the data and the request tokens are similarly encrypted.

19. The computer readable storage devices of claim 14, in which the data represents medical-related information associated with the individuals of the group.

20. The computer readable storage devices of claim 14, in which producing the requested information includes determining if the group includes at least a minimum number of individuals.

23669843.doc

Appendix B

August 23, 2017 email: Examiner to Applicant's Representative

From: Zhao, Don <Don.Zhao@USPTO.GOV>
Sent: Wednesday, August 23, 2017 11:12 AM
To: Natalie Galley
Subject: RE: Application No.: 15/606,265; Attorney Docket No.: 25412-0003003; Interview Agenda
Attachments: 25412-0003003 claims edited by the exmr P158.pdf

Hi Natalie,

I think as we discussed in the interview, we would agree to:

1. Add further detail for the comparing step.
2. Or amend the case look like 15/136,318 and file TD for patentability.

I edited your proposal for your further consideration for advancing the prosecution.
Please see the attachment.

Thanks,
Don

Don Zhao
Primary Examiner of AU2493

U.S. Patent & Trademark Office
Technology Center, AU 2493
500 Dulany St, Jefferson Bldg.
Alexandra, VA 22314
Tel: (571)272-9953 / Fax: (571)273-9953

Draft Claims for **App. No. 15/606,265** for Examiner Zhao
Attorney Docket No. 25412-0003003

Edited by the Examiner on Wednesday, August 23, 2017

1. A computer-implemented method comprising:

receiving a request from a user device for information that characterizes a group composed of multiple individuals from a set of de-identified data representing characteristics of the individuals pre-or post-encounter with a healthcare facility, wherein the request contains identifying data for each member in the group of multiple individuals who have had an encounter with a healthcare facility;

producing, by a hardware processor, a request token for each individual included in the group of individuals;

comparing the request tokens to tokens associated with the de-identified data to ~~find matching tokens~~ find matching tokens to determine whether the group includes at least a minimum number of individuals for the request of report;

producing the requested information that characterizes the group, the identity of the individuals being unattainable from the produced information; and

providing the produced information to report the characteristics of the group of individuals absent authorization from the individuals in the group of individuals identified in the request containing identifying data.

2. The computer-implemented method of claim 1, wherein the provided information is ~~medical information~~ medical data in conformity with the Health Insurance Portability and Accountability Act (HIPAA).

3. The computer-implemented method of claim 1, wherein receiving the request for information that characterizes the group of individuals includes receiving personally identifiable information associated with each of the individuals in the group.

4. The computer-implemented method of claim 1, in which producing the requested information includes encrypting respective data that identifies each individual.

5. The computer-implemented method of claim 1, in which the tokens associated with data and the request tokens are similarly encrypted.

6. The computer-implemented method of claim 1, in which the data represents medical-related information associated with the individuals of the group.

7. A system comprising:

a computing device comprising:

a memory configured to store instructions; and

a processor to execute the instructions to perform operations comprising:

receiving a request from a user device for information that characterizes a group composed of multiple individuals from a set of de-identified data representing characteristics of the individuals pre-or post-encounter with a healthcare facility, wherein the request contains identifying data for each member in the group of multiple individuals who have had an encounter with a healthcare facility;

producing, by a hardware processor, a request token for each individual included in the group of individuals;

comparing the request tokens to tokens associated with the de-identified data to ~~find matching tokens~~ find matching tokens to determine whether the group includes at least a minimum number of individuals for the request of report;

producing the requested information that characterizes the group, the identity of the individuals being unattainable from the produced information; and

providing the produced information to report the characteristics of the group of individuals absent authorization from the individuals in the group of individuals identified in the request containing identifying data.

8. The system of claim 7, wherein the provided information is ~~medical information~~ medical data in conformity with the Health Insurance Portability and Accountability Act (HIPAA).

9. The system of claim 7, wherein the request for information that characterizes a group of individuals includes personally identifiable information associated with each of the individuals of the group.

10. The system of claim 7, in which the data that identifies each individual is encrypted.

11. The system of claim 7, in which the tokens associated with the data and the request tokens are similarly encrypted.

12. The system of claim 7, in which the data server provides the requested information if the group includes at least a minimum number of individuals.

13. The system of claim 7, in which the data represents medical-related information associated with the individuals of the group.

14. One or more computer readable storage devices storing instructions that are executable by a processing device, and upon such execution cause the processing device to perform operations comprising:

receiving a request from a user device for information that characterizes a group composed of multiple individuals from a set of de-identified data representing characteristics of the individuals pre-or post-encounter with a healthcare facility, wherein the request contains identifying data for each member in the group of multiple individuals who have had an encounter with a healthcare facility;

producing, by a hardware processor, a request token for each individual included in the group of individuals;

comparing the request tokens to tokens associated with the de-identified data to ~~find matching tokens~~ find matching tokens to determine whether the group includes at least a minimum number of individuals for the request of report;

producing the requested information that characterizes the group, the identity of the individuals being unattainable from the produced information; and

providing the produced information to report the characteristics of the group of individuals absent authorization from the individuals in the group of individuals identified in the request containing identifying data.

15. The computer readable storage devices of claim 14, wherein the provided information is ~~medical information~~medical data in conformity with the Health Insurance Portability and Accountability Act (HIPAA).

16. The computer readable storage devices of claim 14, wherein receiving the request for information that characterizes the group of individuals includes receiving personally identifiable information associated with each of the individuals in the group.

17. The computer readable storage devices of claim 14, in which producing the requested information includes encrypting respective data that identifies each individual.

18. The computer readable storage devices of claim 14, in which the tokens associated with the data and the request tokens are similarly encrypted.

19. The computer readable storage devices of claim 14, in which the data represents medical-related information associated with the individuals of the group.

20. The computer readable storage devices of claim 14, in which producing the requested information includes determining if the group includes at least a minimum number of individuals.

23669843.doc




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7

Electronic Acknowledgement Receipt

EFS ID:	30668651
Application Number:	15606265
International Application Number:	
Confirmation Number:	1070
Title of Invention:	USING DE-IDENTIFIED HEALTHCARE DATA TO EVALUATE POST-HEALTHCARE FACILITY ENCOUNTER TREATMENT OUTCOMES
First Named Inventor/Applicant Name:	Andrew L. Paris
Customer Number:	26161
Filer:	Natalie K. Galley/Cathy O'Brien
Filer Authorized By:	Natalie K. Galley
Attorney Docket Number:	25412-0003003
Receipt Date:	16-OCT-2017
Filing Date:	26-MAY-2017
Time Stamp:	16:37:35
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		Reply.pdf	1397678	yes	28
			04e4ead6af73c3b4188480a7346ce7514fb1f10c		

	Multipart Description/PDF files in .zip description		
	Document Description	Start	End
	Amendment/Req. Reconsideration-After Non-Final Reject	1	1
	Claims	2	6
	Drawings-only black and white line drawings	7	7
	Applicant Arguments/Remarks Made in an Amendment	8	21
	Drawings-only black and white line drawings	22	28
Warnings:			
Information:			
Total Files Size (in bytes):		1397678	
This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503. <u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application. <u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course. <u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.			

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875	Application or Docket Number 15/606,265	Filing Date 05/26/2017	☐ To be Mailed
---	---	----------------------------------	---------------------------------------

ENTITY: ☐ LARGE ☒ SMALL ☐ MICRO**APPLICATION AS FILED – PART I**

(Column 1)

(Column 2)

FOR	NUMBER FILED	NUMBER EXTRA	RATE (\$)	FEE (\$)
☐ BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A	N/A	
☐ SEARCH FEE (37 CFR 1.16(k), (i), or (m))	N/A	N/A	N/A	
☐ EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A	N/A	
TOTAL CLAIMS (37 CFR 1.16(i))	minus 20 =	*	X \$ =	
INDEPENDENT CLAIMS (37 CFR 1.16(h))	minus 3 =	*	X \$ =	
☐ APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$310 (\$155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).			
☐ MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))				
* If the difference in column 1 is less than zero, enter "0" in column 2.			TOTAL	

APPLICATION AS AMENDED – PART II

(Column 1)

(Column 2)

(Column 3)

AMENDMENT	10/16/2017	CLAIMS REMAINING AFTER AMENDMENT	MINUS	HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE (\$)	ADDITIONAL FEE (\$)
	Total (37 CFR 1.16(i))	* 20	Minus	** 20	= 0	X \$40 =	0
	Independent (37 CFR 1.16(h))	* 3	Minus	***3	= 0	X \$210 =	0
	☐ Application Size Fee (37 CFR 1.16(s))						
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))						
TOTAL ADD'L FEE						0	

(Column 1)

(Column 2)

(Column 3)

AMENDMENT	CLAIMS REMAINING AFTER AMENDMENT	MINUS	HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE (\$)	ADDITIONAL FEE (\$)
	Total (37 CFR 1.16(i))	*	Minus	**	=	X \$ =
	Independent (37 CFR 1.16(h))	*	Minus	***	=	X \$ =
	☐ Application Size Fee (37 CFR 1.16(s))					
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))					
TOTAL ADD'L FEE						

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.

** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".

*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".

The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.

LIE
THERESA LINDSAY

This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

SCORE Placeholder Sheet for IFW Content

Application Number: 15606265

Document Date: 10/16/2017

The presence of this form in the IFW record indicates that the following document type was received in electronic format on the date identified above. This content is stored in the SCORE database.

Since this was an electronic submission, there is no physical artifact folder, no artifact folder is recorded in PALM, and no paper documents or physical media exist. The TIFF images in the IFW record were created from the original documents that are stored in SCORE.

- Drawing

At the time of document entry (noted above):

- USPTO employees may access SCORE content via eDAN using the Supplemental Content tab, or via the SCORE web page.
- External customers may access SCORE content via PAIR using the Supplemental Content tab.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
15/606,265	05/26/2017	Andrew L. Paris III	25412-0003003	1070

26161 7590 08/21/2017
FISH & RICHARDSON P.C. (BO)
P.O. BOX 1022
MINNEAPOLIS, MN 55440-1022

EXAMINER

ZHAO, DON GORDON

ART UNIT	PAPER NUMBER
----------	--------------

2493

NOTIFICATION DATE	DELIVERY MODE
-------------------	---------------

08/21/2017

ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

PATDOCTC@fr.com

<i>Applicant-Initiated Interview Summary</i>	Application No.	Applicant(s)		
	15/606,265	PARIS, ANDREW L.		
	Examiner	Art Unit	AIA (First Inventor to File) Status	Page
	Don Zhao	2493	No	1 of 1

All participants (applicant, applicant's representative, PTO personnel):

1. Don Zhao (Primary Examiner); Telephonic
2. Jeff Barclay (Attorney); Telephonic
3. Natalie Galley (Agent); Telephonic

Date of Interview: 14 August 2017

Claim(s) discussed: 1, 7, and 14

Amendment Proposed: Applicant proposed to change "medical information" to "medical data" and to amend the token comparing step(s) or other token limitations such that the the identity of the individuals is unattainable in produced information/data.

Brief Description of main topic of discussion: Applicant requested discussion for obviate double patenting rejection.

Issues Discussed:

Double Patenting:

Attachment(s): Agenda

/Don Zhao/ Primary Examiner, Art Unit 2493	
Applicant recordation instructions: The formal written reply to the last Office action must include the substance of the interview. (See MPEP section 713.04). If a reply to the last Office action has already been filed, applicant is given a non-extendable time limit of the longer of one month or thirty days from this interview date, or the mailing date of this interview summary form, whichever is later, to file a statement of the substance of the interview. Examiner recordation instructions: Examiners must summarize the substance of any interview of record. A complete and proper recordation of the substance of an interview should include the items listed in MPEP 713.04 for complete and proper recordation including the identification of the general thrust of each argument or issue discussed, a general indication of any other pertinent matters discussed regarding patentability and the general results or outcome of the interview, to include an indication as to whether or not agreement was reached on the issues raised. Applicant is reminded that a complete written statement as to the substance of the interview must be made of record in the application file. It is the applicant's responsibility to provide the written statement, unless the interview was initiated by the Examiner and the Examiner has indicated that a written summary will be provided. See MPEP 713.04 Please further see: MPEP 713.04 Title 37 Code of Federal Regulations (CFR) § 1.133 Interviews, paragraph (b) 37 CFR § 1.2 Business to be transacted in writing	

Applicant Initiated Interview Request FormApplication No.: 15/606,265 First Named Applicant: Vigilytics LLCExaminer: Don Gordon Zhao Art Unit: 2493 Status of Application: Pending**Tentative Participants:**(1) Examiner Zhao (2) Jeff Barclay(3) Natalie Galley (4) _____Proposed Date of Interview: 8/14/17 Proposed Time: 1:30 EST AM/PM**Type of Interview Requested:**(1) ☒ Telephonic (2) ☐ Personal (3) ☐ Video ConferenceExhibit To Be Shown or Demonstrated: ☐ YES ☐ NO

If yes, provide brief description: _____

Issues To Be Discussed

Issues (Rej., Obj., etc)	Claims/Fig. #s	Prior Art	Discussed	Agreed	Not Agreed
(1) <u>Patenability</u>	_____	_____	☐	☐	☐
(2) _____	_____	_____	☐	☐	☐
(3) _____	_____	_____	☐	☐	☐
(4) _____	_____	_____	☐	☐	☐

☐ Continuation Sheet Attached ☐ Proposed Amendment or Arguments Attached**Brief Description of Arguments to be Presented:**Applicant thanks the Examiner for indicating allowable claims, and wishes to discuss claim amendments with reference to the double patenting rejection.An interview was conducted on the above-identified application on _____

NOTE: This form should be completed and filed by applicant in advance of the interview (see MPEP § 713.01). If this form is signed by a registered practitioner not of record, the Office will accept this as an indication that he or she is authorized to conduct an interview on behalf of the principal (37 CFR 1.32(a)(3)) pursuant to 37 CFR 1.34. This is not a power of attorney to any above named practitioner. See the Instruction Sheet for this form, which is incorporated by reference. By signing this form, applicant or practitioner is certifying that he or she has read the Instruction Sheet. After the interview is conducted, applicant is advised to file a statement of the substance of this interview (37 CFR 1.133(b)) as soon as possible. This application will not be delayed from issue because of applicant's failure to submit a written record of this interview.

/Natalie K Galley/

Applicant/Applicant's Representative Signature

Natalie K. Galley

Typed/Printed Name of Applicant or Representative

L1010

Registration Number, if applicable

Examiner/SPE Signature

This collection of information is required by 37 CFR 1.133. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 24 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Zhao, Don

From: Natalie Galley <galley@fr.com>
Sent: Thursday, August 10, 2017 5:07 PM
To: Zhao, Don
Cc: Jeffrey Barclay; APS Outgoing
Subject: Application No.: 15/606,265; Attorney Docket No.: 25412-0003003;
Interview Agenda
Attachments: Examiner interview agenda.doc

Examiner Zhao,

Attached please find an agenda for the interview on August 14th at 1:30 for application 15/606,265. Thank you for your consideration, and we will call you at 571-272-9953 at the appointed time.

Best regards,

Natalie Galley, Ph.D., J.D. :: Law Clerk :: Fish & Richardson P.C.
One Marina Park Drive, Boston, MA 02210-1878
617 956 5911 direct :: 617 542 5070 main :: 617 542 8906 fax

This email message is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized use or disclosure is prohibited. If you are not the intended recipient, please contact the sender by reply email and destroy all copies of the original message.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
15/606,265	05/26/2017	Andrew L. Paris III	25412-0003003	1070

26161 7590 07/14/2017
FISH & RICHARDSON P.C. (BO)
P.O. BOX 1022
MINNEAPOLIS, MN 55440-1022

EXAMINER

ZHAO, DON GORDON

ART UNIT	PAPER NUMBER
----------	--------------

2493

NOTIFICATION DATE	DELIVERY MODE
-------------------	---------------

07/14/2017

ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

PATDOCTC@fr.com

Office Action Summary	Application No. 15/606,265	Applicant(s) PARIS, ANDREW L.	
	Examiner Don Zhao	Art Unit 2493	AIA (First Inventor to File) Status No

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTHS FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 05/26/2017.
☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on _____.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on _____; the restriction requirement and election have been incorporated into this action.
- 4) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims*

- 5) ☒ Claim(s) 1-20 is/are pending in the application.
5a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 6) ☐ Claim(s) _____ is/are allowed.
- 7) ☒ Claim(s) 1-20 is/are rejected.
- 8) ☐ Claim(s) _____ is/are objected to.
- 9) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

* If any claims have been determined allowable, you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see http://www.uspto.gov/patents/init_events/pph/index.jsp or send an inquiry to PPHfeedback@uspto.gov.

Application Papers

- 10) ☐ The specification is objected to by the Examiner.
- 11) ☒ The drawing(s) filed on 05/26/2017 is/are: a) ☐ accepted or b) ☒ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

Certified copies:

- a) ☐ All b) ☐ Some** c) ☐ None of the:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

** See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) ☒ Notice of References Cited (PTO-892) | 3) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) ☒ Information Disclosure Statement(s) (PTO/SB/08a and/or PTO/SB/08b)
Paper No(s)/Mail Date <u>05/26/2017</u> | 4) ☐ Other: _____ |

DETAILED ACTION

Claims 1-20 are presented for examination on merits. The present application is being examined under the pre-AIA first to invent provisions.

Information Disclosure Statement

The information disclosure statement(s) (IDS) submitted on 05/26/2017 is/are in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement(s) is/are being considered by the examiner.

Claim Objections

Claims 1, 3, 5, 7, 9, 14, and 16 are objected to because of the following informalities:

Claims 1, 7 and 14 each recite a series of “medical information” that characterizes a group composed of multiple individuals in different forms as follows.

the requested medical information

the produced medical information

such medical information that characterizes the group; and

the produced medical information

It appears that the Applicant assumes that the same set of medical information stays the same when the medical information is processed throughout the various steps of requesting, producing, and providing. However, it is understood that the medical information may vary along the processing steps, meaning that the subset of the requested information may be smaller in size than the original size of the requested medical information. The Applicant is requested to

Art Unit: 2493

explain or make clear in the claim that the claimed invention always anticipates the same set size of the medical information throughout the process.

Claims 3, 9, and 16 each recite “medical information” in reference to the same medical information as defined in their base claims in the clause “wherein receiving the request for *medical information* that characterizes the group of individuals”, respectively. The Examiner suggests changing it to “the medical information.”

Claim 5 recites “medical data” which should have been recited as “the medical data.”

Appropriate correction is required.

Objections - Drawings

All Figures in the Application are not black and white drawings and consequently caused broken or blurred letters which are difficult to read, for example, FIGS. 4-6. When formal drawings are submitted, any showing of color in a black and white drawing is limited to the symbols used to line a surface to show color (MPEP § 608.02).

The Applicant is advised to submit all figures in black and white with clear labels. Corrected drawing sheets are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as “amended.” If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement

Art Unit: 2493

sheets may be necessary to show the renumbering of the remaining figures. If all the figures on a drawing sheet are canceled, a replacement sheet is not required. A marked-up copy of the drawing sheet (labeled as “Annotated Sheet”) including an annotation showing that all the figures on that drawing sheet have been canceled must be presented in the amendment or remarks section that explains the change to the drawings. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either “Replacement Sheet” or “New Sheet” pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Art Unit: 2493

Claims 1-20 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-26 of U.S. Patent No. US 9323892 B1 (hereinafter "PAT'892"). Although the conflicting claims are not identical, they are not patentably distinct from each other because they both claim the subject matter of producing medical information to report the pre or post-encounter characteristics for the group.

Regarding independent base claim 1, PAT'892 anticipates:

A computer-implemented method (PAT'892, CLM 1) comprising:

receiving a request from a user device for medical information that characterizes a group composed of multiple individuals from a set of de-identified medical data representing pre-or post-encounter characteristics of the individuals (PAT'892, CLM 1:);

producing, by a hardware processor, a request token for each individual included in the group of individuals (PAT'892, CLM 1; receiving a request from a user device for medical information that characterizes a group of individuals composed of multiple individuals from a set of de-identified medical data representing pre- or post-encounter characteristics of the individuals);

comparing the request tokens to tokens associated with the medical data to find matching tokens (PAT'892, CLM 3: comparing the produced token for each individual in the group to the tokens associated with the set of medical data);

producing the requested medical information, the identity of the individuals being unattainable from the produced medical information without the individuals in the group having authorized production of such medical information that characterizes the group (PAT'892, CLM

Art Unit: 2493

1: producing information ... with identifying tokens in the set of de-identified medical data and the associated de-identified medical data that correspond to the produced tokens; CLM 11: unattainable from the tokens); and

providing the produced medical information to report the characteristics of the group of individuals absent authorization from the individuals in the group of individuals (PAT'892, CLM 1: providing the produced medical information to report the characteristics of the group of individuals absent authorization from the individuals).

Regarding independent base claims 7 and 17, PAT'892 anticipates the claimed invention thereof for the same reasoning as presented above for claim 1. Therefore, claims 7 and 17 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable, respectively.

For similar obvious reasons, dependent claims 2-6, 8-13, and 15-20 are treated as obvious variants of the respective base claims 1, 7, and 14, and thus are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable.

Claim Rejections - 35 USC § 112

The following is a quotation of 35 U.S.C. 112(b):

(B) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.

The following is a quotation of 35 U.S.C. 112 (pre-AIA), second paragraph:

Art Unit: 2493

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-20 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention.

The rejection(s) under 35 U.S.C. 112(b) is/are determined by the following reasons:

Claims 1, 7 and 14 each recite the element “the identity of the individuals being unattainable” in the claims. There is insufficient antecedent basis for this limitation in the respective claims.

Claims 1, 7, and 14 each recite the limitation “the request tokens” in the step of “comparing *the request tokens* to tokens associated with the medical data...” There is insufficient antecedent basis for this limitation in the respective claims. It should be noted that the element “the request tokens” is in plural form while the definition of “a request token for each individual” includes the case where there may be only one individual associated with one single request token.

Claims 5, 11, and 18 each recite the limitation “the request tokens” without sufficient antecedent basis for this limitation in the claims, because the definition of the request tokens in the respective base claims 1, 7, and 14 is unclear or lack of sufficient antecedent basis.

Art Unit: 2493

Claims 1, 7 and 14 each recite the limitation "**the medical data**" in the step of "comparing the request tokens to tokens associated with *the medical data...*" There is insufficient antecedent basis for this limitation in the respective claims. The Examiner interprets "the medical data" as broadly recited is different from the set of de-identified medical data representing pre-or post-encounter characteristics of the individuals in the preamble(s).

Claims 5, 11, 13, and 18 each recite the limitation "**the medical data**" without sufficient antecedent basis for this limitation in the claims, respectively.

Claim 10 recites the limitation "the data." There is insufficient antecedent basis for this limitation in the claim.

Claim 12 recites the limitation "the data server." There is insufficient antecedent basis for this limitation in the claim.

The dependent claims 2-6, 8-13, and 15-20 are further rejected under 35 U.S.C. 112(B) as because they depend from the base claims 1, 7, and 14, respectively.

Allowable Subject Matter

Claims 1-20 are allowable over prior art for the following reasons:

In dependent claims 1, 7, and 14 each repeat a substantial portion of the allowable subject matter of the parent case Applicant No. 14/082433, now U.S. Patent #9,323,892. The claims recite key elements and features of the parent case for patentability. These features, in combination with the other limitations in the claim(s) 1, 7, and 14, are not anticipated by, nor made obvious over the prior art of record, rendering the subject matter allowable over prior art.

Conclusion

The prior art made of record and not relied upon is considered pertinent to applicant's disclosure as the prior art additionally discloses certain parts of the claim features (See "PTO-892 Notice of Reference Cited").

Any inquiry concerning this communication or earlier communications from the examiner should be directed to DON ZHAO whose telephone number is (571)272-9953. The examiner can normally be reached on Monday ~ Friday, 7:30 A.M ~ 5:00 P.M EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Carl G. Colin can be reached on (571) 272-3862. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would

Application/Control Number: 15/606,265

Page 10

Art Unit: 2493

like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Don Zhao/

Examiner, Art Unit 2493

07/10/2017

Notice of References Cited	Application/Control No. 15/606,265		Applicant(s)/Patent Under Reexamination PARIS, ANDREW L.	
	Examiner Don Zhao		Art Unit 2493	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	CPC Classification	US Classification
*	A	US-2008/0133273 A1	06-2008	Marshall; Philip	G06Q10/10	705/3
*	B	US-2009/0287502 A1	11-2009	Roberts; Michael F.	G06F19/328	705/3
*	C	US-2011/0184748 A1	07-2011	Fierro; Michael	G06Q10/00	705/2
*	D	US-2006/0020611 A1	01-2006	Gilbert; Eric S.	G06F17/30	1/1
*	E	US-2006/0020611 A1	01-2006	Gilbert; Eric S.	G06F17/30	1/1
*	F	US-2006/0004772 A1	01-2006	Hagan; Thomas	G06F21/6254	1/1
*	G	US-2007/0192140 A1	08-2007	Gropper; Adrian	G06Q50/24	705/3
*	H	US-2002/0188869 A1	12-2002	Patrick, Paul	G06F21/6245	726/4
*	I	US-2006/0004772 A1	01-2006	Hagan; Thomas	G06F21/6254	1/1
*	J	US-7,900,245 B1	03-2011	Geddes; Martin	H04L63/0407	713/159
*	K	US-2008/0306872 A1	12-2008	Felsher; David Paul	G06F19/322	705/51
*	L	US-7,900,245 B1	03-2011	Geddes; Martin	H04L63/0407	713/159
	M	US-				

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	CPC Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

BIB DATA SHEET

CONFIRMATION NO. 1070

SERIAL NUMBER	FILING or 371(c) DATE	CLASS	GROUP ART UNIT	ATTORNEY DOCKET NO.		
15/606,265	05/26/2017	726	2493	25412-0003003		
APPLICANTS Vigilytics LLC, Victor, NY; INVENTORS Andrew L. Paris III, Victor, NY; ** CONTINUING DATA ***** This application is a CON of 15/136,318 04/22/2016 PAT 9665685 which is a CON of 14/082,433 11/18/2013 PAT 9323892 which is a CIP of 12/827,745 06/30/2010 PAT 9118641 which claims benefit of 61/222,428 07/01/2009 and said 14/082,433 11/18/2013 claims benefit of 61/729,207 11/21/2012 ** FOREIGN APPLICATIONS ***** ** IF REQUIRED, FOREIGN FILING LICENSE GRANTED ** ** SMALL ENTITY ** 06/06/2017						
Foreign Priority claimed ☐ Yes ☒ No 35 USC 119(a-d) conditions met ☐ Yes ☒ No Verified and Acknowledged <u>/DON ZHAO/</u> Examiner's Signature		☐ Met after Allowance Initials	STATE OR COUNTRY NY	SHEETS DRAWINGS 7	TOTAL CLAIMS 20	INDEPENDENT CLAIMS 3
ADDRESS FISH & RICHARDSON P.C. (BO) P.O. BOX 1022 MINNEAPOLIS, MN 55440-1022 UNITED STATES						
TITLE USING DE-IDENTIFIED HEALTHCARE DATA TO EVALUATE POST-HEALTHCARE FACILITY ENCOUNTER TREATMENT OUTCOMES						
FILING FEE RECEIVED 730	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:			☐ All Fees ☐ 1.16 Fees (Filing) ☐ 1.17 Fees (Processing Ext. of time) ☐ 1.18 Fees (Issue) ☐ Other _____ ☐ Credit		

Sheet 1 of 2

Substitute Disclosure Form U.S. Department of Commerce Patent and Trademark Office Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	Attorney Docket No. 25412-0003003	Application No.
	Applicant Vigilytics LLC	
	Filing Date	Group Art Unit

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1.	2004/0143403	07/2004	Brandon et al.			
	2.	2005/0234739	10/2005	Schoenberg			
	3.	2005/0261941	11/2005	Scarlat			
	4.	2006/0004772	01/2006	Hagan et al.			
	5.	2006/0020611	01/2006	Gilbert et al.			
	6.	2006/0184524	08/2006	Pollanz			
	7.	2006/0229919	10/2006	Pugh			
	8.	2007/0043594	02/2007	Lavergne			
	9.	2007/0219824	09/2007	Rawlings et al.			
	10.	2008/0010254	01/2008	Settimi			
	11.	2008/0120296	05/2008	Kariathungal et al.			
	12.	2008/0133273	06/2008	Marshall			
	13.	2008/0147554	06/2008	Stevens et al.			
	14.	2009/0024416	01/2009	McLaughlin et al.			
	15.	2009/0070146	03/2009	Haider et al.			
	16.	2009/0112769	04/2009	Dicks			
	17.	2009/0287502	11/2009	Roberts et al.			
	18.	2010/0162355	06/2010	Zimmerman et al.			
	19.	2010/0287190	11/2010	Anderson			
	20.	2011/0184748	07/2011	Fierro et al.			
	21.	2011/0191767	08/2011	Pinsky			
	22.	2011/0191822	08/2011	Pinsky			
	23.	2011/0225007	09/2011	Theis			
	24.	2011/0258000	10/2011	Green et al.			
	25.	2013/0246334	09/2013	Ahuja			
	26.	2014/0053252	02/2014	Kelsey			

Examiner Signature /DON G ZHAO/	Date Considered 07/10/2017
---	--

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form

Datavant Exhibit 1002

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.G.Z/

Sheet 2 of 2

Substitute Disclosure Form U.S. Department of Commerce Patent and Trademark Office Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	Attorney Docket No. 25412-0003003	Application No.
	Applicant Vigilytics LLC	
	Filing Date	Group Art Unit

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	27.	2015/0046192	02/2015	Raduchel			
	28.	9,118,641	08/2015	Paris, III			
	29.	9,323,892	04/2016	Paris, III			
	30.	9,665,685	05/2017	Paris, III			

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
		---	---	---				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	31.	"Group," The American Heritage Dictionary, 2014 Houghton Mifflin Harcourt, Retrieved online: https://ahdictionary.com/word/search.html?q=group (accessed 10/23/2014), 3 pages
	32.	"Health Information Privacy: Business Associates," U.S. Department of Health and Human Services, April 3, 2003, Retrieved online: http://www.hhs.gov/ocr/privacy/hipaa/understanding/coveredentities/businessassociates.html , (accessed 10/09/2014), 2 pages

Examiner Signature /DON G ZHAO/	Date Considered 07/10/2017
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form

Datavant Exhibit 1002

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.G.Z/

<i>Index of Claims</i> 	Application/Control No. 15606265	Applicant(s)/Patent Under Reexamination PARIS, ANDREW L.
	Examiner DON ZHAO	Art Unit 2493

✓	Rejected	-	Cancelled	N	Non-Elected	A	Appeal
=	Allowed	÷	Restricted	I	Interference	O	Objected

☐ Claims renumbered in the same order as presented by applicant		☐ CPA		☐ T.D.		☐ R.1.47			
CLAIM		DATE							
Final	Original	07/10/2017							
	1	✓							
	2	✓							
	3	✓							
	4	✓							
	5	✓							
	6	✓							
	7	✓							
	8	✓							
	9	✓							
	10	✓							
	11	✓							
	12	✓							
	13	✓							
	14	✓							
	15	✓							
	16	✓							
	17	✓							
	18	✓							
	19	✓							
	20	✓							

Measuring service quality and its relationship to future consumer behavior.

DE Headley, SJ Miller - Journal of Health Care Marketing, 1993 - search.ebscohost.com

... Behavioral Intent Extension If the SERVQUAL scale is a reliable **method** for measuring perceived quality of ... a six-factor solution may be justified because the sixth factor had an eigenvalue of ... and Factor 5 of the original samples contain nearly similar items, with a single deletion ...

Cited by 291 Related articles All 6 versions Cite Save

Deviant customer behaviour: A study of techniques of neutralisation

LC Harris, KL Daunt - Journal of Marketing Management, 2011 - Taylor & Francis

... which were negated by otherwise functional behaviour (the metaphor of the ledger **technique** discussed in ... An allied form of dishonesty centred on deliberate acts to avoid payment for usage ... acts have no victim, payment avoiders argue that their actions are merely a reflection of ...

Cited by 42 Related articles All 6 versions Cite Save

Phasic vs sustained fear in rats and humans: role of the extended amygdala in fear vs anxiety

M Davis, DL Walker, L Miles, C Grillon - Neuropsychopharmacology, 2010 - nature.com

... In order to develop a **method** that had better stimulus control of this type of context conditioning, we used the design depicted in Figure 5. Rats received eight presentations on each of 3 days of ... Fear-potentiated startle to a discrete cue predictably paired with an aversive cue ...

Cited by 678 Related articles All 12 versions Cite Save

Using de-identified healthcare data to evaluate post-healthcare facility encounter treatment outcomes

AL Paris III - US Patent 9,665,685, 2017 - Google Patents

... 2 illustrates an exemplary **method** and system that enables a hospital to obtain **medical information** about a group of **people** without violating the privacy of persons in the ... The system 700 includes a processor 710, a memory 720, a storage device 730, and an input/output ...

Cite Save

Using de-identified healthcare data to evaluate post-healthcare facility encounter treatment outcomes

AL Paris III - US Patent 9,323,892, 2016 - Google Patents

... 2 illustrates an exemplary **method** and system that enables a hospital to obtain **medical information** about a group of **people** without violating the privacy of persons in the ... The system 700 includes a processor 710, a memory 720, a storage device 730, and an input/output ...

Related articles All 2 versions Cite Save

An Analysis Of Linking Formative And Summative Evaluations For Program Advancement

AE Carey - 2009 - digitalcommons.wayne.edu

... Each study was carefully examined for their evaluation components Data Gathering **Method A** sample of five ... is any written feedback the students use to describe training during a final evaluation ... Data Analysis The dependent variables are at an interval scale of measurement. ...

Related articles Cite Save

Superior Customer Experience In Voice-to-Voice Encounters: Insights From Three Studies Regarding Interaction And Call Center Management

S Bartsch - 2012 - books.google.com

... Self-Services From the Customer's Perspective.....97 4.6.1 **Method** and Procedure ... customer satisfaction, internal customer satisfaction and retention is a prerequisite and ... Few authors have chosen an integrative approach analyzing two (eg Jack ...

Cited by 5 Related articles Cite Save More

A PILOT STUDY IN THE USE OF HIGH FIDELITY SIMULATION TO IMPROVE EMERGENCY MEDICINE DEATH NOTIFICATION SKILLS

R Ahmed, M Beeson, H Gerzina, C Kyriakides... - journals.lww.com

... encounter. The purpose of this study is to explore the amount and type of clinical skill transferred during a simulated patient training work- shop using A/V guided peer feedback as an instructional method. **METHODS** ...

Related articles All 2 versions Cite Save

Gatekeeping Practices in Interpreted Social Service Encounters

S Pöllabauer - Meta: Journal des traducteurs/Meta: Translators' ..., 2012 - erudit.org

... A combination of different methods was used: 1) The overall communication situation (mainly discussed from a sociological and educational approach) in the two chosen institutions was studied ... This is clearly a very complicated process and an obstacle preventing ...

Cited by 1 Related articles All 3 versions Cite Save

Using Simulation to Train Staff for a Novel Unit Within the Children's Hospital of Philadelphia

A Ades, T Widmer, N Rintoul, J Patykula, A Scholtz - journals.lww.com

... Using a hybrid of an advanced birthing simulator and SP in an end of clerkship Ob/Gyn OSCE is an effective method to assess ob clinical skills in medical students in general but in particular Leopold's maneuvers and oral presentations. ...

All 2 versions Cite Save



A method of producing medical reports on pre-or post-encounter characteristics



Sign in

All News Images Shopping Videos More



Come here often? Make Google your homepage

About 7,600,000 results (1.00 seconds)

NO THANKS

YES, SHOW ME

[PDF] encounter: what does it mean? (or it takes at ... - Dartmouth-Hitchcock

www.dartmouth-hitchcock.org/dhmc-internet-upload/file.../charles%20c.pdf ▼

by L. Weill - Cited by 2693 - Related articles

We suggest as key characteristics of shared decision-making (1) that at least two ... portant to address in the medical encounter, first, because several treatment ...

Good practice in the conduct and reporting of survey research ...

intqhc.oxfordjournals.org/content/15/3/261 ▼

May 1, 2003 - Its purpose is to assist the novice researcher to produce survey work to a high ... sample of people from a pre-determined population (the 'population of interest'; this ... upon difficulties commonly encountered when using these methods. ... Good research has the characteristic that its purpose is to address a ...

Proactive Office Encounter: A Systematic Approach to Preventive and ...

<https://www.ncbi.nlm.nih.gov> > NCBI > Literature > PubMed Central (PMC)

by M Kanter - 2010 - Cited by 26 - Related articles

The medical literature reports that for a primary care physician to ensure that all ... The concept of the Proactive Office Encounter (POE) began as a question: ... Methods ... was built to address individual care gaps in every outpatient setting (Table 2), ... In addition, the patient may be contacted after the visit at the clinician's ...

Services Marketing - SlideShare

<https://www.slideshare.net/sarveshsoni/services-marketing-11347114> ▼

Jan 31, 2012 - Seek information from Strategic Responses to Managing ... Pre-purchase Stage Service Encounter Stage Post-encounter Stage ... System: Service Production and Delivery Servuction System ... Characteristics of Services ... need for Customization -Are you treated as an individual?

[PDF] Research Using Existing Data

freecontent.lww.com/wp-content/.../Chapter-13-Research-Using-Existing-Data.pdf ▼

by DG Grady - Cited by 3 - Related articles

greater precision than the individual study estimates. ... The main advantages of studies using existing data are speed and economy. ... Secondary data sets may come from medical records, health care billing files, death certificates, ... After choosing a research topic and becoming familiar with the literature in that area (...

The role of emotion in decision-making: A cognitive neuroeconomic ...

www.sciencedirect.com/science/article/pii/S1532046406000451 ▼

by LA Gutnik - 2006 - Cited by 98 - Related articles

In this paper, we review these integrative research methods and their applications ... In an immediate decision situation during a sexual encounter, there are only two ... The established paradigm for studying medical decision-making is the ... risk potential were lowered significantly after viewing photographs of people rated ...

[PDF] Clinical Decision Making - Brunel University Research Archive

v-scheiner.brunel.ac.uk/bitstream/2438/1395/1/2005-0319%20R2.pdf ▼

by M Benning - 2007 - Cited by 201 - Related articles

Feb 28, 2007 - between knowledge of pre-existing pathological conditions, explicit patient ... Results: The characteristics of the three models of decision making were identified ... The information procession model is rooted in medical decision making ... This may be undertaken shortly after the initial encounter and may be.

First impression (psychology) - Wikipedia

[https://en.wikipedia.org/wiki/First_impression_\(psychology\)](https://en.wikipedia.org/wiki/First_impression_(psychology)) ▼

In psychology, a first impression is the event when one person first encounters another person and forms a mental image of that person. Impression accuracy varies depending on the observer and the target (person, object, scene, etc.) being observed. First impressions are based on a wide range of characteristics: age, race, ... People are fairly good at assessing personality traits of others in general, but ...

[PDF] Real World Evidence - The Network For Excellence In Health Innovat...

www.nehi.net/writable/publication_files/file/rwe_issue_brief_final.pdf ▼

care decision making more closely to the characteristics of individual patients, ... authoritative medical evidence is generated through prospective randomized ... Pre-regulatory approval: RWE analysis may augment conventional RCT data with ... Post-approval: Analysis of patient outcomes from the use of innovations in real ...

[PDF] Guidelines for Pre- and Post-Testing - I-Tech

www.go2itech.org/resources/technical-implementation.../TIG2.GuidelinesTesting.pdf ▼

Pre- and post-test scores provide information on ... method of evaluating learning, such as the obser- ... is that it will not tell you what people will remember ... in spelling or definition instead of making important ... knowledge to a situation they will likely encounter ... her TB diagnosis her medical history had been normal.

Searches related to A method of producing medical reports on pre-or post-encounter characteristics of the individuals

survey research	descriptive research
types of research design	qualitative research
research methods	scholar
quantitative research	

1 2 3 4 5 6 7 8 9 10 Next

Alexandria, Virginia - From your Internet address - Use precise location - Learn more

[Help](#) [Send feedback](#) [Privacy](#) [Terms](#)

EAST Search History

EAST Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	0	15/606265.APP.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:17
L3	6765	(Rawlings NEAR3 Jean Anderson NEAR3 David Kraus NEAR3 Carl Paris NEAR3 Andrew).INV.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L4	31	L3 AND ((report\$3) near11 (encounter characteristics group))	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L5	1	14/082433.app.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L6	27977	(G06F19/322 G06F19/366 G06Q50/22 G06F21/6245).CPC.	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L7	2283	L6 AND ((report\$3) near11 (encounter characteristics group))	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L8	1	L7 AND ((non?identifiable de\$1identified) near4 (medical healthcare)) same token	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L9	1	L7 AND ((non?identifiable de\$1identified) near2 (medical healthcare)) same token	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L10	1	L7 AND ((non?identifiable de\$1identified) adj2 (data information) with (medical healthcare)) same token	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L11	2167	L7 AND ((report\$3) near11 (encounter characteristics group)) AND (Medical health healthcare)	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L12	1	L7 and (non\$1identified de\$1identified) and authorization near3 absent	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L13	27977	(G06F19/322 G06F19/366 G06Q50/22 G06F21/6245).CPC.	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18

L14	6765	(Rawlings NEAR3 Jean Anderson NEAR3 David Kraus NEAR3 Carl Paris NEAR3 Andrew).INV.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L15	15	L13 AND L3	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L16	14603	726/2,7,9,17,19.ccls.	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L17	4	726/2,7,9,17,19.ccls. AND L3	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L18	0	L13 AND (MEDICAL with (report) same (medical adj provider adj identifier))	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L19	2283	L13 AND ((report\$3) near11 (encounter characteristics group))	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L20	8	L3 AND ((report\$3) near11 (encounter characteristics group)) AND (Medical health healthcare)	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L21	3	(MEDICAL with (information report) same (medical adj provider adj identifier))	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L22	22	(MEDICAL with (information report) same (medical adj3 provider adj3 identifier))	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L23	1	14/082433.app.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L24	11	((Andrew) near2 (Paris)).INV.	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L25	6765	(Rawlings NEAR3 Jean Anderson NEAR3 David Kraus NEAR3 Carl Paris NEAR3 Andrew).INV.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L26	1	12/827745.APP.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L27	731	group near3 (private individual patients) with medical near3 (information record encounter\$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO;	OR	ON	2017/07/10 09:18

			IBM_TDB			
L28	11	L25 and L27	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L29	9	L28 and @ad<"20121121"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L30	6	L28 and @pd<"20121121"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L31	50	INGENIX.AS.	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L32	7	L27 AND INGENIX.AS.	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L33	7	L32 and @ad<"20121121"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L34	7	L32 and @PD<"20121121"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L35	1	L32 and @PD<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L36	1	L32 and @PD<"20090701" and (group near5 (patients or health near3 members))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L37	17	L25 and @PD<"20090701" and (group near5 (patients or health near3 members))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L38	229	L27 and @PD<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO;	OR	ON	2017/07/10 09:18

			IBM_TDB			
L39	183	L38 and (group near5 (patients or health near3 members))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L40	179	L38 and (group near5 (patients or health near3 members)) WITH (medical near5 (information record))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L41	2	(encrypted with (provider adj identifier\$1)) same match\$3 and database	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L42	89	("20030097358" "20040199781" "20050256740" "20050256741" "20050268094" "3752904" "5471382" "5652842" "5664109" "5704044" "5724575" "5754938" "5793969" "5890129" "6012051" "6079021" "6249768" "6302844" "7376677" "20050065912" "20050256742" "20060026156" "5301105" "5606610" "5666492" "5799086" "5799308" "5821871" "5823948" "5926810" "6085322" "6449621" "6732113" "6915265" "20020198473" "20050165623" "20080147554" "20100217973" "5758085" "5832449" "5915240" "5961593" "5991731" "5995939" "6266675" "7184947" "3896266" "4979832" "4993068" "5003539" "5825906" "5956716" "6496931" "7386526" "5005200" "5070452" "5299121" "5758095" "5867821" "5970462" "6014631" "7200578" "20050027564" "20050234740" "20050236474" "20100114607" "5214702" "5371797" "5644778" "6317700" "6397224" "6421650" "6654724" "20040215981" "5502764" "5581749" "5787186" "5876926" "5907677" "5918208" "5920854" "6018713" "20080091474" "6003006" "6024287" "6341267" "6734886" "7309001" "20020143434").PN.	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L43	717	database and (APK ANONYMOUS\$2 adj Practitioner adj identifier)	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L44	599	(associat\$3 cross?reference\$1) same de?identified	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L45	171	de?identif\$3 and provider near2 (credential or identification\$1 or identifier\$1 or ID or certificate or passport descriptor)	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L46	32	(US-20080147554-\$ or US-	US-PGPUB;	OR	ON	2017/07/10

		20020016923-\$ or US-20070130465-\$ or US-20080306872-\$ or US-20080304663-\$ or US-20080133273-\$ or US-20080040151-\$ or US-20050267782-\$ or US-20050119941-\$ or US-20060020611-\$ or US-20070185737-\$ or US-20060004772-\$ or US-20080120296-\$ or US-20080010254-\$ or US-20040078236-\$ or US-20090287502-\$ or US-20080281631-\$ or US-20080137848-\$ or US-20110255690-\$ or US-20070033419-\$ or US-20120246661-\$ or US-20090257586-\$).did. or (US-5721777-\$ or US-8296341-\$ or US-6302844-\$ or US-6874085-\$ or US-8037052-\$ or US-7716487-\$ or US-6947561-\$ or US-8131646-\$ or US-8055910-\$ or US-8108355-\$).did.	USPAT			09:18
L47	162	(random adj3 sequence) and frame with block and portion with key	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L48	2	12/684748.APP.	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L49	1	L48 and (unencrypted near3 (medical adj provider adj identifier))	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L50	1	L49	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L51	183	L38 and (group near5 (patients or health near3 members))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L52	145343	G06F19\$.CPC.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L53	445	L27 AND G06F19\$.CPC.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L54	1	L26 AND G06F19\$.CPC.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L55	114	L25 AND G06F19\$.CPC.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18

L56	19592	G06F19/322.CPC.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L57	3829	G06F19/366.CPC.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L58	71	G06F19/322.CPC. AND (de?identif\$3 and provider near2 (credential or identification\$1 or identifier\$1 or ID or certificate or passport descriptor))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L59	0	L57 AND L58	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L60	0	G06F19/366.CPC. AND de?identif\$3 and provider near2 (credential or identification\$1 or identifier\$1 or ID or certificate or passport descriptor)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L61	25	G06F19/366.CPC. AND de?identif\$3	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L62	0	L58 AND L61	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L63	6	L58 and @PD< "20090701" and (group near5 (patients or health near3 members))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L64	7	L61 and @PD< "20090701" and (group near5 (patients or health near3 members))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L65	2	G06F19/322.CPC. and (encrypted near3 (medical adj provider adj identifier))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18

L66	46	(US-20080147554-\$ or US-20020016923-\$ or US-20070130465-\$ or US-20080306872-\$ or US-20080304663-\$ or US-20080133273-\$ or US-20080040151-\$ or US-20050267782-\$ or US-20050119941-\$ or US-20060020611-\$ or US-20070185737-\$ or US-20060004772-\$ or US-20080120296-\$ or US-20080010254-\$ or US-20040078236-\$ or US-20090287502-\$ or US-20080281631-\$ or US-20080137848-\$ or US-20110255690-\$ or US-20070033419-\$ or US-20120246661-\$ or US-20090257586-\$ or US-20100325148-\$ or US-20100287190-\$ or US-20080306952-\$ or US-20070219824-\$).did. or (US-20070106753-\$ or US-20070106752-\$ or US-20060089857-\$ or US-20070192140-\$ or US-20050177050-\$ or US-20100217973-\$).did. or (US-5721777-\$ or US-8296341-\$ or US-6302844-\$ or US-6874085-\$ or US-8037052-\$ or US-7716487-\$ or US-6947561-\$ or US-8131646-\$ or US-8055910-\$ or US-8108355-\$).did. or (WO-2010129653-\$ or CA-2760773-\$ or WO-2007108814-\$).did. or (WO-2010129653-\$).did.	US-PGPUB; USPAT; FPRS; EPO	OR	ON	2017/07/10 09:18
L67	20	L66 AND G06F19/322.CPC.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L68	10	L67 and @PD<"20090701" and (group near5 (patients or health near3 members))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L69	5	L63 AND L68	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L70	1	726/09	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L71	2597	726/9.ccls.	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L72	3	L71 and @PD<"20090701" and (group near5 (patients or health near3 members))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L73	1	L25 and 726/9.ccls.	US-PGPUB; USPAT;	OR	ON	2017/07/10 09:18

			USOCR			
L74	0	L27 and 726/9.ccls.	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L75	26	L27 and "726".clas.	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L76	6	L75 AND G06F19/322.CPC.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L77	1	L76 and @PD<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L78	1	("20060184524" "20110258000").PN. AND G06F19/322.CPC.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L79	8653	726/26.CCLS.	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L80	0	L63 AND 726/26.CCLS.	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L81	2	L27 AND 726/26.CCLS.	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L82	2	L46 AND 726/26.CCLS.	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L83	55	(US-20080147554-\$ or US- 20020016923-\$ or US-20070130465-\$ or US-20080306872-\$ or US- 20080304663-\$ or US-20080133273-\$ or US-20080040151-\$ or US- 20050267782-\$ or US-20050119941-\$ or US-20060020611-\$ or US- 20070185737-\$ or US-20060004772-\$ or US-20080120296-\$ or US- 20080010254-\$ or US-20040078236-\$ or US-20090287502-\$ or US- 20080281631-\$ or US-20080137848-\$ or US-20110255690-\$ or US- 20070033419-\$ or US-20120246661-\$ or US-20090257586-\$ or US- 20100325148-\$ or US-20100287190-\$ or US-20080306952-\$ or US- 20070219824-\$).did. or (US- 20070106753-\$ or US-20070106752-\$ or US-20060089857-\$ or US- 20070192140-\$ or US-20050177050-\$ or US-20100217973-\$ or US- 20070043594-\$ or US-20030154405-\$	US-PGPUB; USPAT; FPRS; EPO	OR	ON	2017/07/10 09:18

		or US-20080071577-\$ or US-20100162355-\$ or US-20060184524-\$).did. or (US-5721777-\$ or US-8296341-\$ or US-6302844-\$ or US-6874085-\$ or US-8037052-\$ or US-7716487-\$ or US-6947561-\$ or US-8131646-\$ or US-8055910-\$ or US-8108355-\$ or US-7900245-\$ or US-8229742-\$ or US-7650628-\$ or US-5956400-\$).did. or (WO-2010129653-\$ or CA-2760773-\$ or WO-2007108814-\$).did. or (WO-2010129653-\$).did.				
L84	15	L83 and pharmac\$3	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L85	8	L83 and pharmac\$3 and encrypt\$3 with (id identifier token)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L86	4	L85 and (id identifier token) near5 (compar\$3 comparison match\$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L87	3	L85 and (id identifier token) near5 (compar\$3 comparison)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L88	3	L85 and (id identifier token) near5 (match\$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L89	2	L87 and L88	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L90	1	L88 NOT L89	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L91	22	L83 and PRODUCT\$3 near3 information	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L92	9	L91 and (id identifier token) near5	US-PGPUB;	OR	ON	2017/07/10

		(compar\$3 comparison match\$3)	USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB			09:18
L93	2	L89 and (id identifier token) near5 (compar\$3 comparison match\$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L94	8	L83 and (produce producing provid\$3) adj3 medical adj3 information	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L95	2	L86 and L94	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L96	2	L95 and (pharmac\$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L97	2	L95 and (pharmac\$3) and (visit\$3 encounter\$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L98	1	L95 and (pharmac\$3) and (visit\$3 and encounter\$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L99	1	L95 and (pharmac\$3) and (encounter\$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L100	1	L95 and (pharmac\$3) and (encounter\$3) and (medical center)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L101	1	L95 and (pharmac\$3) and (encounter\$3) and (institution)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L102	4	L86 and (unattain\$4 attain\$4 obtain\$3	US-PGPUB;	OR	ON	2017/07/10

		)	USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB			09:18
L103	1	L86 and (unattain\$4 attain\$4 obtain\$3) with pharmac\$3	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L104	1	L86 and health adj2 record	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L105	1	L86 and de-identifi\$3	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L106	14	L83 and de-identifi\$3 with record	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L107	5	L83 and de-identifi\$3 with record and pharmac\$4	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L108	20	L83 and de-identifi\$3	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L109	2	("20080133273" "20090287502").pn. and request\$3	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L110	1	("20080133273" "20090287502").pn. and (compar\$3 match\$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L111	31137	("20080133273" "20090287502").pn. encrypt\$3 WITH ID	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L112	2	("20080133273" "20090287502").pn.	US-PGPUB;	OR	ON	2017/07/10

		AND encrypt\$3 WITH ID	USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB			09:18
L113	1	("20080133273").pn. AND encrypt\$3 WITH ID	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L114	1	("20080133273" "20090287502").pn. and minimum	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L115	55	(US-20080147554-\$ or US- 20020016923-\$ or US-20070130465-\$ or US-20080306872-\$ or US- 20080304663-\$ or US-20080133273-\$ or US-20080040151-\$ or US- 20050267782-\$ or US-20050119941-\$ or US-20060020611-\$ or US- 20070185737-\$ or US-20060004772-\$ or US-20080120296-\$ or US- 20080010254-\$ or US-20040078236-\$ or US-20090287502-\$ or US- 20080281631-\$ or US-20080137848-\$ or US-20110255690-\$ or US- 20070033419-\$ or US-20120246661-\$ or US-20090257586-\$ or US- 20100325148-\$ or US-20100287190-\$ or US-20080306952-\$ or US- 20070219824-\$).did. or (US- 20070106753-\$ or US-20070106752-\$ or US-20060089857-\$ or US- 20070192140-\$ or US-20050177050-\$ or US-20100217973-\$ or US- 20070043594-\$ or US-20030154405-\$ or US-20080071577-\$ or US- 20100162355-\$ or US-20060184524-\$).did. or (US-5721777-\$ or US- 8296341-\$ or US-6302844-\$ or US- 6874085-\$ or US-8037052-\$ or US- 7716487-\$ or US-6947561-\$ or US- 8131646-\$ or US-8055910-\$ or US- 8108355-\$ or US-7900245-\$ or US- 8229742-\$ or US-7650628-\$ or US- 5956400-\$).did. or (WO-2010129653-\$ or CA-2760773-\$ or WO-2007108814-\$).did. or (WO-2010129653-\$).did.	US-PGPUB; USPAT; FPRS; EPO	OR	ON	2017/07/10 09:18
L116	5	L115 and number with match	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L117	2	("20080133273" "20090287502").pn. AND portion	US-PGPUB; USPAT; USOCR; FPRS;	OR	ON	2017/07/10 09:18

			EPO; JPO; IBM_TDB			
L118	4	("20080133273" "20090287502" "20060020611").pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L119	2	L118 AND number near6 (patients users individuals)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L120	2	L118 AND group near6 (patients users individuals)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L121	1	L118 AND group near6 (patients users individuals) with number	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L122	55	(US-20080147554-\$ or US- 20020016923-\$ or US-20070130465-\$ or US-20080306872-\$ or US- 20080304663-\$ or US-20080133273-\$ or US-20080040151-\$ or US- 20050267782-\$ or US-20050119941-\$ or US-20060020611-\$ or US- 20070185737-\$ or US-20060004772-\$ or US-20080120296-\$ or US- 20080010254-\$ or US-20040078236-\$ or US-20090287502-\$ or US- 20080281631-\$ or US-20080137848-\$ or US-20110255690-\$ or US- 20070033419-\$ or US-20120246661-\$ or US-20090257586-\$ or US- 20100325148-\$ or US-20100287190-\$ or US-20080306952-\$ or US- 20070219824-\$).did. or (US- 20070106753-\$ or US-20070106752-\$ or US-20060089857-\$ or US- 20070192140-\$ or US-20050177050-\$ or US-20100217973-\$ or US- 20070043594-\$ or US-20030154405-\$ or US-20080071577-\$ or US- 20100162355-\$ or US-20060184524-\$).did. or (US-5721777-\$ or US- 8296341-\$ or US-6302844-\$ or US- 6874085-\$ or US-8037052-\$ or US- 7716487-\$ or US-6947561-\$ or US- 8131646-\$ or US-8055910-\$ or US- 8108355-\$ or US-7900245-\$ or US- 8229742-\$ or US-7650628-\$ or US- 5956400-\$).did. or (WO-2010129653-\$ or CA-2760773-\$ or WO-2007108814-\$).did. or (WO-2010129653-\$).did.	US-PGPUB; USPAT; FPRS; EPO	OR	ON	2017/07/10 09:18
L123	10	L122 AND group near6 (patients users	US-PGPUB;	OR	ON	2017/07/10

		individuals) with number	USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB			09:18
L124	2	L122 AND group near6 number NEAR5 (patients users individuals)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L125	7	L122 AND (LEAST MINIMUM) near3 number	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L126	616	medical same de-identified	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L127	744	medical same de-identifi\$6	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L128	1104	medical near4 (information database record) and de-identifi\$6	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L129	13	L128 AND (MINIMUM) adj2 number with group	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L130	42	L128 AND (MINIMUM) with group	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L131	277	(MINIMUM) near3 number near3 (individual users) with group	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L132	66	L131 and (medical healthcare)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L133	6	L132 and @pd<"20090701"	US-PGPUB;	OR	ON	2017/07/10

			USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB			09:18
L134	16	L132 and @ad<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L135	1	("20080133273").pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L136	4	"20080133273" "20090287502"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L137	1	L136 and de?identif\$3	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L138	2	L136 and identif\$3	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L139	1	L136 and identif\$3 and group	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L140	1	L136 and identif\$3 same group	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L141	57	(US-20080147554-\$ or US- 20020016923-\$ or US-20070130465-\$ or US-20080306872-\$ or US- 20080304663-\$ or US-20080133273-\$ or US-20080040151-\$ or US- 20050267782-\$ or US-20050119941-\$ or US-20060020611-\$ or US- 20070185737-\$ or US-20060004772-\$ or US-20080120296-\$ or US- 20080010254-\$ or US-20040078236-\$ or US-20090287502-\$ or US- 20080281631-\$ or US-20080137848-\$ or US-20110255690-\$ or US- 20070033419-\$ or US-20120246661-\$	US-PGPUB; USPAT; FPRS; EPO	OR	ON	2017/07/10 09:18

		or US-20090257586-\$ or US-20100325148-\$ or US-20100287190-\$ or US-20080306952-\$ or US-20070219824-\$).did. or (US-20070106753-\$ or US-20070106752-\$ or US-20060089857-\$ or US-20070192140-\$ or US-20050177050-\$ or US-20100217973-\$ or US-20070043594-\$ or US-20030154405-\$ or US-20080071577-\$ or US-20100162355-\$ or US-20060184524-\$ or US-20110231422-\$ or US-20040143403-\$).did. or (US-5721777-\$ or US-8296341-\$ or US-6302844-\$ or US-6874085-\$ or US-8037052-\$ or US-7716487-\$ or US-6947561-\$ or US-8131646-\$ or US-8055910-\$ or US-8108355-\$ or US-7900245-\$ or US-8229742-\$ or US-7650628-\$ or US-5956400-\$).did. or (WO-2010129653-\$ or CA-2760773-\$ or WO-2007108814-\$).did. or (WO-2010129653-\$).did.				
L142	4	L141 and authorization with absent	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L143	7	medical with authorization near3 absent	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L144	10	(non\$1identified de\$1identified) and authorization near3 absent	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L145	10	(non\$1identified de\$1identified) and authorization near3 absent and group	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L146	11	((Andrew) near2 (Paris)).INV.	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L147	6765	(Rawlings NEAR3 Jean Anderson NEAR3 David Kraus NEAR3 Carl Paris NEAR3 Andrew).INV.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L148	1	12/827745.APP.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18

L149	731	group near3 (private individual patients) with medical near3 (information record encounter\$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L150	11	L147 and L149	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L151	9	L150 and @ad<"20121121"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L152	6	L150 and @pd<"20121121"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L153	50	INGENIX.AS.	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L154	7	L149 AND INGENIX.AS.	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L155	1	L154 and @PD<"20090701" and (group near5 (patients or health near3 members))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L156	17	L147 and @PD<"20090701" and (group near5 (patients or health near3 members))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L157	229	L149 and @PD<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L158	183	L157 and (group near5 (patients or health near3 members))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L159	179	L157 and (group near5 (patients or health near3 members)) WITH (medical near5 (information record))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18

L160	2	(encrypted with (provider adj identifier\$1)) same match\$3 and database	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L161	89	("20030097358" "20040199781" "20050256740" "20050256741" "20050268094" "3752904" "5471382" "5652842" "5664109" "5704044" "5724575" "5754938" "5793969" "5890129" "6012051" "6079021" "6249768" "6302844" "7376677" "20050065912" "20050256742" "20060026156" "5301105" "5606610" "5666492" "5799086" "5799308" "5821871" "5823948" "5926810" "6085322" "6449621" "6732113" "6915265" "20020198473" "20050165623" "20080147554" "20100217973" "5758085" "5832449" "5915240" "5961593" "5991731" "5995939" "6266675" "7184947" "3896266" "4979832" "4993068" "5003539" "5825906" "5956716" "6496931" "7386526" "5005200" "5070452" "5299121" "5758095" "5867821" "5970462" "6014631" "7200578" "20050027564" "20050234740" "20050236474" "20100114607" "5214702" "5371797" "5644778" "6317700" "6397224" "6421650" "6654724" "20040215981" "5502764" "5581749" "5787186" "5876926" "5907677" "5918208" "5920854" "6018713" "20080091474" "6003006" "6024287" "6341267" "6734886" "7309001" "20020143434").PN.	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L162	717	database and (APK ANONYMOUS\$2 adj Practitioner adj identifier)	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L163	599	(associat\$3 cross?reference\$1) same de?identified	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L164	171	de?identif\$3 and provider near2 (credential or identification\$1 or identifier\$1 or ID or certificate or passport descriptor)	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L165	32	(US-20080147554-\$ or US-20020016923-\$ or US-20070130465-\$ or US-20080306872-\$ or US-20080304663-\$ or US-20080133273-\$ or US-20080040151-\$ or US-20050267782-\$ or US-20050119941-\$ or US-20060020611-\$ or US-20070185737-\$ or US-20060004772-\$ or US-20080120296-\$ or US-20080010254-\$ or US-20040078236-\$ or US-20090287502-\$ or US-20080281631-\$ or US-20080137848-\$ or US-20110255690-\$ or US-20070033419-\$ or US-20120246661-\$ or US-20090257586-\$).did. or (US-	US-PGPUB; USPAT	OR	ON	2017/07/10 09:18

		5721777-\$ or US-8296341-\$ or US-6302844-\$ or US-6874085-\$ or US-8037052-\$ or US-7716487-\$ or US-6947561-\$ or US-8131646-\$ or US-8055910-\$ or US-8108355-\$).did.				
L166	162	(random adj3 sequence) and frame with block and portion with key	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L167	2	12/684748.APP.	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L168	183	L157 and (group near5 (patients or health near3 members))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L169	145343	G06F19\$.CPC.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L170	445	L149 AND G06F19\$.CPC.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L171	114	L147 AND G06F19\$.CPC.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L172	19592	G06F19/322.CPC.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L173	3829	G06F19/366.CPC.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L174	71	G06F19/322.CPC. AND (de?identif\$3 and provider near2 (credential or identification\$1 or identifier\$1 or ID or certificate or passport descriptor))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L175	25	G06F19/366.CPC. AND de?identif\$3	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L176	0	L174 AND L175	US-PGPUB;	OR	ON	2017/07/10

			USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB			09:18
L177	71	G06F19/322.CPC. AND (de?identif\$3 and provider near2 (credential or identification\$1 or identifier\$1 or ID or certificate or passport descriptor))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L178	6	L174 and @PD<"20090701" and (group near5 (patients or health near3 members))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L179	1	726/09	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L180	2597	726/9.ccls.	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L181	3	L180 and @PD<"20090701" and (group near5 (patients or health near3 members))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L182	1	L147 and 726/9.ccls.	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L183	0	L149 and 726/9.ccls.	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L184	26	L149 and "726".clas.	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L185	6	L184 AND G06F19/322.CPC.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L186	1	L185 and @PD<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L187	1	("20060184524" "20110258000").PN. AND G06F19/322.CPC.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L188	8653	726/26.CCLS.	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18

L189	0	L178 AND 726/26.CCLS.	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L190	2	L149 AND 726/26.CCLS.	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L191	2	L165 AND 726/26.CCLS.	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L192	55	(US-20080147554-\$ or US-20020016923-\$ or US-20070130465-\$ or US-20080306872-\$ or US-20080304663-\$ or US-20080133273-\$ or US-20080040151-\$ or US-20050267782-\$ or US-20050119941-\$ or US-20060020611-\$ or US-20070185737-\$ or US-20060004772-\$ or US-20080120296-\$ or US-20080010254-\$ or US-20040078236-\$ or US-20090287502-\$ or US-20080281631-\$ or US-20080137848-\$ or US-20110255690-\$ or US-20070033419-\$ or US-20120246661-\$ or US-20090257586-\$ or US-20100325148-\$ or US-20100287190-\$ or US-20080306952-\$ or US-20070219824-\$).did. or (US-20070106753-\$ or US-20070106752-\$ or US-20060089857-\$ or US-20070192140-\$ or US-20050177050-\$ or US-20100217973-\$ or US-20070043594-\$ or US-20030154405-\$ or US-20080071577-\$ or US-20100162355-\$ or US-20060184524-\$).did. or (US-5721777-\$ or US-8296341-\$ or US-6302844-\$ or US-6874085-\$ or US-8037052-\$ or US-7716487-\$ or US-6947561-\$ or US-8131646-\$ or US-8055910-\$ or US-8108355-\$ or US-7900245-\$ or US-8229742-\$ or US-7650628-\$ or US-5956400-\$).did. or (WO-2010129653-\$ or CA-2760773-\$ or WO-2007108814-\$).did. or (WO-2010129653-\$).did.	US-PGPUB; USPAT; FPRS; EPO	OR	ON	2017/07/10 09:18
L193	15	L192 and pharmac\$3	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L194	8	L192 and pharmac\$3 and encrypt\$3 with (id identifier token)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L195	4	L194 and (id identifier token) near5 (compar\$3 comparison match\$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18

L196	0	L194 and (id identifier token) near5 (compar\$3 comparison match\$3) same group	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L197	0	L194 and (id identifier token) near5 (compar\$3 comparison match\$3) same set	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L198	3	L194 and (id identifier token) near5 (compar\$3 comparison)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L199	3	L194 and (id identifier token) near5 (match\$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L200	2	L198 and L199	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L201	13014	L179 L180 L181 "s661" "s662" L182 L183 L184 "s666" L185 L186 L187 L188 L189 L190 "s673" L191 L192 L193 L194 L195 L196 L197 L198 L199 L200	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L202	10054	726/7,9,17,19.ccls.	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L203	1	L202 and @PD<"20090701" and (group near5 (patients or health near3 members)) and (authorization authenticaton) near3 (absent without)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L204	10054	726/7,9,17,19.ccls.	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L205	3	L204 and @PD<"20090701" and (group near5 (patients or health near3 members)) and (authorization authenticaton)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	ON	2017/07/10 09:18
L206	59	(US-20080147554-\$ or US-20020016923-\$ or US-20070130465-\$ or US-20080306872-\$ or US-20080304663-\$ or US-20080133273-\$ or US-20080040151-\$ or US-20050267782-\$ or US-20050119941-\$	US-PGPUB; USPAT; FPRS; EPO	OR	ON	2017/07/10 09:18

		or US-20060020611-\$ or US-20070185737-\$ or US-20060004772-\$ or US-20080120296-\$ or US-20080010254-\$ or US-20040078236-\$ or US-20090287502-\$ or US-20080281631-\$ or US-20080137848-\$ or US-20110255690-\$ or US-20070033419-\$ or US-20120246661-\$ or US-20090257586-\$ or US-20100325148-\$ or US-20100287190-\$ or US-20080306952-\$ or US-20070219824-\$).did. or (US-20070106753-\$ or US-20070106752-\$ or US-20060089857-\$ or US-20070192140-\$ or US-20050177050-\$ or US-20100217973-\$ or US-20070043594-\$ or US-20030154405-\$ or US-20080071577-\$ or US-20100162355-\$ or US-20060184524-\$ or US-20110231422-\$ or US-20040143403-\$ or US-20070157297-\$ or US-20020188869-\$).did. or (US-5721777-\$ or US-8296341-\$ or US-6302844-\$ or US-6874085-\$ or US-8037052-\$ or US-7716487-\$ or US-6947561-\$ or US-8131646-\$ or US-8055910-\$ or US-8108355-\$ or US-7900245-\$ or US-8229742-\$ or US-7650628-\$ or US-5956400-\$).did. or (WO-2010129653-\$ or CA-2760773-\$ or WO-2007108814-\$).did. or (WO-2010129653-\$).did.				
L207	9	L206 and report\$3 same authorization	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2017/07/10 09:18
L208	0	"20060004772".pn. and (weaken\$3 groups sufficiently large) with (individual near\$3 identif\$3) and (track\$3) with individule	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2017/07/10 09:18
L209	18	("5220501" "5517405" "5592553" "5696824" "5754938" "5768382" "5790668" "5815665" "5857021" "5875302" "5890129" "5915001" "5996076" "6006333" "6016480" "6038315" "6052730" "6317834").PN. OR ("8296341").URPN.	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L210	18	("5220501" "5517405" "5592553" "5696824" "5754938" "5768382" "5790668" "5815665" "5857021" "5875302" "5890129" "5915001" "5996076" "6006333" "6016480" "6038315" "6052730" "6317834").PN. OR ("8296341").URPN. and (without absent) near\$5 authorization	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18

L211	18	("5220501" "5517405" "5592553" "5696824" "5754938" "5768382" "5790668" "5815665" "5857021" "5875302" "5890129" "5915001" "5996076" "6006333" "6016480" "6038315" "6052730" "6317834").PN.	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L212	2	L211 and (without absent) near5 authorization	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L213	14	report\$3 with group SAME (without absent) near5 authorization	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L214	1	"8078625".PN. and (response respond\$3)	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L215	5	"20110184748." "pn." and (report\$3 characteristic)	US-PGPUB; USPAT; USOCR	OR	ON	2017/07/10 09:18
L216	60	(US-20080147554-\$ or US-20020016923-\$ or US-20070130465-\$ or US-20080306872-\$ or US-20080304663-\$ or US-20080133273-\$ or US-20080040151-\$ or US-20050267782-\$ or US-20050119941-\$ or US-20060020611-\$ or US-20070185737-\$ or US-20060004772-\$ or US-20080120296-\$ or US-20080010254-\$ or US-20040078236-\$ or US-20090287502-\$ or US-20080281631-\$ or US-20080137848-\$ or US-20110255690-\$ or US-20070033419-\$ or US-20120246661-\$ or US-20090257586-\$ or US-20100325148-\$ or US-20100287190-\$ or US-20080306952-\$ or US-20070219824-\$).did. or (US-20070106753-\$ or US-20070106752-\$ or US-20060089857-\$ or US-20070192140-\$ or US-20050177050-\$ or US-20100217973-\$ or US-20070043594-\$ or US-20030154405-\$ or US-20080071577-\$ or US-20100162355-\$ or US-20060184524-\$ or US-20110231422-\$ or US-20040143403-\$ or US-20070157297-\$ or US-20020188869-\$ or US-20110184748-\$).did. or (US-5721777-\$ or US-8296341-\$ or US-6302844-\$ or US-6874085-\$ or US-8037052-\$ or US-7716487-\$ or US-6947561-\$ or US-8131646-\$ or US-8055910-\$ or US-8108355-\$ or US-7900245-\$ or US-8229742-\$ or US-7650628-\$ or US-5956400-\$).did. or (WO-2010129653-\$ or CA-2760773-\$ or WO-2007108814-\$).did. or (WO-2010129653-\$).did.	US-PGPUB; USPAT; FPRS; EPO	OR	ON	2017/07/10 09:18
L217	20	L216 and hipaa	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO;	OR	ON	2017/07/10 09:18

			DERWENT; IBM_TDB			
L218	60	(US-20080147554-\$ or US-20020016923-\$ or US-20070130465-\$ or US-20080306872-\$ or US-20080304663-\$ or US-20080133273-\$ or US-20080040151-\$ or US-20050267782-\$ or US-20050119941-\$ or US-20060020611-\$ or US-20070185737-\$ or US-20060004772-\$ or US-20080120296-\$ or US-20080010254-\$ or US-20040078236-\$ or US-20090287502-\$ or US-20080281631-\$ or US-20080137848-\$ or US-20110255690-\$ or US-20070033419-\$ or US-20120246661-\$ or US-20090257586-\$ or US-20100325148-\$ or US-20100287190-\$ or US-20080306952-\$ or US-20070219824-\$).did. or (US-20070106753-\$ or US-20070106752-\$ or US-20060089857-\$ or US-20070192140-\$ or US-20050177050-\$ or US-20100217973-\$ or US-20070043594-\$ or US-20030154405-\$ or US-20080071577-\$ or US-20100162355-\$ or US-20060184524-\$ or US-20110231422-\$ or US-20040143403-\$ or US-20070157297-\$ or US-20020188869-\$ or US-20110184748-\$).did. or (US-5721777-\$ or US-8296341-\$ or US-6302844-\$ or US-6874085-\$ or US-8037052-\$ or US-7716487-\$ or US-6947561-\$ or US-8131646-\$ or US-8055910-\$ or US-8108355-\$ or US-7900245-\$ or US-8229742-\$ or US-7650628-\$ or US-5956400-\$).did. or (WO-2010129653-\$ or CA-2760773-\$ or WO-2007108814-\$).did. or (WO-2010129653-\$).did.	US-PGPUB; USPAT; FPRS; EPO	OR	ON	2017/07/10 09:18
L219	32	("20060004772" "20060229919" "20110258000" "20060020611" "20080133273" "20090070146" "20040143403" "20090287502" "20080147554" "20110184748" "20060184524" "20100162355" "20070043594" "20110225007").PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2017/07/10 09:18
L220	23	L218 NOT "32"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2017/07/10 09:18
L221	10	L220 and medical same report	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2017/07/10 09:18
L222	7	L221 and @ad<"20090701"	US-PGPUB;	OR	ON	2017/07/10

			USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB			09:18
L232	60	(US-20080147554-\$ or US-20020016923-\$ or US-20070130465-\$ or US-20080306872-\$ or US-20080304663-\$ or US-20080133273-\$ or US-20080040151-\$ or US-20050267782-\$ or US-20050119941-\$ or US-20060020611-\$ or US-20070185737-\$ or US-20060004772-\$ or US-20080120296-\$ or US-20080010254-\$ or US-20040078236-\$ or US-20090287502-\$ or US-20080281631-\$ or US-20080137848-\$ or US-20110255690-\$ or US-20070033419-\$ or US-20120246661-\$ or US-20090257586-\$ or US-20100325148-\$ or US-20100287190-\$ or US-20080306952-\$ or US-20070219824-\$).did. or (US-20070106753-\$ or US-20070106752-\$ or US-20060089857-\$ or US-20070192140-\$ or US-20050177050-\$ or US-20100217973-\$ or US-20070043594-\$ or US-20030154405-\$ or US-20080071577-\$ or US-20100162355-\$ or US-20060184524-\$ or US-20110231422-\$ or US-20040143403-\$ or US-20070157297-\$ or US-20020188869-\$ or US-20110184748-\$).did. or (US-5721777-\$ or US-8296341-\$ or US-6302844-\$ or US-6874085-\$ or US-8037052-\$ or US-7716487-\$ or US-6947561-\$ or US-8131646-\$ or US-8055910-\$ or US-8108355-\$ or US-7900245-\$ or US-8229742-\$ or US-7650628-\$ or US-5956400-\$).did. or (WO-2010129653-\$ or CA-2760773-\$ or WO-2007108814-\$).did. or (WO-2010129653-\$).did.	US-PGPUB; USPAT; FPRS; EPO	OR	OFF	2017/07/10 09:18
L233	39	("20060004772" "20060229919" "20070219824" "20080010254" "20110258000" "20060020611" "20080133273" "20090070146" "20040143403" "20090287502" "20080147554" "20110184748" "20080120296" "20060184524" "20100162355" "20070043594" "20110225007").PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2017/07/10 09:18
L234	47	L232 NOT L233	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2017/07/10 09:18
L235	37	L234 AND @AD<"20090701"	US-PGPUB; USPAT; USOCR;	OR	OFF	2017/07/10 09:18

			FPRS; EPO; JPO; DERWENT; IBM_TDB			
L236	8	L235 AND TOKEN	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2017/07/10 09:18
L237	29	L235 NOT L236	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2017/07/10 09:18

EAST Search History (Interference)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L2	0	15/"Term Removed"	US-PGPUB; USPAT	OR	ON	2017/07/10 09:17
L223	27970	(G06F19/322 G06F19/366 G06Q50/22 G06F21/6245).CPC.	US-PGPUB; USPAT	OR	ON	2017/07/10 09:18
L224	403	L223 AND (((report\$3) near11 (encounter characteristics group))).CLM.	US-PGPUB; USPAT	OR	ON	2017/07/10 09:18
L225	1	L224 AND (((non?identifiable de\$1identified) near4 (medical healthcare)) same token).CLM.	US-PGPUB; USPAT	OR	ON	2017/07/10 09:18
L226	2229	(Rawlings NEAR3 Jean Anderson NEAR3 David Kraus NEAR3 Carl Paris NEAR3 Andrew).INV.	US-PGPUB; USPAT	OR	ON	2017/07/10 09:18
L227	3	L226 AND (((non?identifiable de\$1identified) near4 (medical healthcare)) same token).CLM.	US-PGPUB; USPAT	OR	ON	2017/07/10 09:18
L228	3	Vigilytics.AS.	US-PGPUB; USPAT	OR	ON	2017/07/10 09:18
L229	3	L228 AND (((report\$3) near11 (encounter characteristics group))).CLM.	US-PGPUB; USPAT	OR	ON	2017/07/10 09:18
L230	3	L228 AND (((non?identifiable de\$1identified) near4 (medical healthcare)) same token).CLM.	US-PGPUB; USPAT	OR	ON	2017/07/10 09:18
L231	1	L223 AND L228	US-PGPUB; USPAT	OR	ON	2017/07/10 09:18

7/ 10/ 2017 9:36:39 AM
C:\ Users\ dzhao\ Documents\ EAST\ Workspaces\ 15-606265 P158 con of de-ID rpt med info.wsp

Search Notes 	Application/Control No. 15606265	Applicant(s)/Patent Under Reexamination PARIS, ANDREW L.
	Examiner DON ZHAO	Art Unit 2493

CPC- SEARCHED		
Symbol	Date	Examiner
G06F19/322, G06F19/366, G06Q50/22, G06F21/6245	7/10/2017	DZ

CPC COMBINATION SETS - SEARCHED		
Symbol	Date	Examiner

US CLASSIFICATION SEARCHED			
Class	Subclass	Date	Examiner

SEARCH NOTES		
Search Notes	Date	Examiner
EAST Searches include CPC, KWIC, keyword searches in combination with CPC, and inventor searches. No double patenting found.	7/10/2017	DZ
NPL searches using GOOGLE. See attached search note printout(s).	7/17/2017	DZ

INTERFERENCE SEARCH			
US Class/ CPC Symbol	US Subclass / CPC Group	Date	Examiner

	/DON ZHAO/ Primary Examiner. Art Unit 2493
--	---

PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875						Application or Docket Number 15/606,265			
APPLICATION AS FILED - PART I									
(Column 1)		(Column 2)		SMALL ENTITY		OR OTHER THAN SMALL ENTITY			
FOR	NUMBER FILED	NUMBER EXTRA	RATE(\$)	FEE(\$)		RATE(\$)	FEE(\$)		
BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A	N/A	70		N/A			
SEARCH FEE (37 CFR 1.16(k), (l), or (m))	N/A	N/A	N/A	300		N/A			
EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A	N/A	360		N/A			
TOTAL CLAIMS (37 CFR 1.16(j))	20	minus 20 = *	x 40 =	0.00	OR				
INDEPENDENT CLAIMS (37 CFR 1.16(h))	3	minus 3 = *	x 210 =	0.00					
APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$310 (\$155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).			0.00					
MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))				0.00					
			TOTAL	730		TOTAL			
* If the difference in column 1 is less than zero, enter "0" in column 2.									
APPLICATION AS AMENDED - PART II									
(Column 1)		(Column 2)		(Column 3)		SMALL ENTITY		OR OTHER THAN SMALL ENTITY	
AMENDMENT A	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE(\$)	ADDITIONAL FEE(\$)		RATE(\$)	ADDITIONAL FEE(\$)	
	Total (37 CFR 1.16(i))	*	Minus **	=	x =	OR	x =		
	Independent (37 CFR 1.16(h))	*	Minus ***	=	x =	OR	x =		
	Application Size Fee (37 CFR 1.16(s))					OR			
	FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))					OR			
			TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE			
(Column 1)		(Column 2)		(Column 3)		SMALL ENTITY		OR OTHER THAN SMALL ENTITY	
AMENDMENT B	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE(\$)	ADDITIONAL FEE(\$)		RATE(\$)	ADDITIONAL FEE(\$)	
	Total (37 CFR 1.16(i))	*	Minus **	=	x =	OR	x =		
	Independent (37 CFR 1.16(h))	*	Minus ***	=	x =	OR	x =		
	Application Size Fee (37 CFR 1.16(s))					OR			
	FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))					OR			
			TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE			
* If the entry in column 1 is less than the entry in column 2, write "0" in column 3. ** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20". *** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3". The "Highest Number Previously Paid For" (Total or Independent) is the highest found in the appropriate box in column 1.									



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	TOT CLAIMS	IND CLAIMS
15/606,265	05/26/2017	3626	730	25412-0003003	20	3

CONFIRMATION NO. 1070

FILING RECEIPT

26161
FISH & RICHARDSON P.C. (BO)
P.O. BOX 1022
MINNEAPOLIS, MN 55440-1022



Date Mailed: 06/08/2017

Receipt is acknowledged of this non-provisional patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please submit a written request for a Filing Receipt Correction. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections**

Inventor(s)

Andrew L. Paris III, Victor, NY;

Applicant(s)

Vigilytics LLC, Victor, NY;

Power of Attorney: The patent practitioners associated with Customer Number 26161

Domestic Priority data as claimed by applicant

This application is a CON of 15/136,318 04/22/2016 PAT 9665685
which is a CON of 14/082,433 11/18/2013 PAT 9323892
which is a CIP of 12/827,745 06/30/2010 PAT 9118641
which claims benefit of 61/222,428 07/01/2009
and said 14/082,433 11/18/2013
claims benefit of 61/729,207 11/21/2012

Foreign Applications for which priority is claimed (You may be eligible to benefit from the **Patent Prosecution Highway** program at the USPTO. Please see <http://www.uspto.gov> for more information.) - None.

Foreign application information must be provided in an Application Data Sheet in order to constitute a claim to foreign priority. See 37 CFR 1.55 and 1.76.

Permission to Access Application via Priority Document Exchange: Yes

Permission to Access Search Results: Yes

Applicant may provide or rescind an authorization for access using Form PTO/SB/39 or Form PTO/SB/69 as appropriate.

If Required, Foreign Filing License Granted: 06/06/2017

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US 15/606,265**

Projected Publication Date: Request for Non-Publication Acknowledged

Non-Publication Request: Yes

Early Publication Request: No

**** SMALL ENTITY ****

Title

USING DE-IDENTIFIED HEALTHCARE DATA TO EVALUATE POST-HEALTHCARE FACILITY
ENCOUNTER TREATMENT OUTCOMES

Preliminary Class

705

Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition Applications: No

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4258).

LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

SelectUSA

The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for business investment, innovation, and commercialization of new technologies. The U.S. offers tremendous resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to promote and facilitate business investment. SelectUSA provides information assistance to the international investor community; serves as an ombudsman for existing and potential investors; advocates on behalf of U.S. cities, states, and regions competing for global investment; and counsels U.S. economic development organizations on investment attraction best practices. To learn more about why the United States is the best country in the world to develop technology, manufacture products, deliver services, and grow your business, visit <http://www.SelectUSA.gov> or call +1-202-482-6800.

May 26, 2017

Attorney Docket No.: 25412-0003003

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Inventors: ANDREW L. PARIS III

Title: USING DE-IDENTIFIED HEALTHCARE DATA TO EVALUATE POST-
HEALTHCARE FACILITY ENCOUNTER TREATMENT OUTCOMES

This is a continuation application and claims priority under 35 U.S.C. §120 to U.S. Application Serial No. 15/136,318, filed April 22, 2016, which is a continuation of U.S. Application Serial No. 14/082,433, filed November 18, 2013 (now U.S. Patent No. 9,323,892 issued on April 26, 2016), which is a continuation-in-part application of U.S. Application Serial No. 12/827,745, filed June 30, 2010, (now U.S. Patent No. 9,118,641 issued on August 25, 2015), which claims priority under 35 U.S.C. §119(e) to U.S. provisional application No. 61/222,428, filed on July 1, 2009; U.S. Application Serial No. 14/082,433, filed November 18, 2013, also claims priority under 35 USC §119(e) to U.S. Patent Application Serial No. 61/729,207, filed on November 21, 2012; the entire contents of each are hereby incorporated by reference.

Enclosed are the following papers, including those required to receive a filing date under 37 CFR 1.53(b):

	<u>Pages</u>
Specification	20
Claims	4
Abstract	1
Declaration	1
Drawings	7

Enclosures:

- Application Data Sheet, 9 pages.
- Information disclosure statement, 1 page.
PTO-1449, 2 pages.
- Power of Attorney, 1 page.
- Nonpublication Request, 1 page.
- Statement under rule 3.73(c), 2 pages.

The applicant claims small entity status under 37 CFR 1.27.

Street Address
Fish & Richardson P.C.
One Marina Park Drive
Boston, MA 02210-1878

Mail Address
P.O. Box 1022
Minneapolis, MN 55440-1022

617 542 5070 main
877 769 7945 fax



Commissioner for Patents
May 26, 2017
Page 2

Basic Filing Fee			\$70
Search Fee			\$300
Examination Fee			\$360
Total Claims 20	over 20	0 x \$40	\$0
Independent Claims 3	over 3	0 x \$210	\$0
Total Filing fee			\$730

The total filing fee is being paid concurrently on the Electronic Filing System by deposit account authorization. Apply any other required fees or any credits to Deposit Account No. 06-1050, referencing the attorney docket number shown above.

I hereby authorize the USPTO to communicate in response to email communications from the undersigned and practitioners under Customer No. in accordance with 37 CFR 1.33 and 37 CFR 1.34 concerning any subject matter of this application via email. I understand that a copy of these communications will be made of record in the application file. (MPEP 502.03).

If this application is considered to be incomplete, or if a telephone conference would otherwise be helpful, call the undersigned at (617) 956-5911.

Send all correspondence to:

26161

Customer Number

Respectfully submitted,

/Natalie K Galley/

Natalie K. Galley, Ph.D.
Registration No. L1010

Enclosures
NKG/cao
23652779.doc

Using De-identified Healthcare Data to Evaluate Post-Healthcare Facility Encounter Treatment Outcomes

CLAIM OF PRIORITY

5 [001] This is a continuation application and claims priority under 35 U.S.C. §120 to U.S. Application Serial No. 15/136,318, filed April 22, 2016, which is a continuation of U.S. Application Serial No. 14/082,433, filed November 18, 2013 (now U.S. Patent No. 9,323,892 issued on April 26, 2016), which is a continuation-in-part application of U.S. Application Serial No. 12/827,745, filed June 30, 2010, (now U.S. Patent No. 9,118,641 issued on August 25, 2015), which claims priority under 35 U.S.C. §119(e) to U.S. provisional application No. 61/222,428, filed on 10 July 1, 2009; U.S. Application Serial No. 14/082,433, filed November 18, 2013, also claims priority under 35 USC §119(e) to U.S. Patent Application Serial No. 61/729,207, filed on November 21, 2012; the entire contents of each are hereby incorporated by reference.

BACKGROUND

15 [002] The present disclosure relates to processing and transmitting personal data, the dissemination of which is restricted by federal law.

20 [003] Due to federal privacy laws and the inconsistency of electronic medical record deployments, healthcare facilities (e.g., hospitals, nursing homes, residential mental health facilities, prison medical wards) are often unable to obtain information about health care services patients receive before or after healthcare facility encounters. Having access to these data may allow healthcare facilities to better serve patients. Gaining an understanding of care that occurs in the outpatient setting is needed to evaluate potential for changes in the process of inpatient care. 25 Not having this information may lead to unrecognized suboptimal care and ultimately to healthcare facility readmission for which the healthcare facility may be held accountable. Outpatient healthcare providers such as pharmacies and physicians generate private healthcare data about patients, including medical and

prescription drug data, and administrative healthcare claims data. Data that associates patient identity with health information is known as protected health information (PHI). Healthcare providers can store protected health information in electronic databases for future use in patient care and insurance claims processing. Healthcare facilities could identify changes in the process of care provided (e.g., patient and provider education, adherence follow-up) by having information on trends in health care utilization before and after health care facility encounters. Federal privacy laws, however, make obtaining this information a cumbersome process which would add considerable expense to operations.

SUMMARY

[004] The systems and techniques described here relate to de-identifying patient identities from healthcare facility encounters and retrieving information from pre or post encounter activity.

[005] In one aspect, a computer-implemented method includes producing medical information from a set of private data representing pre or post-encounter characteristics of the individuals, where the individuals have had an encounter with a healthcare facility. The identity of the individuals is unattainable from the produced medical information. The method includes using the produced medical information to report the pre or post-encounter characteristics for the group.

[006] Implementations may include any of all of the following features. Producing medical information that characterizes the group of encounters may include producing a request token for each individual included in the group of encounters. Producing such a request token for each individual may include encrypting respective data that identifies each individual. Producing medical information that characterizes the group of encounters may include comparing the request tokens to tokens associated with the medical information to be produced. The tokens associated with the medical information to be produced and the request tokens may be similarly encrypted. Producing medical information that

characterizes the group of encounters may include determining if the comparison provides at least a minimum number of matches. Producing medical information that characterizes the group may include requesting a predefined portion of the medical information. Additionally, producing medical information that characterizes the group may include determining if the group includes at least a minimum number of individuals. The private data may represent medical information associated with pre or post-encounter medical activity for the individuals within the group. The private data may be obtained from pharmacies or other medical care providers.

[007] In another aspect a system includes an encryption server for producing a request token for each individual included in a group identified in a request for medical information that characterizes the group consisting of individuals who had an encounter with a healthcare facility. The system may also include a data server for producing the medical information that characterizes the group from a set of private data representing pre or post-encounter characteristics of the individuals. The identity of the individuals is unattainable from the produced medical information. The data server is also configured to provide the produced medical information to report the characteristics of the group of encounters.

[008] Implementations may include any of all of the following features. The data server may provide a request token for each individual included in the group of encounters to produce the medical information that characterizes the group of encounters. The request token for each individual may represent encrypted data that identifies the corresponding individual. The data server may be configured to compare the request tokens to tokens associated with the medical information to be produced. The tokens associated with the medical information to be produced and the request tokens may be similarly encrypted. The data server may be configured to determine if the comparison provides at least a minimum number of matches. The request may represent a predefined portion of information to use for producing the medical information that characterizes the group of encounters. The encryption

server may be configured to determine if the group includes at least a minimum number of individuals. The private data may represent medical information associated with pre or post-encounter medical activity of the individuals within the group. The private data may be obtained from pharmacies or other medical care providers.

[009] In another aspect, one or more computer readable media storing instructions that are executable by a processing device, and upon such execution cause the processing device to perform operations that include producing medical information that characterizes a group of individuals from a set of private data representing pre or post encounter characteristics of the individuals. The individuals have had an encounter with a healthcare facility. The identity of the individuals is unattainable from the produced medical information. The operations also include providing the produced medical information to report the characteristics of the group.

[010] Implementations may include any of all of the following features. Producing medical information that characterizes the group may include producing a request token for each individual included in the group. Producing such a request token for each individual may include encrypting respective data that identifies each individual. Producing medical information that characterizes the group of encounters may include comparing the request tokens to tokens associated with the medical information to be produced. The tokens associated with the medical information to be produced and the request tokens may be similarly encrypted. Producing medical information that characterizes the group may include determining if the comparison provides at least a minimum number of matches. Producing medical information that characterizes the group may include requesting a predefined portion of the information. Additionally, producing medical information that characterizes the group of encounters may include determining if the group includes at least a minimum number of individuals. The private data may represent medical information associated with pre or post-encounter medical

activity of the individuals of the group of encounters. The private data may be obtained from pharmacies or other medical care providers.

[011] The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.

DESCRIPTION OF DRAWINGS

FIG. 1 illustrates exemplary circumstances in which protected health information is stored by healthcare providers, claims clearing houses, and other source sites, and requested by a hospital.

FIG. 2 illustrates an exemplary method and system that enables a hospital to obtain medical information about a group of people without violating the privacy of persons in the group.

FIG. 3 illustrates an exemplary system incorporating an encryption server and a de-identified data server to enable a user who is not permitted to obtain the private data of a group of individuals who have been discharged from a hospital to instead obtain a report that characterizes the group of discharges as a whole.

FIG. 4 illustrates an exemplary message requesting de-identified data about a group of discharges.

FIG. 5 is a flowchart that represents exemplary operations of a token generator.

FIG. 6 is a flowchart that represents exemplary operations of a token matcher.

FIG. 7 represents a computer system and related components.

Like reference symbols in the various drawings indicate like elements.

DETAILED DESCRIPTION

5 [012] Referring to FIG. 1, when a doctor treats Jack 102 for high blood pressure, a surgeon removes Jack's gallstones, and a pharmacist fills Jack's prescription for insulin, Jack leaves a trail of electronic records 104 with healthcare professionals (e.g., healthcare professional 106), in their offices (e.g., doctor's office, nurse's station, etc.), in healthcare facilities (e.g., a hospital 108, a pharmacy 110, a nursing home, etc.) and the like. The electronic records 104 contain medical data 112 about Jack, for example his illnesses 114 and treatments 116. Each piece of medical data 112 is associated with personally identifiable information 118 that
10 identifies Jack and distinguishes him from all other patients, such as his first name 120, last name 122, date of birth 124, gender 126, and zip code 128. Together, the pieces of medical data 112 and the personally identifiable information 118 make up Jack's protected health information (PHI) 130.

15 [013] Each of Jack's healthcare providers may submit health insurance claims 105 containing PHI 130, as well as additional PHI 130, to a claims clearing house 137. The claims clearing house 137 may store the PHI 130 of many patients 134, including Jack, in a PHI database 136. A de-identifier 142 can process the PHI 130 to generate irreversibly de-identified data 140 by removing all personally identifiable information 118 or otherwise transforming the PHI 130 so that it
20 cannot be associated with a particular person. A claims warehouse 139 stores de-identified data 140 about many patients 134. Claims clearing houses 137 and claims warehouses 139 are optimized for retrieving and providing PHI 136 and de-identified data 140 for use in further processing, but health care providers such as healthcare professionals 106 and pharmacies 110 may also serve as source sites
25 138 for de-identified data in a distributed system.

[014] By searching for Jack's personally identifiable information 118 in its electronic records 104, the pharmacy 110 is able to look up the various drugs in Jack's PHI 130 and, for example, check for bad interactions among them. Jack does not object to this use of his PHI 130 because it improves the quality of his

healthcare. On the other hand, Jack would object to the pharmacy 110 giving his PHI 130 to third parties without his permission because that would disclose personal, private information about him that Jack's potential employers, for example, might use to discriminate against him.

5 **[015]** Federal laws, such as the Health Insurance Portability and Accountability Act (HIPAA), protect Jack by prohibiting the source sites 138 possessing Jack's PHI 130 from releasing it to third parties without Jack's permission. Under HIPAA, the source sites 138 can release only irreversibly de-identified data 140 without Jack's permission.

10 **[016]** A healthcare facility, for example a hospital 150, may be interested in outpatient medical information contained in Jack's PHI 130 that occurs post-discharge. Since the hospital may not have access to post discharge medical information it may not have the knowledge to fully understand the potential risk of rehospitalizations or other medical events for a group 154. In that case, the
15 hospital 150 would like to use the PHI 136 from the group 154 to assess the risk of rehospitalization or other medical events. The hospital can use this information to make adjustments to treatments and improve the quality of care. Unfortunately, the group 154 may also be too large for the hospital 150 to practically obtain permission from each person in the group, without which HIPAA prohibits the
20 healthcare providers 138 from releasing the PHI 136 to the hospital 150 for care not related to the hospitalization. Practically speaking, even when hospitals have the authority to obtain the requested data they may not have a mechanism for doing so. The de-identified data 140, which the healthcare providers or other source sites 138 could release without permission, is not useful to the hospital 150 because the
25 hospital has no way to know whether it corresponds to the people in the group 154. With no way to obtain pre and post hospitalization medical data for the group, the hospital 150 cannot determine post discharge medical events for the group.

[017] Referring to FIG. 2, to provide the hospital 150 with the pre and post hospitalization medical data necessary to generate the post discharge report for the group 154, without revealing the protected health information of persons in the group 154, the exemplary system 200 associates unique tokens 202 with the irreversibly de-identified data 140. The tokens 202 correspond to persons treated by healthcare providers but do not reveal the identities of the treated individuals. The hospital 150 can send a data request 203 to a third party 205, who in turn can generate request tokens 204, one for each person in the group 154. The third party 205 can send the request tokens 204 to a data aggregator 206. The data aggregator 206 stores de-identified data 140 and associated tokens 202. By searching for the request tokens 204 among the stored tokens 202, the data aggregator 206 can process the de-identified data to generate requested de-identified data 208 that corresponds to the group 154. A data processor 210 can process the requested de-identified data 208 to generate a report 212 containing metrics such as medication utilization reports that are useful to the hospital 150 in assessing the overall post discharge health status of the group 154.

[018] By using the tokens 202 and request tokens 204, no parties other than the authorized source sites 138 can associate de-identified data 140 with the identity of any person in the group of patients 134 or discharges (e.g., the group 154). The hospital 150 requesting the report 212 can never receive data associated with individuals. Further, the information in the report 212 may be processed into metrics that characterize a large group and cannot be used to infer information about individuals. De-identified data records may be provided to the data processor 210 (e.g., a third party data processor), but that third party may not have access to any personally identifiable information 118 about the group 154. Nor may any party with access to the de-identified data 140, other than the healthcare providers 138, also have access to the de-identifier 142. These features of the system 200 maintain the privacy of the protected health information 130.

5 [019] While we describe a system in which a hospital 150 needs to estimate the post discharge health status of a group of discharges, the system 200 can work for applications in which information characterizing a group needs to be generated from the private data of group members. In one arrangement, the system may implement Microsoft Windows-based computers in connection with internet-based components. However, other implementations may use other types of components that support the processing of pre and post hospitalization medical data from healthcare databases.

10 [020] While the hospital 150 is referred to as a location interested in the post discharge health status of a group of discharges, one or more other types of healthcare facilities may utilize the techniques and methodologies described herein. Such healthcare facilities may include dialysis centers, specialty clinics, retirement homes, rehabilitation centers, or other types of entities where post encounter follow up may be of interest.

15 [021] Referring to FIG. 3, in an exemplary system 300, a user 302 specifies a group of people using identifying data for each group member. Referring briefly to FIG. 4, an exemplary set of identifying data 404 is illustrated. Returning to FIG. 3, the user may obtain the personally identifiable information from a database 304 by retrieving it in the form of a group file 330. The user 302 generates a request message 306, which may be a computer file, which uniquely identifies each member of the group using the identifying data 304. Typically, the group contains at least a minimum number of unique members. A request message 306 may be generated at a remote computer operated by the user 302.

20 [022] The request message 306 contains a set of identifying data 404 (see FIG. 4) for each group member, as well as data that identifies a user 402 (see FIG. 4), such as the user's name, email address, phone number and facsimile number, and a batch number 406 that identifies the request. The group members' identifying data 404 (see FIG. 4) may include first name, last name, date of birth, gender, and zip code

as well as other identifiers, such as social security number, that may be added to ensure that members are uniquely identified. In some examples, fewer identifiers may be used. The request message 306 may also include optional indications that the user 302 requests a particular type of report 212 or requests additional processing to enhance the value of the report. The request message may also contain additional non-identified (not containing any personally identifiable information) data 405 to be used by a report generator 328. These additional non-identified data 405 will be encrypted upon submission allowing access to only a report generator 328. Alternatively, the additional data 405 may be passed directly to the report generator 328 as shown by dotted line 329. These non-identified data 405 may include service dates, diagnosis information, or other pre-encounter and/or post-encounter details.

[023] The request message 306 is sent over a communications network 310 (e.g., the Internet, a LAN, etc.) to an encryption server 312. If the request message 306 contains a minimum number of unique group members, the encryption server 312 creates a unique token, or identifier, for each person in the message 306. The encryption server creates each token by applying a token generator 314 that encrypts the personally identifiable information of each group member and passes the pre-encrypted non-identified data through the system to a report writer. The set of tokens corresponding to all the group members constitutes a batch of request tokens 204. The minimum number of group members, for example ten, is chosen to make it effectively impossible to associate individual group members with individual tokens in the batch of request tokens 204.

[024] The encryption server 312 provides the request tokens 204 to the de-identified data server 318. The de-identified data server 318 stores records of de-identified data and corresponding tokens 320 obtained from source sites 138 such as pharmacies, healthcare professionals, rehabilitation centers, and electronic claims clearing houses. Other sources of data can include prison records, arrest records, the national death index or other death records, medical laboratories,

dialysis centers, nursing homes, radiology providers, potentially military records, employment records, financial records, or DMV records. Each token obtained from the source sites 138 may have been created using the same token generator 314 used by the encryption server 312, or using any other means that generates the identical token for the same personally identifiable information.

[025] For example, a pharmacy tracks the prescription histories of the patients being served. De-identified prescription histories and corresponding tokens are sent to the de-identified data server 318. At the request of a user 302, such as a hospital, the encryption server 312 generates tokens identical to the patients' tokens using the same personally identifiable information. A unique token corresponding to the same personally identifiable information permits the pharmacy and the hospital to refer to the same anonymous people without the hospital ever associating protected health information with a particular person. To produce tokens and request tokens, one or more encryption techniques may be utilized, for example, hash functions and other methodologies may be implemented.

[026] A token matcher 326, executed by the de-identified data server 318, performs a look-up in the de-identified database 320 to find all tokens in the database that match the tokens sent from the encryption server 312. All available data for matched tokens, the requested de-identified data 208, is retrieved for use in the report generator 328. The de-identified data may include, for example, prescription data, medical claims, and hospital claims. The de-identified data server 318 or the data processor 210 may use the report generator 328 to process the requested de-identified data 208 in a way that leaves it irreversibly de-identified. An example of such processing is an algorithm that transforms the data into a post discharge health status assessment. The report generator formats the processed data into an electronic or hardcopy report 212 that is returned to the user.

[027] While the report 212 is described as generated on a computer system, it may also be generated in part or entirely outside the computer system. For

example, the report 212 could be conveyed to the user via regular mail or other similar technique. In particular, the report may be generated and printed at the site of the de-identified data server 318 and subsequently communicated to the user 302 without using the computer network. The report generator 328 may also reside in the data processor 210 separate from the de-identified data server 318.

[028] In one arrangement, once the relevant information and options have been selected, the user 302 submits the request by clicking a submit button. The request message 306 may be encrypted prior to being transmitted over a computer network 310. At the encryption server 312, the request message 306 is unencrypted and stored. The encryption server 312 may send an optional confirmation message to the user 302. The confirmation message may include the time and date that the message was received, and may indicate the service level and options selected by the user 302.

[029] Referring to FIG. 4, the user 302 can input the user's identifying information 402, including name, email address, phone number and/or facsimile number, in the first record, or set of fields, of the request message 306. The user can then input the personally identifiable information 404 for each of the group members, including first name, last name, gender, date of birth, and zip code. The user may also input additional data 405 such as service dates, diagnosis information, or other encounter details that will be rendered non-identified and encrypted upon submission. Equivalently, the user can incorporate the group file 330 into the request message 306. Information about the ward 408 from which the group was discharged, or other purpose for which the report 212 is being requested may also be included in the request message 306. The format of the request message 306 may be adjusted based on the user's 302 needs.

[030] The request message 306 may also include information about the level of service 410 requested by the user 302, for example the quantity, quality or type of information. A first level of service may request up to six months of pre and post

hospitalization medical data; a second level may request up to twelve months of data; and a third level may request a two year pre and post hospitalization medical data. Alternatively, instead of providing the user 302 with a variety of service level options 410, the system 300 may simply retrieve all of the pre and post hospitalization medical data available for the group.

[031] The user 302 may also request additional, optional information 412. For example, the user 302 may request information regarding the drug categories and drug indications associated with the drugs in the de-identified data. Drug indications include the medical conditions associated with each drug. Drug categories include the type of drug. This data can be passed to the data processor 210 to include in the report 212. Alternatively, this data may be returned as part of every report 212.

[032] Referring to FIG. 5, a flowchart 500 represents a particular arrangement of operations of a token generator (e.g., the token generator 314 shown in FIG. 3). Operations include receiving 502 the request message (e.g., request message 306) containing the personally identifiable information of each person in the group (e.g., such as the group 154 shown in FIG. 1). Upon receiving the request message, operations may also include determining 504 whether the message includes the minimum number of persons. If the message does not include the minimum number of persons, the token generator returns to receive 502 a request message. A limit on the minimum number of persons ensures that a report (e.g., the report 212) covers enough people such that it is difficult (if not impossible) to infer any association between particular persons and the information in the report. If the message does include the minimum number of people, operations of the token generator include producing 508 tokens from the identifying data of each person. Producing the tokens may include applying an encryption algorithm to the identifying data of each person. The tokens uniquely identify each person in the group 154.

5 **[033]** Operations also include determining 510 if the request message includes a batch number. If the message does not include a batch number, operations include generating 512 a batch number. Operations also include providing 516 the tokens, batch number and report options. The individual tokens are placed in a batch file and may be encrypted before being transmitted over the network.

[034] Each batch file of request tokens 204 also specifies the information needed for the report 212. The request tokens are transmitted to the de-identified data server 318, unencrypted and processed using rules for searching, matching, and retrieving healthcare data.

10 **[035]** Referring to FIG. 6, a flowchart 600 represents a particular arrangement of operations of a token matcher (e.g., the token matcher 326 shown in FIG. 3). Operations include receiving 602 request tokens (e.g., such as the request tokens 204 shown in FIG. 2). Operations may also include receiving 604 a token (e.g., such as the token 202) and associated de-identified data (e.g., such as the de-identified data 140), typically from source sites (e.g., such as the source site 138 shown in FIG. 1). Upon receiving a request token, de-identified data and a token, operations include determining 606 whether the request token matches the token. If no match is found, operations include returning to receive 604 more tokens and de-identified data. If a match is found, operations include processing 608 the de-identified data. Processing may include storage for later retrieval. In some arrangements, operations may also include determining whether a minimum number of matches has been detected. If such a minimum number of matches has not occurred in comparing the request tokens and the tokens, action may be taken (e.g., pause or restart processing) until the predefined number of matches has been detected (e.g., so as not to increase the probability of one or more individuals being identified by a process of elimination).

25 **[036]** In addition to determining that a minimum number of matches has been found operations may also include processing of other privacy-preserving rules.

For example, a rule may not allow the same user 302 (e.g., hospital 150) to submit more than one request message 306 containing substantially the same identifying data 404 within a defined period of time, e.g., six months. Identifying substantially the same identifying data 404 from a user 302 may involve comparing the identifying data 404 from different stored request messages 306 and checking that at least a minimum variation exists in the request messages 306. For example, this may involve checking that the identifying data 404 for at least five patients does not match the identifying data 404 for any previous search request 306 by the user 302. Especially when combined with the size requirements and less than 100% capture rate, such rules greatly reduce the possibility of identifying any one person's data.

[037] The de-identified data (e.g., such as the de-identified data 140) may include a list of drugs prescribed over the requested period for the members of the group (e.g., such as the group 154). The list of drugs prescribed may include the drug name, form, strength, days supplied, and date dispensed. The de-identified data could also include data from other sources such as those listed above, and include diagnosis, procedures, prison release date, date of death, date of arrest, etc. As part of processing 608 the de-identified data, operations may include determining the drug category and drug indications for each drug prescribed. Operations may also include accessing a database relating the drug category and indications to each possible drug. The database may be maintained within the de-identified data server 318 database, or may be accessed on a remote server maintained by a third party.

[038] Upon processing the de-identified data, operations also include determining 610 if additional tokens remain in the batch of request tokens (e.g., such as the request tokens 204). If additional tokens remain, operations include receiving 602 more request tokens. If there are no additional request tokens, operations may include outputting 612 the processed, de-identified data.

5 **[039]** Operations may also include providing the number of tokens submitted, the number matched, and the overall match rate. The collected data covers the interval of historical data according to the level of service requested (e.g., as represented by the level of service 410 in FIG. 4). De-identified diagnosis and procedures data may also be included from administrative medical claims from a doctor's office (e.g., office 106) or a healthcare facility (e.g., the hospital 108).

10 **[040]** In addition to accessing and incorporating drug indication information for each drug prescribed to persons in the group (e.g., such as group 154), operations may include further processing of the requested de-identified data. For instance, operations may include determining the probability that a particular drug indicates a particular condition. In this example, in addition to providing the possible indications, the requested de-identified data would include the likelihood that
15 anonymous individuals associated with the request tokens (e.g., such as request tokens 204) have each of the conditions indicated by the prescribed drugs. Operations may also include using expert rule systems to provide health status information based on the prescription drug medical data. Alternatively, operations may include using diagnosis codes from medical claims data to assess health status. In some arrangements, operations may also include integrating the de-identified data with the non-identified data 405.

20 **[041]** The requested de-identified data 208 may be sent for further processing to a third party data processor (e.g., data processor 210) who may apply proprietary algorithms, modify the data format, or generate additional reports, provided that no re-identifiable information is transmitted to the user 302. Third parties may not have access to the request message 306 and the group file 330 so that no
25 association may be inferred between the de-identified data 140 and particular persons in the group 154.

[042] In some implementations, the report 212 can include analysis results. The analysis results can include statistical analyses, correlations of varying post-

discharge characteristics, comorbidity rates, or other metadata. The analysis results can be determined by the third party data processor. The analysis results can be generated automatically, or by human intervention. For example, in addition to the report 212, a human analyst can respond to the user 302 with custom analysis relating to the user's 302 request message 306.

[043] The report 212 provides the hospital 150 with information for making an informed decision about the relationship between the hospitalization and the health status of the group of discharges. Hospitals could identify changes in the process of care provided during or after the hospitalization by having information on trends in outpatient health care utilization. In particular, the hospital 150 may change internal policies including discharge instructions, structure of care, process of care, or other relevant operating procedures based on the information in the report 212. Patterns from multiple reports over time may be used to determine which actions to take, if any. The report 212 may be used alone to make decisions about the health status of the group 154, or may simply indicate that additional investigation is needed.

[044] In some implementations, all reports 212 can be saved and archived by the system 200. Data on the saved reports 212 can be made available to the hospital 150. For example, a hospital 150 may query the system 200 about a group 154 of patients sharing a characteristic, and deliver a report for the group as well as a second report. The second group could include, for example, comparative data for all patients discharged from the hospital.

[045] FIG. 7 is a schematic diagram of a generic computer system 700. The system 700 can be used for the operations described in association with any of the computer-implemented methods described previously, according to one implementation. The system 700 includes a processor 710, a memory 720, a storage device 730, and an input/output device 740. Each of the components 710, 720, 730, and 740 are interconnected using a system bus 750. The processor 710 is

capable of processing instructions for execution within the system 700. In one implementation, the processor 710 is a single-threaded processor. In another implementation, the processor 710 is a multi-threaded processor. The processor 710 is capable of processing instructions stored in the memory 720 or on the storage device 730 to display graphical information for a user interface on the input/output device 740.

[046] The memory 720 stores information within the system 700. In some implementations, the memory 720 is a computer-readable medium. The memory 720 is a volatile memory unit in some implementations and is a non-volatile memory unit in other implementations.

[047] The storage device 730 is capable of providing mass storage for the system 700. In one implementation, the storage device 730 is a computer-readable medium. In various different implementations, the storage device 730 may be a floppy disk device, a hard disk device, an optical disk device, or a tape device.

[048] The input/output device 740 provides input/output operations for the system 700. In one implementation, the input/output device 740 includes a keyboard and/or pointing device. In another implementation, the input/output device 740 includes a display unit for displaying graphical user interfaces.

[049] The features described can be implemented in digital electronic circuitry, or in computer hardware, firmware, software, or in combinations of them. The apparatus can be implemented in a computer program product tangibly embodied in an information carrier, e.g., in a machine-readable storage device, for execution by a programmable processor; and method steps can be performed by a programmable processor executing a program of instructions to perform functions of the described implementations by operating on input data and generating output. The described features can be implemented advantageously in one or more computer programs that are executable on a programmable system including at least one programmable processor coupled to receive data and instructions from,

and to transmit data and instructions to, a data storage system, at least one input device, and at least one output device. A computer program is a set of instructions that can be used, directly or indirectly, in a computer to perform a certain activity or bring about a certain result. A computer program can be written in any form of programming language, including compiled or interpreted languages, and it can be deployed in any form, including as a stand-alone program or as a module, component, subroutine, or other unit suitable for use in a computing environment.

[050] Suitable processors for the execution of a program of instructions include, by way of example, both general and special purpose microprocessors, and the sole processor or one of multiple processors of any kind of computer. Generally, a processor will receive instructions and data from a read-only memory or a random access memory or both. The essential elements of a computer are a processor for executing instructions and one or more memories for storing instructions and data. Generally, a computer will also include, or be operatively coupled to communicate with, one or more mass storage devices for storing data files; such devices include magnetic disks, such as internal hard disks and removable disks; magneto-optical disks; and optical disks. Storage devices suitable for tangibly embodying computer program instructions and data include all forms of non-volatile memory, including by way of example semiconductor memory devices, such as EPROM, EEPROM, and flash memory devices; magnetic disks such as internal hard disks and removable disks; magneto-optical disks; and CD-ROM and DVD-ROM disks. The processor and the memory can be supplemented by, or incorporated in, ASICs (application-specific integrated circuits).

[051] To provide for interaction with a user, the features can be implemented on a computer having a display device such as a CRT (cathode ray tube) or LCD (liquid crystal display) monitor for displaying information to the user and a keyboard and a pointing device such as a mouse or a trackball by which the user can provide input to the computer.

[052] The features can be implemented in a computer system that includes a back-end component, such as a data server, or that includes a middleware component, such as an application server or an Internet server, or that includes a front-end component, such as a client computer having a graphical user interface or an Internet browser, or any combination of them. The components of the system can be connected by any form or medium of digital data communication such as a communication network. Examples of communication networks include, e.g., a LAN, a WAN, and the computers and networks forming the Internet.

[053] The computer system can include clients and servers. A client and server are generally remote from each other and typically interact through a network, such as the described one. The relationship of client and server arises by virtue of computer programs running on the respective computers and having a client-server relationship to each other.

[054] A number of implementations have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the following claims.

WHAT IS CLAIMED IS:

1. A computer-implemented method comprising:

receiving a request from a user device for medical information that characterizes a
5 group composed of multiple individuals from a set of de-identified medical data
representing pre-or post-encounter characteristics of the individuals;

producing, by a hardware processor, a request token for each individual included in
the group of individuals;

10 comparing the request tokens to tokens associated with the medical data to find
matching tokens;

producing the requested medical information, the identity of the individuals being
unattainable from the produced medical information without the individuals in the group
having authorized production of such medical information that characterizes the group;
and

15 providing the produced medical information to report the characteristics of the group
of individuals absent authorization from the individuals in the group of individuals.

2. The computer-implemented method of claim 1, wherein the provided medical
information is in conformity with the Health Insurance Portability and Accountability Act
(HIPAA).

20 3. The computer-implemented method of claim 1, wherein receiving the request for
medical information that characterizes the group of individuals includes receiving
personally identifiable information associated with the individuals of the group.

4. The computer-implemented method of claim 1, in which producing the requested
medical information includes encrypting respective data that identifies each individual.

25 5. The computer-implemented method of claim 1, in which the tokens associated with
medical data and the request tokens are similarly encrypted.

6. The computer-implemented method of claim 1, in which the medical data represents medical-related information associated with the individuals of the group.

7. A system comprising:

a computing device comprising:

5 a memory configured to store instructions; and
 a processor to execute the instructions to perform operations comprising:
 receiving a request from a user device for medical information that
characterizes a group composed of multiple individuals from a set of de-identified
medical data representing pre-or post-encounter characteristics of the individuals;
10 producing a request token for each individual included in the group of
individuals;
 comparing the request tokens to tokens associated with the medical data to
find matching tokens;
 producing the requested medical information with the identity of the
15 individuals being unattainable from the produced medical information without the
individuals in the group having authorized production of such medical information that
characterizes the group; and
 providing the produced medical information to report the characteristics of
the group of individuals absent authorization from the individuals in the group of
20 individuals.

8. The system of claim 7, wherein the provided medical information is in conformity with the Health Insurance Portability and Accountability Act (HIPAA).

9. The system of claim 7, wherein the request for medical information that
characterizes a group of individuals includes personally identifiable information
25 associated with the individuals of the group.

10. The system of claim 7, in which the data that identifies each individual is encrypted.

11. The system of claim 7, in which the tokens associated with the medical data and the request tokens are similarly encrypted.

12. The system of claim 7, in which the data server provides the requested medical information if the group includes at least a minimum number of individuals.

5 13. The system of claim 7, in which the medical data represents medical-related information associated with the individuals of the group.

14. One or more computer readable storage devices storing instructions that are executable by a processing device, and upon such execution cause the processing device to perform operations comprising:

10 receiving a request from a user device for medical information that characterizes a group composed of multiple individuals from a set of de-identified medical data representing pre-or post-encounter characteristics of the individuals;

 producing, by a hardware processor, a request token for each individual included in the group of individuals;

15 comparing the request tokens to tokens associated with the medical data to find matching tokens;

 producing the requested medical information with the identity of the individuals being unattainable from the produced medical information without the individuals in the group having authorized production of such medical information that characterizes the group; and

20 providing the produced medical information to report the characteristics of the group of individuals absent authorization from the individuals in the group of individuals.

15 15. The computer readable storage devices of claim 14, wherein the provided medical information is in conformity with the Health Insurance Portability and Accountability Act (HIPAA).

16. The computer readable storage devices of claim 14, wherein receiving the request for medical information that characterizes the group of individuals includes receiving personally identifiable information associated with the individuals of the group.

17. The computer readable storage devices of claim 14, in which producing the requested medical information includes encrypting respective data that identifies each individual.

18. The computer readable storage devices of claim 14, in which the tokens associated with the medical data and the request tokens are similarly encrypted.

19. The computer readable storage devices of claim 14, in which the medical data represents medical-related information associated with the individuals of the group.

20. The computer readable storage devices of claim 14, in which producing the requested medical information includes determining if the group includes at least a minimum number of individuals.

ABSTRACT

A computer-implemented method includes producing medical information that characterizes a group of individuals from a set of private data representing pre or post-
5 encounter characteristics of the individuals, wherein the individuals have had encounters with a healthcare facility. The identity of the individuals is unattainable from the produced medical information. The method also includes providing the produced medical information to report the pre or post-encounter characteristics of the group.

10 2365279.doc




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor : Andrew L. Paris III
Serial No. :
Filed :
Title : USING DE-IDENTIFIED HEALTHCARE DATA TO EVALUATE
POST-HEALTHCARE FACILITY ENCOUNTER TREATMENT
OUTCOMES

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Please consider the references listed on the enclosed Disclosure Form. Under 35 USC §120, this application relies on the earlier filing date of application serial number 14/082,433, filed on November 18, 2013. The references corresponding to Desig. ID Nos. 16, 19, 21-22 and 28-30 have not been considered in the prior application. All other references listed on the enclosed Disclosure Form were submitted to and/or cited by the Office in the prior application, and so copies of those references have not been provided in this application.

This statement is being filed with the application. Apply any necessary charges or credits to deposit account 06-1050, referencing the above attorney docket number.

Respectfully submitted,

Date: 5/26/17

/Natalie K Galley/

Natalie K. Galley, Ph.D.
Reg. No. L1010

Customer Number
Fish & Richardson P.C.
Telephone: (617) 956-5911
Facsimile: (877) 769-7945

23652759.doc

Substitute Disclosure Form U.S. Department of Commerce Patent and Trademark Office Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	Attorney Docket No. 25412-0003003	Application No.
	Applicant Vigilytics LLC	
	Filing Date	Group Art Unit

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1.	2004/0143403	07/2004	Brandon et al.			
	2.	2005/0234739	10/2005	Schoenberg			
	3.	2005/0261941	11/2005	Scarlat			
	4.	2006/0004772	01/2006	Hagan et al.			
	5.	2006/0020611	01/2006	Gilbert et al.			
	6.	2006/0184524	08/2006	Pollanz			
	7.	2006/0229919	10/2006	Pugh			
	8.	2007/0043594	02/2007	Lavergne			
	9.	2007/0219824	09/2007	Rawlings et al.			
	10.	2008/0010254	01/2008	Settimi			
	11.	2008/0120296	05/2008	Kariathungal et al.			
	12.	2008/0133273	06/2008	Marshall			
	13.	2008/0147554	06/2008	Stevens et al.			
	14.	2009/0024416	01/2009	McLaughlin et al.			
	15.	2009/0070146	03/2009	Haider et al.			
	16.	2009/0112769	04/2009	Dicks			
	17.	2009/0287502	11/2009	Roberts et al.			
	18.	2010/0162355	06/2010	Zimmerman et al.			
	19.	2010/0287190	11/2010	Anderson			
	20.	2011/0184748	07/2011	Fierro et al.			
	21.	2011/0191767	08/2011	Pinsky			
	22.	2011/0191822	08/2011	Pinsky			
	23.	2011/0225007	09/2011	Theis			
	24.	2011/0258000	10/2011	Green et al.			
	25.	2013/0246334	09/2013	Ahuja			
	26.	2014/0053252	02/2014	Kelsey			

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form U.S. Department of Commerce Patent and Trademark Office Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	Attorney Docket No. 25412-0003003	Application No.
	Applicant Vigilytics LLC	
	Filing Date	Group Art Unit

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	27.	2015/0046192	02/2015	Raduchel			
	28.	9,118,641	08/2015	Paris, III			
	29.	9,323,892	04/2016	Paris, III			
	30.	9,665,685	05/2017	Paris, III			

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
		---	---	---				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	31.	"Group," The American Heritage Dictionary, 2014 Houghton Mifflin Harcourt, Retrieved online: https://ahdictionary.com/word/search.html?q=group (accessed 10/23/2014), 3 pages
	32.	"Health Information Privacy: Business Associates," U.S. Department of Health and Human Services, April 3, 2003, Retrieved online: http://www.hhs.gov/ocr/privacy/hipaa/understanding/coveredentities/businessassociates.html , (accessed 10/09/2014), 2 pages

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

**DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN
APPLICATION DATA SHEET (37 CFR 1.76)****Title of
Invention****USING DE-IDENTIFIED HEALTHCARE DATA TO EVALUATE POST-HEALTHCARE FACILITY
ENCOUNTER TREATMENT OUTCOMES**

As the below named inventor, I hereby declare that:

This declaration ☒ The attached application, or
is directed to ☐ United States application or PCT international application
number _____
filed on _____

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001
by fine or imprisonment of not more than five (5) years, or both.**WARNING:**

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTORInventor: Andrew L. Paris IIIDate (Optional): 11/15/2013Signature: *Andrew L. Paris III*

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 118 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-6199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

POWER OF ATTORNEY TO PROSECUTE APPLICATIONS BEFORE THE USPTO

I hereby revoke all previous powers of attorney given in the application identified in the attached statement under 37 CFR 3.73(c).

I hereby appoint:



Practitioners associated with Customer Number:

26161

OR

Practitioner(s) named below (if more than ten patent practitioners are to be named, then a customer number must be used):

Name	Registration Number

Name	Registration Number

As attorney(s) or agent(s) to represent the undersigned before the United States Patent and Trademark Office (USPTO) in connection with any and all patent applications assigned only to the undersigned according to the USPTO assignment records or assignments documents attached to this form in accordance with 37 CFR 3.73(c).

Please change the correspondence address for the application identified in the attached statement under 37 CFR 3.73(c) to:



The address associated with Customer Number:

26161

OR

☐	Firm or Individual Name			
	Address			
	City	State	Zip	
	Country			
	Telephone	Email		

Assignee Name and Address: Vigilytics LLC
559 Fox Hunt Drive
Victor, New York 14564

A copy of this form, together with a statement under 37 CFR 3.73(c) (Form PTO/AIA/96 or equivalent) is required to be filed in each application in which this form is used. The statement under 37 CFR 3.73(c) may be completed by one of The practitioners appointed in this form, and must identify the application in which this Power of Attorney is to be filed.

SIGNATURE of Assignee of Record

The individual whose signature and title is supplied below is authorized to act on behalf of the assignee

Signature		Date	01/22/2014
Name	Andrew L. Paris, III	Telephone	585-924-1667
Title	Resident		

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Datavant Exhibit 1002

STATEMENT UNDER 37 CFR 3.73(c)Applicant/Patent Owner: Vigilytics LLC

Application No./Patent No.: _____ Filed/Issue Date: _____

Titled: USING DE-IDENTIFIED HEALTHCARE DATA TO EVALUATE POST-HEALTHCARE FACILITY ENCOUNTER TREATMENT OUTCOMES

Vigilytics LLC, a corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that, for the patent application/patent identified above, it is (choose one of the option 1, 2, 3 or 4 below):

1. ☒ The assignee of the entire right, title, and interest.
2. ☐ An assignee of less than the entire right, title and interest (check applicable box):
- ☐ The extent (by percentage) of its ownership interest is _____. Additional Statement(s) by the owners holding the balance of the interest must be submitted to account for 100% of the ownership interest.
- ☐ There are unspecified percentages of ownership. The other parties, including inventors, who together own the entire right, title and interest are:

Additional Statement(s) by the owner(s) holding the balance of the interest must be submitted to account for the entire right, title, and interest.

3. ☐ The assignee of an undivided interest in the entirety (a complete assignment from one of the joint inventors was made). The other parties, including inventors, who together own the entire right, title, and interest are:

Additional Statement(s) by the owner(s) holding the balance of the interest must be submitted to account for the entire right, title, and interest.

4. ☐ The recipient, via a court proceeding or the like (e.g., bankruptcy, probate), of an undivided interest in the entirety (a complete transfer of ownership interest was made). The certified document(s) showing the transfer is attached.

The interest identified in option 1, 2 or 3 above (not option 4) is evidenced by either (choose one of the options A or B below):

- A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 038669, Frame 0971, or for which a copy thereof is attached.
- B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

2. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

[Page 1 of 2]

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

STATEMENT UNDER 37 CFR 3.73(c)

3. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

4. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

5. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

6. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet(s).

☒ As required by 37 CFR 3.73(c)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (*i.e.*, a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

/Natalie K Galley/ _____

Signature

5/26/17 _____

Date

Natalie K. Galley, Ph.D. _____

Printed or Typed Name

L1010 _____

Title or Registration Number

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

NONPUBLICATION REQUEST UNDER 35 U.S.C. 122(b)(2)(B)(i)	First Named Inventor		Andrew L. Paris III
	Title	USING DE-IDENTIFIED HEALTHCARE DATA TO EVALUATE POST-HEALTHCARE FACILITY ENCOUNTER TREATMENT OUTCOMES	
	Attorney Docket Number		25412-0003003

I hereby certify that the invention disclosed in the attached application **has not and will not be** the subject of an application filed in another country, or under a multilateral international agreement, that requires publication at eighteen months after filing.

I hereby request that the attached application not be published under 35 U.S.C. 122(b).

/Natalie K Galley/

Signature

5/26/17

Date

Natalie K. Galley, Ph.D.

Typed or printed name

L1010

Registration Number, if applicable

(617) 956-5911

Telephone Number

This request must be signed in compliance with 37 CFR 1.33(b) and submitted with the application **upon filing**.

Applicant may rescind this nonpublication request at any time. If applicant rescinds a request that an application not be published under 35 U.S.C. 122(b), the application will be scheduled for publication at eighteen months from the earliest claimed filing date for which a benefit is claimed.

If applicant subsequently files an application directed to the invention disclosed in the attached application in another country, or under a multilateral international agreement, that requires publication of applications eighteen months after filing, the applicant **must** notify the United States Patent and Trademark Office of such filing within forty-five (45) days after the date of the filing of such foreign or international application. **Failure to do so will result in abandonment of this application (35 U.S.C. 122(b)(2)(B)(iii)).**

This collection of information is required by 37 CFR 1.213(a). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 6 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	25412-0003003
		Application Number	
Title of Invention	USING DE-IDENTIFIED HEALTHCARE DATA TO EVALUATE POST-HEALTHCARE FACILITY ENCOUNTER TREATMENT OUTCOMES		
The application data sheet is part of the provisional or nonprovisional application for which it is being submitted. The following form contains the bibliographic data arranged in a format specified by the United States Patent and Trademark Office as outlined in 37 CFR 1.76. This document may be completed electronically and submitted to the Office in electronic format using the Electronic Filing System (EFS) or the document may be printed and included in a paper filed application.			

Secrecy Order 37 CFR 5.2:

☐	Portions or all of the application associated with this Application Data Sheet may fall under a Secrecy Order pursuant to 37 CFR 5.2 (Paper filers only. Applications that fall under Secrecy Order may not be filed electronically.)
--------------------------	---

Inventor Information:

Inventor	1				Remove	
Legal Name						
Prefix	Given Name	Middle Name	Family Name	Suffix		
	Andrew	L.	Paris	III		
Residence Information (Select One) • ☒ US Residency ☐ Non US Residency ☐ Active US Military Service						
City	Victor	State/Province	NY	Country of Residence	US	
Mailing Address of Inventor:						
Address 1	559 Fox Hunt Drive					
Address 2						
City	Victor	State/Province	NY			
Postal Code	14564	Country	US			
All Inventors Must Be Listed - Additional Inventor Information blocks may be generated within this form by selecting the Add button. Add						

Correspondence Information:

Enter either Customer Number or complete the Correspondence Information section below. For further information see 37 CFR 1.33(a).	
☐ An Address is being provided for the correspondence Information of this application.	
Customer Number	26161
Email Address	Add Email Remove Email

Application Information:

Title of the Invention	USING DE-IDENTIFIED HEALTHCARE DATA TO EVALUATE POST-HEALTHCARE FACILITY ENCOUNTER TREATMENT OUTCOMES		
Attorney Docket Number	25412-0003003	Small Entity Status Claimed	☒
Application Type	Nonprovisional		
Subject Matter	Utility		
Total Number of Drawing Sheets (if any)	7	Suggested Figure for Publication (if any)	

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	25412-0003003
		Application Number	
Title of Invention	USING DE-IDENTIFIED HEALTHCARE DATA TO EVALUATE POST-HEALTHCARE FACILITY ENCOUNTER TREATMENT OUTCOMES		

Filing By Reference:

Only complete this section when filing an application by reference under 35 U.S.C. 111(c) and 37 CFR 1.57(a). Do not complete this section if application papers including a specification and any drawings are being filed. Any domestic benefit or foreign priority information must be provided in the appropriate section(s) below (i.e., "Domestic Benefit/National Stage Information" and "Foreign Priority Information").

For the purposes of a filing date under 37 CFR 1.53(b), the description and any drawings of the present application are replaced by this reference to the previously filed application, subject to conditions and requirements of 37 CFR 1.57(a).

Application number of the previously filed application	Filing date (YYYY-MM-DD)	Intellectual Property Authority or Country

Publication Information:

☐ Request Early Publication (Fee required at time of Request 37 CFR 1.219)

☒ **Request Not to Publish.** I hereby request that the attached application not be published under 35 U.S.C. 122(b) and certify that the invention disclosed in the attached application **has not and will not be** the subject of an application filed in another country, or under a multilateral international agreement, that requires publication at eighteen months after filing.

Representative Information:

Representative information should be provided for all practitioners having a power of attorney in the application. Providing this information in the Application Data Sheet does not constitute a power of attorney in the application (see 37 CFR 1.32). Either enter Customer Number or complete the Representative Name section below. If both sections are completed the customer Number will be used for the Representative Information during processing.

Please Select One:	☒ Customer Number	☐ US Patent Practitioner	☐ Limited Recognition (37 CFR 11.9)
Customer Number	26161		

Domestic Benefit/National Stage Information:

This section allows for the applicant to either claim benefit under 35 U.S.C. 119(e), 120, 121, 365(c), or 386(c) or indicate National Stage entry from a PCT application. Providing benefit claim information in the Application Data Sheet constitutes the specific reference required by 35 U.S.C. 119(e) or 120, and 37 CFR 1.78.

When referring to the current application, please leave the "Application Number" field blank.

Prior Application Status	Pending	Remove	
Application Number	Continuity Type	Prior Application Number	Filing or 371(c) Date (YYYY-MM-DD)
	Continuation of	15136318	2016-04-22

Application Data Sheet 37 CFR 1.76		Attorney Docket Number		25412-0003003	
		Application Number			
Title of Invention		USING DE-IDENTIFIED HEALTHCARE DATA TO EVALUATE POST-HEALTHCARE FACILITY ENCOUNTER TREATMENT OUTCOMES			

Prior Application Status		Patented		Remove	
Application Number	Continuity Type	Prior Application Number	Filing Date (YYYY-MM-DD)	Patent Number	Issue Date (YYYY-MM-DD)
15136318	Continuation of	14082433	2013-11-18	9323892	2016-04-26
Prior Application Status		Patented		Remove	
Application Number	Continuity Type	Prior Application Number	Filing Date (YYYY-MM-DD)	Patent Number	Issue Date (YYYY-MM-DD)
14082433	Continuation in part of	12827745	2010-06-30	9118641	2015-08-25
Prior Application Status		Expired		Remove	
Application Number	Continuity Type	Prior Application Number	Filing or 371(c) Date (YYYY-MM-DD)		
12827745	Claims benefit of provisional	61222428	2009-07-01		
Prior Application Status		Expired		Remove	
Application Number	Continuity Type	Prior Application Number	Filing or 371(c) Date (YYYY-MM-DD)		
14082433	Claims benefit of provisional	61729207	2012-11-21		
Additional Domestic Benefit/National Stage Data may be generated within this form by selecting the Add button.					Add

Foreign Priority Information:

This section allows for the applicant to claim priority to a foreign application. Providing this information in the application data sheet constitutes the claim for priority as required by 35 U.S.C. 119(b) and 37 CFR 1.55. When priority is claimed to a foreign application that is eligible for retrieval under the priority document exchange program (PDX)ⁱ the information will be used by the Office to automatically attempt retrieval pursuant to 37 CFR 1.55(i)(1) and (2). Under the PDX program, applicant bears the ultimate responsibility for ensuring that a copy of the foreign application is received by the Office from the participating foreign intellectual property office, or a certified copy of the foreign priority application is filed, within the time period specified in 37 CFR 1.55(g)(1).

			Remove
Application Number	Country ⁱ	Filing Date (YYYY-MM-DD)	Access Code ⁱ (if applicable)
Additional Foreign Priority Data may be generated within this form by selecting the Add button.			Add

Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition Applications

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	25412-0003003
		Application Number	
Title of Invention	USING DE-IDENTIFIED HEALTHCARE DATA TO EVALUATE POST-HEALTHCARE FACILITY ENCOUNTER TREATMENT OUTCOMES		

☐ This application (1) claims priority to or the benefit of an application filed before March 16, 2013 and (2) also contains, or contained at any time, a claim to a claimed invention that has an effective filing date on or after March 16, 2013.

NOTE: By providing this statement under 37 CFR 1.55 or 1.78, this application, with a filing date on or after March 16, 2013, will be examined under the first inventor to file provisions of the AIA.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	25412-0003003
		Application Number	
Title of Invention	USING DE-IDENTIFIED HEALTHCARE DATA TO EVALUATE POST-HEALTHCARE FACILITY ENCOUNTER TREATMENT OUTCOMES		

Authorization or Opt-Out of Authorization to Permit Access:

When this Application Data Sheet is properly signed and filed with the application, applicant has provided written authority to permit a participating foreign intellectual property (IP) office access to the instant application-as-filed (see paragraph A in subsection 1 below) and the European Patent Office (EPO) access to any search results from the instant application (see paragraph B in subsection 1 below).

Should applicant choose not to provide an authorization identified in subsection 1 below, applicant **must opt-out** of the authorization by checking the corresponding box A or B or both in subsection 2 below.

NOTE: This section of the Application Data Sheet is **ONLY** reviewed and processed with the **INITIAL** filing of an application. After the initial filing of an application, an Application Data Sheet cannot be used to provide or rescind authorization for access by a foreign IP office(s). Instead, Form PTO/SB/39 or PTO/SB/69 must be used as appropriate.

1. Authorization to Permit Access by a Foreign Intellectual Property Office(s)

A. Priority Document Exchange (PDX) - Unless box A in subsection 2 (opt-out of authorization) is checked, the undersigned hereby **grants the USPTO authority** to provide the European Patent Office (EPO), the Japan Patent Office (JPO), the Korean Intellectual Property Office (KIPO), the State Intellectual Property Office of the People's Republic of China (SIPO), the World Intellectual Property Organization (WIPO), and any other foreign intellectual property office participating with the USPTO in a bilateral or multilateral priority document exchange agreement in which a foreign application claiming priority to the instant patent application is filed, access to: (1) the instant patent application-as-filed and its related bibliographic data, (2) any foreign or domestic application to which priority or benefit is claimed by the instant application and its related bibliographic data, and (3) the date of filing of this Authorization. See 37 CFR 1.14(h)(1).

B. Search Results from U.S. Application to EPO - Unless box B in subsection 2 (opt-out of authorization) is checked, the undersigned hereby **grants the USPTO authority** to provide the EPO access to the bibliographic data and search results from the instant patent application when a European patent application claiming priority to the instant patent application is filed. See 37 CFR 1.14(h)(2).

The applicant is reminded that the EPO's Rule 141(1) EPC (European Patent Convention) requires applicants to submit a copy of search results from the instant application without delay in a European patent application that claims priority to the instant application.

2. Opt-Out of Authorizations to Permit Access by a Foreign Intellectual Property Office(s)

☐ A. Applicant **DOES NOT** authorize the USPTO to permit a participating foreign IP office access to the instant application-as-filed. If this box is checked, the USPTO will not be providing a participating foreign IP office with any documents and information identified in subsection 1A above.

☐ B. Applicant **DOES NOT** authorize the USPTO to transmit to the EPO any search results from the instant patent application. If this box is checked, the USPTO will not be providing the EPO with search results from the instant application.

NOTE: Once the application has published or is otherwise publicly available, the USPTO may provide access to the application in accordance with 37 CFR 1.14.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	25412-0003003
		Application Number	
Title of Invention	USING DE-IDENTIFIED HEALTHCARE DATA TO EVALUATE POST-HEALTHCARE FACILITY ENCOUNTER TREATMENT OUTCOMES		

Applicant Information:

Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title 37 of CFR to have an assignment recorded by the Office.

Applicant	1	Remove
If the applicant is the inventor (or the remaining joint inventor or inventors under 37 CFR 1.45), this section should not be completed. The information to be provided in this section is the name and address of the legal representative who is the applicant under 37 CFR 1.43; or the name and address of the assignee, person to whom the inventor is under an obligation to assign the invention, or person who otherwise shows sufficient proprietary interest in the matter who is the applicant under 37 CFR 1.46. If the applicant is an applicant under 37 CFR 1.46 (assignee, person to whom the inventor is obligated to assign, or person who otherwise shows sufficient proprietary interest) together with one or more joint inventors, then the joint inventor or inventors who are also the applicant should be identified in this section. Clear		
☒ Assignee	Legal Representative under 35 U.S.C. 117	Joint Inventor
Person to whom the inventor is obligated to assign.		Person who shows sufficient proprietary interest
If applicant is the legal representative, indicate the authority to file the patent application, the inventor is:		
Name of the Deceased or Legally Incapacitated Inventor:		
If the Applicant is an Organization check here. ☒		
Organization Name	Vigilytics LLC	
Mailing Address Information For Applicant:		
Address 1	559 Fox Hunt Drive	
Address 2		
City	Victor	State/Province NY
Country	US	Postal Code 14564
Phone Number		Fax Number
Email Address		
Additional Applicant Data may be generated within this form by selecting the Add button. Add		

Assignee Information including Non-Applicant Assignee Information:

Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title 37 of CFR to have an assignment recorded by the Office.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	25412-0003003
		Application Number	
Title of Invention	USING DE-IDENTIFIED HEALTHCARE DATA TO EVALUATE POST-HEALTHCARE FACILITY ENCOUNTER TREATMENT OUTCOMES		

Assignee	1			
Complete this section if assignee information, including non-applicant assignee information, is desired to be included on the patent application publication. An assignee-applicant identified in the "Applicant Information" section will appear on the patent application publication as an applicant. For an assignee-applicant, complete this section only if identification as an assignee is also desired on the patent application publication.				
				Remove
If the Assignee or Non-Applicant Assignee is an Organization check here.				☐
Prefix	Given Name	Middle Name	Family Name	Suffix
Mailing Address Information For Assignee including Non-Applicant Assignee:				
Address 1				
Address 2				
City		State/Province		
Country ⁱ		Postal Code		
Phone Number		Fax Number		
Email Address				
Additional Assignee or Non-Applicant Assignee Data may be generated within this form by selecting the Add button.				Add

Signature:

NOTE: This Application Data Sheet must be signed in accordance with 37 CFR 1.33(b). However, if this Application Data Sheet is submitted with the **INITIAL** filing of the application and either box A or B is not checked in subsection 2 of the "Authorization or Opt-Out of Authorization to Permit Access" section, then this form must also be signed in accordance with 37 CFR 1.14(c).

This Application Data Sheet **must** be signed by a patent practitioner if one or more of the applicants is a **juristic entity** (e.g., corporation or association). If the applicant is two or more joint inventors, this form must be signed by a patent practitioner, **all** joint inventors who are the applicant, or one or more joint inventor-applicants who have been given power of attorney (e.g., see USPTO Form PTO/AIA/81) on behalf of **all** joint inventor-applicants.

See 37 CFR 1.4(d) for the manner of making signatures and certifications.

Signature	/Natalie K Galley/		Date (YYYY-MM-DD)	2017-05-26
First Name	Natalie K.	Last Name	Galley	Registration Number
				L1010
Additional Signature may be generated within this form by selecting the Add button.				Add

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	25412-0003003
		Application Number	
Title of Invention	USING DE-IDENTIFIED HEALTHCARE DATA TO EVALUATE POST-HEALTHCARE FACILITY ENCOUNTER TREATMENT OUTCOMES		

This collection of information is required by 37 CFR 1.76. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 23 minutes to complete, including gathering, preparing, and submitting the completed application data sheet form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Electronic Patent Application Fee Transmittal

Application Number:

Filing Date:

Title of Invention:

USING DE-IDENTIFIED HEALTHCARE DATA TO EVALUATE POST-HEALTHCARE FACILITY ENCOUNTER TREATMENT OUTCOMES

First Named Inventor/Applicant Name:

Andrew L. Paris III

Filer:

Natalie K. Galley/Matthew Doherty

Attorney Docket Number:

25412-0003003

Filed as Small Entity

Filing Fees for Utility under 35 USC 111(a)

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Basic Filing:				
UTILITY FILING FEE (ELECTRONIC FILING)	4011	1	70	70
UTILITY SEARCH FEE	2111	1	300	300
UTILITY EXAMINATION FEE	2311	1	360	360

Pages:

Claims:

Miscellaneous-Filing:

Petition:

Patent-Appeals-and-Interference:

Datavant Exhibit 1002

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Post-Allowance-and-Post-Issuance:				
Extension-of-Time:				
Miscellaneous:				
Total in USD (\$)				730

Electronic Acknowledgement Receipt

EFS ID:	29323310
Application Number:	15606265
International Application Number:	
Confirmation Number:	1070
Title of Invention:	USING DE-IDENTIFIED HEALTHCARE DATA TO EVALUATE POST-HEALTHCARE FACILITY ENCOUNTER TREATMENT OUTCOMES
First Named Inventor/Applicant Name:	Andrew L. Paris III
Customer Number:	26161
Filer:	Natalie K. Galley/Denise Siede
Filer Authorized By:	Natalie K. Galley
Attorney Docket Number:	25412-0003003
Receipt Date:	26-MAY-2017
Filing Date:	
Time Stamp:	12:20:23
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	DA
Payment was successfully received in RAM	\$ 730
RAM confirmation Number	052617INTEFSW00012643061050
Deposit Account	
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

File Listing:					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Transmittal of New Application	PAPltr0003003.pdf	97621	no	2
			4ec9221c16878a79663078f2937fb5e004fed13		
Warnings:					
Information:					
2		Spec0003003.pdf	183378	yes	25
			3ca5e25bd575824bdeed115660c4fbf5ac4cb85ec		
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Specification		1	20	
	Claims		21	24	
	Abstract		25	25	
Warnings:					
Information:					
3	Drawings-only black and white line drawings	Figs0003003.pdf	2614601	no	7
			b35794d4252d9e4b8dfd6ae2803b80ccdf256a1c		
Warnings:					
Information:					
4	Transmittal Letter	Trasnmittal0003003.pdf	42242	no	1
			7d8cd52ff792285cddb771ac232f554cf68ba156		
Warnings:					
Information:					
5	Information Disclosure Statement (IDS) Form (SB08)	1449_0003003.pdf	102375	no	2
			cb6aa9815380de9bd73930637bb24f4caf0eba8b		
Datavant Exhibit 1002					

Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
6	Oath or Declaration filed	Dec0003003.pdf	1164521	no	1
			08c874b1c447bf704127daa819f645e1ee9702cc		
Warnings:					
Information:					
7	Power of Attorney	POA0003003.pdf	75416	no	1
			9309ba7bc81ce8811af01b4f4a93f07a6f700ba8		
Warnings:					
Information:					
8	Assignee showing of ownership per 37 CFR 3.73	373Statement0003003.pdf	74506	no	2
			b9366ef02385bbf980c34ad2f79b5a1bd452a302		
Warnings:					
Information:					
9	Nonpublication request from applicant	NonPub0003003.pdf	101398	no	1
			790e35df6f6cd8d8043cd926bf6e5479a8e26058		
Warnings:					
Information:					
10	Application Data Sheet	ADS0003003.pdf	1823091	no	9
			1861543d7599fc1814da610d59b616a5a014e32e		
Warnings:					
Information:					
11	Fee Worksheet (SB06)	fee-info.pdf	34775	no	2
			14158994a1e373dc9cc5d2cfd068c6486d366959		
Warnings:					
Information:					
Total Files Size (in bytes):			6313924		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

SCORE Placeholder Sheet for IFW Content

Application Number: 15606265

Document Date: 05/26/2017

The presence of this form in the IFW record indicates that the following document type was received in electronic format on the date identified above. This content is stored in the SCORE database.

- Drawings – Other than Black and White Line Drawings

Since this was an electronic submission, there is no physical artifact folder. no artifact folder is recorded in PALM. and no paper documents or physical media exist. The TIFF images in the IFW record were created from the original documents that are stored in SCORE.

To access the documents in the SCORE database, refer to instructions below.

At the time of document entry (noted above):

- Examiners may access SCORE content via the eDAN interface.
- Other USPTO employees can bookmark the current SCORE URL (<http://Score.uspto.gov/ScoreAccessWeb/>).
- External customers may access SCORE content via the Public and Private PAIR interfaces.